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Abstract 
 
Introduction The epithelial-specific integrin αvβ6 usually is undetectable on 
normal, adult, human tissue but is upregulated during tissue re-modelling and 
carcinogenesis.  
 
Objective To develop and characterise agents for targeting αvβ6 in cancer. 
 
Methods A series of peptides was generated from known high-affinity αvβ6 ligands. 
These peptides were then assessed for their ability to inhibit αvβ6-dependent cell 
adhesion. The lead 20 mer peptide, A20FMDV2, was identified. Flow cytometry, 
with two genetically identical cell lines that differed only in their expression of αvβ6 
– A375P puro(negative) and A375Pβ6(positive)-, confirmed specificity for binding 
of A20FMDV2 to v6. The A20FMDV2 sequence was synthesised with both a 
biotin and DTPA-chelator group added.  This was radiolabelled with Indium-111 and 
purity and structural integrity analysed by HPLC. 
Prior to in vivo experiments the endogenous expression of αvβ6 in nu/nu athymic 
mice was determined by examining 20 different organs (in triplicate) by 
immunohistochemistry. For in vivo experiments, athymic mice were inoculated 
subcutaneously with A375Pβ6 (right shoulder) and A375P puro (left shoulder).  A 
radiolabelled variant of A20FMDV2 (
111
In-DTPA-A20FMDV2) was injected into 
xenografted mice.  Some mice were imaged on a NanoSPECT/CT imager and 
biodistribution confirmed by determining the radioactivity associated with excised 
organs. 
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Results Immunohistochemistry of mouse tissues revealed, as expected, strong 
expression of v6 in the A375Pβ6 tumour but none in the A375Ppuro tumour. In 
addition, expression of vβ6 was found in normal murine hair follicles, gallbladder, 
urinary bladder, secretory endometrium, the stomach and along the GI tract. 
Flow cytometry with A375Ppuro and A375Pβ6 cells confirmed that DTPA-chelate 
addition to A20FMDV2 did not affect its specificity or affinity for v6. HPLC 
confirmed that DTPA-biotinylated-A20FMDV2 was labelled successfully with 
Indium-111 resulting in a single radiolabelled peak. Ex-vivo gamma counts revealed 
seven-fold higher uptake of the radiolabelled-peptide in the A375Pβ6 tumour 
compared with the A375Ppuro tumour. Biodistribution data were consistent with the 
endogenous αvβ6 expression as determined by immunohistochemistry. 
NanoSPECT/CT imaging clearly identified that the A375P6 tumour retained more 
radioactive peptide than the A375Ppuro tumour at 30, 60 and 120 minutes after 
injection.  Images also showed uptake in the GI tract. 
 
 
Conclusion We have determined that the peptide DTPA-A20FMDV2 is specific for 
v6, can be labelled with Indium-111 and selectively localises in vivo to v6-
positive tissues, including human cancer. This is the first peptide described for the 
successful imaging, by SPECT, of v6-positive cancers. 
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Chapter I: Introduction to Cancer 
 
1.1 Cancer 
 
Cancer is a term that encompasses many diseases which involve dynamic changes 
within the genome [1]; leading to the genomes of incipient cancer cells acquiring 
mutant alleles of proto-oncogenes, tumour-suppressor genes, and other genes that 
control, directly or indirectly, cell proliferation [2]. Consequently cancer cells have 
the ability to divide without control, to form tumour masses and to ‘invade’ other 
normal tissues. Cancer is propagated by possible ‘seeding’ into the blood and 
lymphatic systems, resulting in dissemination of the malignant tissue to other parts of 
the body (metastasis). 
Cancer is a major cause of morbidity and mortality in the United Kingdom (UK). In 
the UK, 297,991 persons were diagnosed with cancer in 2007; while 156,723 
individuals died from this constellation of diseases in 2008 [3]. There are more than 
200 different types of cancer; however, breast, lung, colorectal and prostate account 
for over half of all new cases of cancer [4]. Overall it is estimated that approximately 
2% of the population of the UK are alive having received a diagnosis of cancer: that 
is, around 1.2 million people [5]. The 20 most commonly diagnosed cancers in the 
UK are shown in Figure 1.  
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Figure 1 The Twenty Most Commonly Diagnosed Cancers in UK (2004), 
excluding non-melanoma skin cancers. Taken from Cancer statistics registrations, 
Great Britain [4].  
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Furthermore, in the 30-year period 1975 to 2004, the overall age-standardised 
incidence rate for cancer has increased in Great Britain, by 25%, with a 15% increase 
in men and a 32% increase in women [4]. 
 
 
Figure 2 Age-standardised (European) incidence rates, all cancers excluding 
non-melanoma skin cancers, GB, 1975-2004. Taken from Mortality  statistics, 
Great Britain [6]. 
 
 
In spite of better preventive strategies, screening programmes and improving 
therapeutic interventions, there still were 153,491 deaths from cancer, in the UK 
during 2005; when cancer was responsible for 26% of all deaths [6]. While lung 
cancer remains the greatest killer, breast cancer has the greatest incidence, largest 
prevalence and is the third most common cause of cancer death in all persons. The 
most frequent cause of death in breast cancer patients can be attributed to metastasis 
of tumour cells and their growth at distant regions rather than the in situ effects of the 
malignancy at the primary site. 
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The diagnosis of malignancy usually involves history taking and clinical examination 
of the patient, blood tests, non-invasive imaging, biopsy and histology [7]. 
Furthermore, modern therapeutic interventions rely primarily on non-invasive 
imaging techniques to guide the intensity and duration of therapy. Therefore imaging 
is crucial to early diagnosis and monitoring of cancer. That is, improvements in 
imaging technologies have the potential to diagnose cancer at earlier stages (non-
metastatic) and guide treatments to make them more effective; thereby improving 
survival and reducing toxicity. However, many of the current imaging modalities, 
such as computed tomography (CT) and magnetic resonance imaging (MRI), crudely 
rely on reduction in tumour size as an indicator of response to therapy. Anatomical 
or structural imaging is fraught with issues around interpretation, since it analyses 
over a single timepoint and is only reliable in assessing well-defined lesions larger 
than 10mm [8]. Furthermore, tumour size reduction is not always a surrogate marker 
for response to therapy. Reduction in the viable cancer cell fraction of a tumour does 
not always result in a volume reduction, since cancerous tissue can be replaced by 
necrotic, fibrotic or cystic changes and morphological images may be unable to 
differentiate between these different tissue types [9]. Furthermore, the newer anti-
vascular and cytostatic targeted agents aim at tumour growth stabilisation, rather than 
tumour shrinkage, and thus no major volume changes are to be expected. This 
difficulty, potentially, could result in the incorrect withdrawal of effective therapy 
and thus impact adversely on patient survival. Moreover, anatomical imaging gives 
no information on biological markers, which could help in the selection of the most 
efficient therapy and indicate prognosis. These issues are tackled by the relatively 
newer functional or molecular imaging modalities, such as positron emission 
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tomography (P.E.T.) and single photon emission computed tomography (S.P.E.C.T.). 
In these modalities, biological markers can be targeted using radiolabelled small 
molecules which, therefore, can be traced in the body. This technique could, 
potentially, evaluate small volume disease (lesions less then 10 mm), which is 
classed as ‘indeterminate’ by conventional anatomical scanning [8]. A recent study 
showed that quantitative FDG-PET was significantly more accurate than CT size-
based criteria at assessing histopathologic response to chemotherapy, in high-grade 
soft-tissue sarcomas [10]. Furthermore, if the biological marker is present, it would 
allow appropriate selection of targeted therapy and a means to monitor response of 
minimal residual disease. However, before a biological marker can be applied in the 
aforementioned roles, it must be selected using in vitro characterisation and validated 
in pre-clinical models. A flow plan for how an imaging probe could be taken through 
to clinical evaluation is outlined in Figure 3. 
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Figure 3 The development and evolution of a targeted probe for a biological 
marker of cancer. 
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1.2 Integrins  
The “integrin” terminology first was applied in a 1987 review article [11]. Integrins 
are a superfamily of trans-membrane, heterodimeric, cell adhesion glycoproteins. 
They comprise a pair of non-covalently linked α and β subunits [12]. The different 
combinations of α and β subunits result in more than twenty different integrin 
receptors (Figure 4) and this variability in heterodimer composition determines 
ligand binding specificity [13]. Integrin variants also have been characterised which 
result from differential splicing and post-translational modifications [14]. Integrins 
recognise specific amino acid sequences in their ligands and at least eight of the 
possible subunit combinations recognise the RGD (Arg-Gly-Asp) motif [15].  
 
Figure 4 The Integrin Receptor Family. Taken from Hynes RO [13]. 
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1.2.1 Integrin Structure 
Cells continually secrete, assemble and remodel an insoluble network of 
proteins - the extracellular matrix (ECM). The ECM provides a pliable, but resistant, 
scaffold for the organisation of cells in tissues and exerts control on the behaviour of 
cells. The effects of the ECM on cells are mediated mainly by integrins [16]. 
Integrin-binding ECM ligands include fibronectin, vitronectin, collagen, laminin and 
tenascin-C [17] (see Table 1, page 38). Integrins link their ECM ligands to the actin-
based microfilament system; with the exception of α6β4, which links through the 
cytokeratin microfilament system [13]. 
 
Figure 5 Simplified diagram of the Integrin Receptor and its relation to the Cell 
Membrane. Taken from Alberts B et al [18]. 
 34 
Each integrin subunit is a type I transmembrane protein [19], composed of a 
large extracellular domain, a single transmembrane region and, in most cases, a short 
non-catalytic cytoplasmic tail (Figure 5). All integrin dimers are dissociated by ionic 
detergents, indicating that the subunits are held together by non-covalent interactions 
[20]. 
The x-ray crystal structure of the extracellular domain of αvβ3 has been 
determined [21]. The extracellular domains of both subunits represent the interface 
for the ‘ligand binding pocket’. Electron microscopic integrin images reveal a 
globular head, approximately 70–100 Å in diameter. With the aid of primary 
sequence analysis, the N-terminal region of all α subunits was discovered to be made 
up of seven repeats; each of which contains approximately 60 amino acids. The 
seven repeats are quite similar in sequence, with the exception of the final three or 
four. These final repeats contain inserted sequences that are similar to the EF-hand; a 
13-residue bivalent-cation-binding motif found in proteins such as calmodulin and 
parvalbumin [20]. These repeats form the basis of a seven-bladed β-propeller fold in 
the α subunit. Furthermore, a subset of nine α subunits also contain an approximate 
200-amino-acid insert that is homologous to the A domain of von Willebrand factor 
[20]. The additional insert seems to bestow a different mode of integrin activation 
and ligand binding on those integrins which express this structure.  
The extracellular domain of the β-subunit also has been predicted to contain 
an A-domain-like polypeptide segment. The major contact between the two subunits 
is with this βA-domain and the β-propeller fold of the α subunit. Furthermore, the 
location of the ligand-binding pocket is at the junction of the β propeller and the βA 
domain, in the integrin head. The β-subunit also contains a plexin-semaphorin-
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integrin (PSI) domain [22], an immunoglobulin fold, termed the hybrid domain, a 
novel cystatin-like fold and four cysteine-rich epidermal growth factor (EGF)-like 
repeats (stabilising the large extracellular amino terminal loop[23]). This is finally 
followed by a β-tail domain (see Figure 6).  
 
 
Figure 6 Schematic representation of the αvβ3 integrin structure. (a) Bent image 
of αvβ3 integrin. (b) Straightened image of αvβ3 integrin. Taken from Humphries MJ 
et al [24]. 
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The short β-cytoplasmic tail contains regions which bind and link integrins to 
the actin cytoskeletal system (e.g. α-actinin [25]). However, the cytoplasmic tail 
domains of integrins also can recruit signalling proteins, which regulate integrin 
adhesiveness to the extracellular matrix (ECM) [26]. For instance, the α-chain 
cytoplasmic domain is able to bind to calreticulin, via its highly conserved 
KXGFFKR sequence motif [27]. Calreticulin is a highly conserved, ubiquitously 
expressed intracellular protein, which regulates calcium transmembrane channel 
influx, and has been implicated in the regulation integrin conformation and thus its 
affinity [27, 28]. This represents one of the components of ‘inside-out’ signalling 
associated with integrins (see later).  
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1.2.2 Integrin Function 
 
Integrins dynamically integrate the extracellular matrix with the intracellular 
cytoskeleton, and transmit both mechanical and chemical signals. They impart 
polarity to the cell and organise its cytoskeleton during adhesion and migration. 
Integrin signalling exerts a rigorous control on cell proliferation, migration and cell 
survival [16]. 
Integrins are able to recognise multiple ligands. Table 1 (page 38) includes 
some of the major extracellular ligands of integrins. The list broadly comprises 
extracellular matrix proteins (bone matrix proteins, collagens, fibronectins, 
fibrinogen, laminins, thrombospondins, vitronectin, and von Willebrand factor), 
‘counter-receptors’ (cross-talk) and numerous micro-organisms (using integrins for 
cell entry). Most integrins recognise relatively short peptide motifs and ligand 
specificities rely on both subunits of a given αβ heterodimer [13]. Furthermore, the 
preference of any given integrin for any particular substrate (from among its ligands) 
is determined by relative affinity, availability within a specific microenvironment, 
and the conformational state of the ligand, which controls exposure of its integrin 
recognition sequence [17]. 
 
 
 
 
 
 
 38 
 
Ligand Integrin 
Adenovirus penton base protein αvβ3, αvβ5 
Bone sialoprotein αvβ3, αvβ5 
Borrelia burgdorferi αIIbβ3 
Candida albicans αMβ2 
Collagens α1β1, α2β1, α11β1, αIbβ3 
Denatured collagen α5β1, αvβ3, αIIbβ3 
Cytotactin/tenascin-C α8β1, α9β1, αvβ3, αvβ6 
Decorsin αIIbβ3 
Disintegrins αvβ3, αIIbβ3 
E cadherin αEβ7 
Echovirus 1 α2β1 
Epiligrin α3β1 
Factor X αMβ2 
Fibronectin α2β1, α3β1, α4β1, α4β7, α5β1, α8β1, 
αvβ1, 
avb3, avb5, avb6, avb8, aIIbb3 
Fibrinogen α5β1, αMβ2, αvβ3, αxβ2, αIIbβ3 
HIV Tat protein αvβ3, αvβ5 
iC3b αMβ2, αxβ2 
ICAM-1 αLβ2, αMβ2 
ICAM-2,3,4,5 αLβ2 
Invasin α3β1, α4β1, α5β1, α6β1 
Laminin α1β1, α2β1, α6β1, α7β1, α6β4, αvβ3 
MAdCAM-1 α4β7 
Matrix metalloproteinase-2 αvβ3 
Neutrophil inhibitory factor αMβ2 
Osteopontin αvβ3 
Plasminogen αIIbβ3 
Prothrombin αvβ3, αIIbβ3 
Sperm fertilin α6β1 
Thrombospondin α3β1, αvβ3, αIIbβ3 
VCAM-1 α4β1, α4β7 
Vitronectin αvβ1, αvβ3, αvβ5, αIIbβ3 
von Willebrand factor αvβ3, αIIbβ3 
 
Table 1 The major extracellular ligands of integrins. Adapted from Plow, EF et al 
[17] 
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Following ligand binding, integrins cluster into supramolecular complexes, 
termed focal contacts, which link integrins to the cytoskeleton (Figure 7). These 
focal contacts serve to transmit force or tension at adhesion sites to maintain strong 
anchoring attachments to the underlying ECM and to act as signalling centres [29].  
 
 
 
Figure 7 Integrins and the Actin cytoskeletal system.  Taken from Miranti CK et 
al [30]. 
 
The aggregation of integrins juxtaposes many signalling and structural molecules, 
which are associated with their cytoplasmic tails, allowing them to interact. Adherent 
normal cells must be anchored to an appropriate ECM to survive. Normal epithelial 
cells often undergo inappropriate apoptosis when deprived of the ECM – ‘anchorage 
dependence’ [31]. Indeed, the apoptosis resulting from lack of anchorage has been 
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termed ‘anoikis’[32]. Control of anchorage dependence appears to be reliant on 
various integrin-related signalling pathways [33]. It should be noted that these 
integrin-associated apoptotic cues do not seem to function properly in certain cancer 
cells and represent a characteristic of neoplastic transformation (see later). 
Integrins can signal through the cell membrane in either direction – ‘bidirectional 
signalling’. Unlike other receptors, ligand binding with integrins generally is not 
constitutive but is regulated to reflect the activation state of the cell. Specifically, 
high affinity binding of integrins to ligands is elicited in response to cell "activation" 
signals (so-called "inside-out signalling”) that alter the tertiary and quaternary 
structure of the extracellular region, making the integrin ligand-competent. Ligand 
binding in turn induces structural rearrangements in integrins that trigger "outside-in" 
signalling. Therefore, the extracellular binding activity of integrins is regulated from 
the inside of the cell, while the binding of the ECM elicits signals that are transmitted 
into the cell [34]. 
 
1.2.2.1 Outside-In Signalling  
Integrin-mediated ‘outside-in’ signalling occurs when ligand binding activates 
intracellular signalling pathways [34]. Outside-in signalling can be divided, broadly, 
into two descriptive categories (Figure 8). The first is 'direct signalling', in which 
ligand binding and resultant clustering of integrins is the only extracellular stimulus. 
In this way, adhesion to ECM proteins can activate cytoplasmic tyrosine kinases (e.g. 
focal adhesion kinase [FAK]) and serine/threonine kinases (e.g. mitogen-activated 
protein kinase [MAPK] cascade), produce ionic flux (e.g. Ca
2+
, Na
+
/H
+
) and initiate 
small GTPases, recruit adaptor proteins and induce lipid metabolism [35].  
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The second category of integrin signalling is 'collaborative signalling', in which 
integrin-mediated cell adhesion modulates signalling events initiated through other 
types of receptors; particularly receptor tyrosine kinases (RTKs) that are activated by 
polypeptide growth factors [35]. These kinases can phosphorylate cytoskeletal 
proteins and regulate stress-fibre formation, cell shape and migration. For example, 
ECM binding to α6β4 or α6β1, seems to increase the activation of ErbB-2, in 
carcinoma cells [36]. Indeed, Falconi et al demonstrated that concomitant over-
expression of ErbB-2 and β4 proteins confers proliferative and invasive advantages 
to transformed cells and strongly suggest that the interaction of α6β4 and ErbB-2 
receptors has a role in malignant progression [36]. 
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Figure 8 Regulation of Intracellular Signalling by Integrins.  Taken from Guo 
and  Giancotti [16]. 
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1.2.2.2 Inside-Out Signalling 
Inside-out signalling occurs when signals are received by other receptors and 
this activates various intracellular signalling pathways. These intracellular cues 
interact with integrin cytoplasmic domains, propagate conformational changes  and, 
thereby, alter the way in which their extracellular domains associate with the 
extracellular environment [37]. That is, alteration of the extracellular domain 
(described later) can modulate the affinity of integrins for their ECM and regulate 
integrin adhesiveness to their ligands. Furthermore, intracellular cues also affect 
receptor clustering (avidity modulation), which also regulates ligand binding. The 
mechanism of regulation for integrin clustering can be via intracellular signalling 
events that remodel the cytoskeletal-integrin complexes or alter receptor diffusion 
rates within the cell membrane [38, 39].  Therefore, integrins are also involved in bi-
directional signalling, regulated by affinity and avidity modulation, to control cell 
invasion and migration [35, 40, 41].  
One such intracellular cue is the activity of small GTPases (proteins that bind 
and hydrolyse GTP), of the Rho and Ras families. The activation of these GTPases is 
under the control of integrins themselves, as well as other cell-surface receptors (see 
Figure 9). It has been shown that the activation of R-Ras leads to enhancement of 
integrin affinity to ECM substrates [42]; in contrast, H-Ras activation inhibited 
integrin affinity (no substrate binding)[43]. Similarly, activation of the small GTP-
binding proteins RAC and cdc42 (and subsequent protein kinase C (PKC) induction) 
can lead to integrin clustering and thus an increase in integrin avidity [26, 44]. 
Therefore, meticulous regulation of these signalling events is necessary for efficient 
cell adhesion and migration (see Figure 13). 
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Figure 9 Inside Out Signalling and Integrin Modulation. Taken from Hughes and 
Pfaff [41]. 
 
 
 
A Mechanism for Affinity Modulation 
Although, each cell type can control its adhesive interactions partly by 
synthesising specific subsets of integrins at different stages of differentiation, this is 
a relatively slow process. Integrins must be controlled so as to undergo rapid 
adhesion and binding to the ECM, at certain times e.g. clot formation during 
bleeding. Equally important, integrins must then be inactivated to avoid cell adhesion 
and ECM binding at inopportune times and locations - adherent cells need to detach 
to undergo mitosis or during physiological migration [45]. That is, it may cause harm 
if normally motile cells suddenly became immobilised. Therefore, integrin signalling 
has to be controlled in a dynamic manner with a rapid mechanism for switching 
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between ‘inactive’ to ‘active’ states. Researchers in the integrin field use the term 
‘activation’ or ‘priming’ to denote the switch from an inactive to an active state [24]. 
The active, or primed state, correlates with the acquisition of ligand binding ability 
by integrins. Steric regulation or conformational switches seems to be important in 
regulating integrin activation and affinity regulation. Specifically, an initial 
‘physiological’ highly bent integrin can transform (via a switchblade-like opening) 
into an extended structure, and the ligand binding pocket and the αA domain are 
able, as a consequence, to modify their orientation [20]. The extended structure of 
the integrin results in the head groups becoming ‘open’, with the exposure of 
concealed epitopes (see later), and this lends itself to ligand binding. Electron 
microscopic images of recombinant integrins, in the presence of calcium (non-
supportive for ligand binding) and manganese (promotes ligand binding), confirmed 
predominantly bent and extended forms, respectively [46].  It is this change in the 
integrin conformation that allows strict control of ligand binding and subsequent 
adhesion. However, it is more than likely that this is a simplified view, with several 
intermediate steps and conformations involved (See Figure 10). 
The hypothesis for exposure of concealed epitopes was first proposed by 
Ginsberg et al, in 1988 [47]. The authors described the appearance of ligand-induced 
binding site (LIBS) epitopes, on αIIbβ3, in response to ligand or ligand-mimetic 
binding. However, intracellular cues can also expose neo-epitopes and therefore the 
term activation-dependent binding site probably is more appropriate [46]. These neo-
epitopes are recognised by a subset of anti-integrin monoclonal antibodies and are 
located primarily on the β-subunit at a series of sites along the whole length of the 
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polypeptide [46, 48]. Furthermore, an NMR structure of β2 integrin domains 
confirmed that epitopes become exposed when integrins are activated [49]. 
 
 
 
 
Figure 10 Proposed Quarternary Structural Rearrangements in Integrin 
Activation. Taken and adapted from Tagaki et al [46] 
. 
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1.2.2.3 Cation-Dependent Integrin Regulation 
All integrins bind their ligands in a divalent cation-dependent manner with 
manganese and magnesium generally promoting binding, and calcium having the 
opposite effect [50]. Each integrin heterodimer contains several divalent cation-
binding sites of relatively low affinity and the bound cations exert profound effects 
on integrin function [17]. Additionally, the presence of divalent cations can maintain 
the integrity, and form the interface, of the ligand binding pocket: The αA(when 
present) and βA-domains of integrins are intricately involved with the β-propeller 
fold (of the α subunit) to form the ligand binding pocket [24]. Lee et al [51] 
demonstrated a magnesium / manganese co-ordination site on the surface of the αA-
domain, which plays an important role in protein ligand binding. The authors termed 
this co-ordination site - ‘the metal ion-dependent adhesion site’ (MIDAS). 
Disruption of the MIDAS, using mutagenesis experiments, reduced protein ligand 
binding [51]. The authors also proposed that the β subunits of integrins contain a 
MIDAS motif, within their modified A domains. Subsequent crystal structure 
experiments on  αvβ3 have confirmed this MIDAS, but it also is flanked by two 
other cation-binding sites within the ligand-binding pocket of the βA-domain; termed 
ADMIDAS (adjacent to MIDAS) and LIMBS (ligand-induced metal-binding site) 
[24]. The MIDAS phenomenon explains the cation dependence of ligand binding, 
and thus cell adhesion. Therefore, collectively, divalent ions and cation binding sites 
can act as effectors, promoting ligand binding; as antagonists, inhibiting ligand 
binding; and as selectors, changing the ligand binding specificity.  
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In summary, integrins have been shown to be involved in bi-directional 
signalling and their affinity and avidity are under tight control. This strict modulation 
is necessary for gene transcription, cell differentiation, cell survival, cell proliferation 
and migration [52]. 
 
1.3 Integrins and Cancer 
Cancer primarily causes death through spread to different organs from that in 
which the primary tumour arose (metastasis). In order for tumours to metastasise and 
grow, neoplastic and endothelial cells must proliferate, invade and remodel their 
surrounding environment, migrate through surrounding tissues, disseminate, survive 
and differentiate [2, 53]. As cancer cells become metastatic, they develop altered 
affinity and avidity for their extracellular matrix (ECM). The phenotypic change 
initially is mediated by alterations in the expression of integrins, release of proteases 
that remodel the ECM and the deposition of new ECM molecules. These activate 
signalling cascades that regulate gene expression, cytoskeletal organisation, cell 
adhesion and cell survival. These cascades promote cancer cell passage through to 
the stroma, entrance into new tissues and survival within different 
microenvironments [26]. The following is a description of how integrins are vital to 
neoplastic cell growth, dissemination and survival:- 
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Figure 11 The Main Steps in the Formation of a Metastasis. Taken from Fidler 
IJ[53]. 
 
 
1.3.1 Proliferation 
 Proliferation without limits (‘immortalisation’) is necessary for tumours to 
have expansive growth in both primary and metastatic sites [2]. Mainiero et al have 
linked the integrin, α6β4, with the control of proliferation of basal keratinocytes [54]. 
The authors used primary human keratinocytes which adhere to laminin 5, via α6β4 
and α3β1 [55]. Mainiero and colleagues [54] used immunoblotting experiments to 
display that adherence of these keratinocytes, via the β4 subunit, resulted in tyrosine 
phosphorylation of Shc isoforms and subsequent recruitment of Grb2. 
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[
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P]orthophosphate labelling of (serum and phosphate starved) keratinocytes, 
consecutive immunoprecipitation of Ras, successive nucleotide elution and 
separation by Thin-Layer Chromatography (TLC) permitted phosphorimaging 
quantification of the guanine nucleotides bound to Ras [56]. Mainiero incorporated 
this ‘Ras-GTP loading assay’ and showed that α6β4-mediated cell adhesion causes 
activation of Ras, probably through Grb2’s association with the Ras-GTP exchange 
factor mSOS. Furthermore, the authors used immunoprecipitation and in vitro kinase 
assays to show that mitogen-activated protein kinase Erk is activated, via Ras and 
RhoA proteins, upon β4 ligation. Erk is known to regulate transcription from the Fos 
serum response element (SRE) by phosphorylation and cooperation with the Rho 
family proteins [57]. Luciferase assays demonstrated that ligation of α6β4 is required 
for optimal induction of Fos SRE-dependent transcription, in response to EGF. 
Furthermore, 5’-bromo-2’-deoxyuridine (BrdU) incorporation illustrated that ligation 
of α6β4 allows progression through G1 and entry into S phase, in keratinocytes 
which have been treated with EGF. Indeed, Mainiero et al suggested that ligation of 
α6β4 is required and sufficient to promote keratinocyte proliferation, in response to 
laminin 5 [54]. 
 As well as direct transcriptional control, integrins can complex and cross-talk 
with other receptors to control proliferation. The collaborative signalling between 
ErbB-2 and the β4 subunit, and its proliferative and invasive advantages to 
transformed cells, already has been mentioned above [36]. 
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1.3.2 Invasion 
The transition from a benign to an invasive cell is driven by a discrete series 
of adhesive changes and the partial degradation and extensive remodelling of the 
local ECM. Integrins cooperate with various oncogenic signals to promote the many 
phases of this process [16]. 
Cancer cells can assume a more invasive and migratory phenotype by 
modulating their adhesive capacity and intracellular signalling activities by altering 
their integrin expression and affinity profiles:- 
Neoplastic cells can undergo dramatic alterations in levels of integrin 
expression for ECM substrates. Some integrins are either overexpressed or no longer 
expressed whereas others become phosphorylated, affecting their cytoskeletal and 
extracellular ligand binding properties [23]. The changes in integrin expression and 
the cell surface distribution seem to be specific to the tumour cell type. These 
changes in certain types of integrin levels aim to promote neoplastic cell 
proliferation, migration and cell survival [16]. It has been shown that inducing 
expression of the αv integrin subunit in a melanoma cell line increases its 
tumourigenicity [58]. Furthermore, Shaw et al demonstrated that neo-expression of 
α6β4 increases the invasiveness of MDA-MB-435 cells through Matrigel, in standard 
chemoinvasion assays [59]. Using experimental combinations of 
immunoprecipitation, kinase assays, a dominant-negative PI3K subunit and a PI3K 
inhibitor, the authors proposed that the increased invasiveness is dependent on PI3K 
signalling [59]. 
In addition, there is increasing evidence indicating that dysregulated joint 
integrin–RTK signalling contributes to the disruption of cell–cell adhesion and the 
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promotion of invasion, in cancer cells [16]. Numerous studies have demonstrated 
that the progression to invasive carcinoma involves loss of function of adhesion 
molecules involved in maintenance of the epithelial phenotype, namely, cadherins 
[60, 61] and catenins [62-64]. Classic cadherins, such as E-cadherin, have a key role 
in epithelial cell–cell adhesion. E-cadherin has been shown to be modulated by 
integrin-RTK signalling, through transcriptional repression (via SNAIL/SLUG 
transcriptional factors) and endocytosis of receptor complexes [65]. 
 
 
Matrix Degradation And Remodelling 
Tumour invasion requires partial degradation of the ECM at the invasion 
front. In particular, neoplastic cells have to induce local degradation of basement 
membranes, because these structures are not permeable to cells under physiological 
conditions [16]. However, ECM degradation must occur in a controlled fashion. 
Sufficient ECM must remain, after degradation, so that neoplastic cells still have the 
ability to adhere and generate the traction required for migration. 
 Integrins are involved in the regulation of proteolytic enzymes that degrade 
the basement membrane and thereby facilitate invasion [16, 26]. The matrix 
metalloproteinases (MMPs) are the main proteases that are involved in remodelling 
of the ECM [66]. Stromal cells close to the invasive front of metastatic breast 
tumours have elevated levels of matrix metalloproteinase activity compared with 
non-malignant control cells [67]. MMPs are secreted as inactive zymogens (pro-
MMPs) that require proteolytic activation by extracellular proteases. This mechanism 
of activation permits precise regulation and localisation of MMPs, and integrins have 
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been shown to play a central role: MMP-2 is activated on the cell surface by a 
multimeric complex that is composed of MMP-2, membrane type 1 MMP (MT1-
MMP) and tissue inhibitor of metalloproteinase 2 (TIMP2) [26, 66]. Zymography, 
competitive adhesion assays and immunohistochemical co-localisation experiments, 
on melanoma and glioma cell lines, indicate that this multimeric MMP-activating 
complex also includes the integrin αvβ3 [68, 69]. MMP-2 initially binds to TIMP2, 
which sequentially combines with the transmembrane metalloproteinase MT1-MMP. 
Following this, MT1-MMP cleaves the amino-terminal pro-domain of MMP-2, 
resulting in an intermediate, partially active form. This intermediate form is capable 
of binding integrin αvβ3, at the leading edge of the cell surface. This interaction fully 
activates MMP-2 and thereby localises its proteolytic activity to the invasive front of 
cells [26]. 
 I have mentioned already that ECM degradation must occur in a controlled 
fashion. ECM degradation must allow passage of the neoplastic cell through 
impermeable basement membranes to promote migration; but excessive ECM 
degradation would reduce potential cellular traction and inhibit migration [70]. A 
negative-feedback regulation of ECM degradation has been proposed in the 
regulation of integrin and protease interactions [26, 71]. An auto-proteolytic 
fragment of MMP2 (haemopexin-like domain), termed PEX, is one such regulatory 
mechanism. PEX can compete with MMP-2 for αvβ3 combination and thereby block 
full protease activation [72]. In addition to these effects upon the motile behaviour of 
tumour cells it also is recognised that growth factors, sequestered in the extracellular 
matrix, are liberated by MMP activity leading to increased cancer cell proliferation; 
an aid to invasive activity [73]. 
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 Therefore, αvβ3’s role in tumour invasion and metastasis seems partly to 
involve MMP-2 control and might explain the αvβ3-facilitated transition from radial 
to vertical phase of growth, in melanomas [74]. This vertical growth assists in 
penetration of the basement membrane and thus invasion of the underlying stroma. 
αvβ3 also associates with the urokinase plasminogen activator (uPA) receptor, uPAR 
[75]. Activated uPA converts plasminogen to plasmin. Plasmin, a broad-spectrum 
protease, is able to degrade ECM components both directly and through the 
activation of MMPs. Therefore, this integrin association provides a further 
mechanism to recruit proteolytic activity to the leading edge of migrating cancer 
cells (see Figure 12). 
   
 
 
 
Figure 12 Integrins, Matrix Degradation And Remodelling. Taken from Guo and  
Giancotti [16] 
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Integrins also regulate matrix degradation and MMP expression through 
signalling mechanisms (i.e. not just by physical association and thus recruitment of 
protease to the cell surface). As described in the Outside-In Signalling section, 
integrins can signal through FAK and transient recruitment of Src-family protein 
tyrosine kinases. Hauck et al examined FAK signalling outcomes by performing 
experiments on Rous sarcoma virus-transformed NIH-3T3 fibroblasts and 
transfecting FRNK (a dominant negative protein of FAK) [76]. The authors used 
immunoprecipitation, in vitro kinase assays and semi-quantitative RT-PCR to show 
that FAK-mediated activation of ERK2 and JNK enhances gene transcription of 
MMP2 and MMP9. Zymography confirmed increased secretion of MMP2 and 
MMP9, as a result of FAK signalling. Hauck hypothesised that this is an important 
mechanism for integrins to enhance tumour invasion and metastasis, as seen in their 
in vitro invasion assays and in vivo models [76]. 
 Furthermore, remodelling the ECM exposes new cell-binding sites, which 
promotes the migration of tumour cells. For example, cleavage of collagen IV by 
MMPs exposes a cryptic αvβ3-binding site, which is important for the migration of 
αvβ3-expressing endothelial cells and impacts on tumour angiogenesis [16]. 
Therefore, αvβ3-aided activation of MMP2 encourages local matrix degradation and 
invasion, but also contributes to the generation of new αvβ3-binding sites, and thus 
promotes migration. 
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1.3.3 Migration 
Cell migration is a complex multi-step process that requires the continuous, 
coordinated formation and disassembly of adhesions [77]. Integrin-dependent 
modifications of the actin cytoskeleton are necessary for cell migration, via the Rho-
family GTPases [78]. 
Initially, cells project filopodia. A filopodium is a long, thin membrane 
projection at the leading edge of the cell in the direction of movement. They are 
composed of F-actin bundles and merge into lamellipodia. Actin polymerisation 
(through Rac) induces extension of filopodia / lamellipodia and this process is 
facilitated by a localised decrease in membrane tension [79]. Lamellipodia attach to 
the ECM and simultaneously the cells break existing ECM contacts at their trailing 
edge. 
The interaction of integrins with the extracellular matrix stabilises this 
attachment / adhesion, by recruiting FAK signalling, phosphorylation of cytoskeletal 
proteins and alterations in gene expression [77]. It has become evident that cell 
direction and motility are dependent on integrin-mediated Cdc42, ERK/MAPK and 
JNK signalling [80].  
At the rear of migrating cells, the release of adhesions results in retraction of 
the cell (‘rear retraction’) and a net movement of the cell forward. Rho stimulates the 
congregation of actin-myosin fibres, and their subsequent contraction, which 
contributes to rear retraction [16, 78]. Retraction of the trailing cell edge is 
dependent on the adhesive environment and occurs either by intracellular fracture of 
cytoskeleton-integrin bonds in highly adhesive environments (during slow 
migration), or by simple extracellular dissociation of integrin–extracellular matrix 
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linkages, in less adhesive environments (during fast migration) [77, 81, 82]. 
Therefore, integrins carry out essential roles during cell migration (normal and 
neoplastic). 
Alterations in the expression of integrins also can promote migration. Certain 
neoplastic cells lose the integrins that secure their adhesion to the basement 
membrane and maintain or overexpress the integrins that foster their migration. 
Alternatively, other integrins become phosphorylated, affecting their cytoskeletal and 
extracellular ligand binding properties [23]. As mentioned already, the changes in 
integrin expression and the alteration in their cell surface distribution seem to be 
specific to the tumour cell type.  
In addition, there is evidence indicating that integrin receptors associate with 
other receptors to promote migration, through collaborative signalling. Both EGF 
[83] and Met [84] receptors induce tyrosine phosphorylation of the β4 cytoplasmic 
tail. This action converts α6β4 from a pro-adhesive to a pro-migratory receptor, 
through disassembly of hemidesmosomes, activation of kinase signalling cascades 
and recruitment of adaptor molecules e.g. PI3K and  SHC [16, 84]. 
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Figure 13 Cell Migration, Integrins and Rho-family GTPases. Taken and adapted 
from Raftopoulou and Hall [78].  
 
Furthermore, neoplastic cells can increase their migratory potential, through 
altering their adhesiveness, in a manner which increases the affinity of their 
integrins. Selective blocking of ‘high-affinity αvβ3’, for example, has been reported 
to impair the directed migration of endothelial cells [85]. 
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1.3.4 Dissemination 
The process of metastasis involves cells breaking away from their primary tumours 
in the tissue of origin. It necessitates all of the processes described above and 
therefore is likely to involve dependence on integrin manipulation. Furthermore, 
metastatic cells must induce angiogenesis to escape the limits that passive diffusion 
of nutrients and oxygen impose on expansive tumour growth [86]. The vicious cycle 
is completed by the fact that neovascularisation provides a further gateway for 
tumour cells to enter the circulation and ‘re-seed’. Integrins have a well-documented 
role in tumour angiogenesis [87]. It seems that integrins are targets of both 
angiogenic activators (e.g. VEGF) and inhibitors (e.g. endostatin). The combination 
of integrins and these factors influences angiogenesis. However, the extensive 
literature research in integrins and angiogenesis [88] or lymphangiogenesis is beyond 
the scope of this review. Instead, this section will continue with survival and homing 
mechanisms during dissemination. Tumour cells are subjected to tremendous shear 
forces on entering a turbulent vascular system. Integrins and other adhesion 
molecules permit adhesion of neoplastic cells to leukocytes and platelets [89]. This 
potentially protects the tumour cells from the shear forces and fashions small tumour 
emboli, promoting dissemination. 
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Figure 14 Homing of Neoplastic cells to Target Organs. Taken from Guo and 
Giancotti [16]. 
 
Most cancers have a characteristic dissemination pattern, with a predilection to 
metastasise to certain organs [90]. For instance, breast cancer tends to have a 
predilection to metastasise to the liver, bone and lungs; and rarely to the kidneys and 
spleen, despite the good blood supply of these organs. Stephen Paget first proposed 
the existence of this non-random pattern to metastasis and introduced his ‘seed and 
soil’ theory, in 1889 [91]. That is, some organs provide a more fertile milieu, 
compared to others, for the growth of certain metastases.  This suggests that 
metastasis depends on cross-talk between selected cancer cells (the ‘seeds’) and 
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specific organ microenvironments (the ‘soil’). This is in direct contrast to James 
Ewing’s theory, which suggested that dissemination occurs by purely anatomic 
pathways and mechanical mechanisms e.g. calibre of capillaries [92]. It was only in 
the 1980s, that Paget’s original theory was proven. Ian Hart and Isaiah Fidler used a 
C57BL/6 mouse model, in which kidneys, ovaries and 1mm
3
 lung fragments were 
transplanted into the quadriceps femoris muscle of syngeneic mice. After a 2- to 3-
week recovery period (to allow wound repair and organ vascularisation), these mice 
bearing transplants had intravenous injections of 5 x 10
4
 viable B16 melanoma cells. 
Three weeks following injection, the mice were killed and autopsied. Metastases in 
the in situ organs and grafted organs were determined under a dissecting microscope. 
Furthermore, metastases in the grafted organ sites were confirmed histologically. 
Results revealed that metastatic lesions developed in lungs and ovaries and this was 
reflected in the grafts of pulmonary or ovarian tissue, whereas they failed to develop 
in control grafts of similarly implanted renal tissue or at the site of a surgical trauma. 
Since renal grafts appeared to survive and vascularise as well as lung or ovarian 
grafts, it seemed that there was a distinct organ preference for tumour growth [93]. 
The authors also illustrated that radiolabelled tumour cells may indeed reach and be 
arrested in the microvasculature of many organs and were equally likely to be 
trapped in the kidney tissue as in either of the other transplants. Nevertheless, tumour 
cell proliferation into visible metastases still only occurred in some but not all organs 
[93, 94]. This indicates that sites of metastasis are determined not solely by the 
characteristics of the neoplastic cells but also by the microenvironment of the host 
tissue.  
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‘Homing’ to target organs requires adhesion within the vasculature of the arresting 
tissue. This adhesion will need to arrest the tumour cell during blood flow, and may 
protect cells from its shear forces, and permit extravasation. Integrins, and their 
adhesive capacity, have been implicated in this cell arrest. The site of tumour cell 
metastasis is influenced by the composition of the extracellular matrix (ECM) and 
the integrins expressed by the tumour cells [95] (see Figure 14). Furthermore, the 
complex of tumour cells, leukocytes or platelets provides additional adhesive 
mechanisms. That is, the integrins expressed on leukocytes and platelets can home 
the complexed tumour cell embolus to the target organ. Therefore, the various 
activated integrins expressed on the tumour cell complex will have a predilection to 
bind to certain ligands in the extracellular matrix. The distribution of these 
extracellular ligands, in the capillary beds of visceral organs, may help account for 
the characteristic metastatic pattern of certain cancers.  
 
1.3.5 Survival mechanisms during Invasion and Metastasis 
Neoplastic cells require various survival mechanisms to promote continued 
existence within the different microenvironments of metastatic sites. Lack of 
extracellular adhesion (a feature during parts of the metastatic cascade) induces 
normal cells to undergo anoikis. This anchorage dependence survival of cells, and its 
reliance on various integrin-related signalling pathways, has already been mentioned. 
Cells that have undergone neoplastic transformation are much less dependent on 
ECM adhesion for their survival and proliferation [34]. One mechanism of anchorage 
independence may lie with the formation of constitutive complexes between 
integrins and RTKs. Trusolino et al have reported that Met forms a selective 
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complex with the α6β4 integrin, using immunoprecipitation, immunoblotting and 
immuno-histochemistry studies to establish the existence of this interaction [84].  
Upon HGF stimulation of Met, α6β4 is tyrosine phosphorylated and Shc and PI3K 
recruitment occurs. This signalling recruitment provides an additional signalling 
platform that amplifies HGF-triggered activation of Ras- and PI3K-dependent 
pathways. Interestingly, the authors also looked at the necessity for integrin ligation 
to provide HGF-potentiation. A β4 mutant subunit was produced, which was devoid 
of most of the normal extracellular domain and thus incapable of binding laminins. 
Remarkably, HGF activation could still be potentiated, in the presence of the mutant 
subunit, as efficiently and durably as with wild-type β4. The fact that α6β4 signals 
are independent of cell adhesion but contingent on tyrosine kinase activation 
suggests that neoplastic cells might evade matrix dependence by turning integrins 
from adhesive devices into non-adhesive integrators of oncogenic signalling 
pathways [84].  
Nevertheless, despite their relative anchorage independence, neoplastic cells 
still benefit from integrin signals, during tumourigenesis. Integrin binding to ECM 
ligands initiates several pro-survival mechanisms to prevent apoptosis. Multiple 
mechanisms have been proposed which include FAK signalling mediated inhibition 
of caspase-8 [96], fibronectin binding to α5β1 with resultant bcl-2 up-regulation [97], 
or NFκβ activation after laminin-induced ligation of β4 integrin [98]. These studies 
reveal that ligation of integrins can protect against exogenous apoptotic insults in 
cancer cells that are already capable of anchorage-independent survival.  
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1.4 αvβ6 
In this study I have chosen to concentrate on only one integrin associated 
with tumour progression: v6. The gene for the v subunit is coded at chromosome 
2q31-q32 and the protein is 150kDa [99]. The 6 subunit was first identified in 
cultured epithelial cells as part of the v6 heterodimer [100] and its human gene 
regional localisation is chromosome 2q24-q31 (see Figure 15). The 6 subunit is 
100 – 110 kDa [99] and its cytoplasmic domain is required for linking integrins to 
the cytoskeleton [12]. 
 
 
 
Figure 15 Genomic loci of the v6 subunits. Taken and adapted from 
http://www.genecards.org. 
 
 
1.4.1 Transcriptional Regulation of αvβ6  
Bates et al first described Ets-1 as a transcription regulator of the β6 integrin, 
using luciferase assays [101]. The authors identified 4 potential consensus Ets-
binding sites in the first 1 kb of the human β6 promoter (see Figure 16). However, 
gel shift assays and site-directed mutagenesis revealed that Ets-1 only bound strongly 
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to site 1. Furthermore, Scott et al used Tumour Necrosis Factor-α-deficient (TNFα-/-
) mice to demonstrate that αvβ6 is upregulated by TNFα [102]. A GEArrayTM 
Original series kit was incorporated to expression profile the TNFα-/- keratinocytes 
and compare them to wild-type keratinocytes. TNFα-/- keratinocytes expressed 
significantly less αvβ6 mRNA than wild-type keratinocytes, and this correlated with 
reduced β6 protein as assessed by immunoblot. Scott showed that administration of 
exogenous TNFα to TNFα-/- keratinocytes upregulated αvβ6 protein, in a dose-
dependent manner [102]. In an earlier paper, Bates and Mercurio reported that 
Transforming Growth Factor-β worked synergistically with TNFα to increase levels 
of αvβ6 [103]. It has been suggested that both these cytokines work via the Ets-1 
transcription factor [104], however further research is required before confirmation 
of this relationship is achieved. 
 
 
Figure 16 Schematic of the human integrin β6 promoter. The transcription start 
site (TSS) and translation start site (ATG) are indicated. Putative Ets-binding sites 
are shown (triangles), and the 4 corresponding sequences are listed, including 
location detail. The consensus DNA-binding sequence (GGAA) is shown in bold. 
Taken from Bates et al [101]. 
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Azare et al used Affymetrix analysis, quantitative PCR, luciferase assays and 
short hairpin RNA experiments to show that signal transducer and activator of 
transcription 3 (STAT3) mediates transcriptional regulation of β6 [105]. The authors 
examined the β6 promoter and discovered numerous STAT3 binding recognition 
sites (see Figure 17) and confirmed this with cross-linking immunoprecipitation 
assays. Indeed, Azare established upregulated β6 protein translation, as a result of 
this increased transcription, using immunoblotting, flow-cytometric and immuno-
histochemical experiments. Functionally, the resultant increased β6 protein 
expression led to increased cell migration and anchorage independent growth [105]. 
Interestingly, the same paper revealed that STAT3 also transcriptionally regulates 
fibronectin and Tenascin C (known v6 ligands, described in the next section). 
 
 
Figure 17 Schematic of the human integrin β6 promoter. Potential Stat3 binding 
sites are indicated as triangles; those marked by dark triangles are optimal (TTN5AA) 
and those marked by light triangles have either a TTN4AA or a TTN6AA sequence or 
an AT-rich region at the N positions on the β6 promoter. Arrows indicate the 
directions of transcription, and nucleotide positions are shown below the diagram. 
Taken from Azare et al [105]. 
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1.4.2 v6 Ligands 
v6 binds to a number of ECM proteins, including fibronectin, tenascin-C, 
vitronectin, all via their tripeptide recognition sequence arginine-glycine-aspartic 
acid (RGD). In addition, TGF- LAP isoforms 1 [106] and 3 [107] are ligands for 
v6 and binding can lead to latent TGF- activation. Furthermore, v6 also 
mediates virus binding, internalisation and, thus, infection of foot-and-mouth 
disease, via its RGD-containing capsid protein [108]. The v6 ligands will be 
described briefly in the following section:-  
 
1.4.2.1 Transforming Growth Factor- β (TGF-β) 
In mammals, there are three isoforms of TGF- β; TGF- β 1, 2 and 3, each of 
which is the product of a separate gene. The TGF-β cytokine family is involved in 
the regulation of cell proliferation, differentiation, migration, survival, extracellular 
matrix synthesis, angiogenesis and apoptosis [109]. In normal circumstances, TGF- β 
is anti-mitogenic and thereby inhibits epithelial cell proliferation with induction of 
extracellular matrix component production. Excessive TGF-β activity will lead to 
exaggerated scar formation / granulation and subsequent loss of function [110]. 
Conversely, reduced TGF- β activity will lead to increased epithelial cell 
proliferation, and this may include cancerous cells. TGF-β has been implicated in 
normal embryonal development, tissue repair and modulation of the immune system. 
Therefore, the location and concentration of TGF- β needs to be controlled tightly for 
these processes to function appropriately.  
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One mechanism involved in the rigid control of TGF-β is that the isoforms 
initially are secreted in an inactive or latent form [111]. The latent form arises from 
their synthesis in union with latency associated peptide (LAP). This product is 
cleaved in the endoplasmic reticulum (by the endoprotease furin) and assembled into 
a double homodimer (non-covalent) association of TGF-β with LAP, termed the 
small latent complex (SLC). In this latent form, TGF-β cannot interact with its 
receptors. However, LAP enhances proper folding and secretion of TGF-β [112]. If 
LAP is disulphide linked to another protein family, latent TGF-β binding proteins 
(LTBPs), the resulting complex is termed the large latent complex (LLC). The 
LTBPs are usually directly cross-linked to fibronectin in the extracellular matrix (see 
Figure 18). Thus, this protein targets latent TGF-β to the extracellular matrix and 
thereby can exert a degree of control on its location. Investigators have shown that 
latent TGF-β can be released from the matrix by limited proteolysis of LTBP, by 
proteases such as thrombin, mast cell chymase, neutrophil elastase and plasmin 
[111].  These molecules suggest the processes of matrix remodelling or inflammation 
are indirectly linked with TGF-β activation. Structural features of LAP and/or LTBP 
allow the latent complex to associate with the cell surface and potentially become 
activated – ‘latent activation of TGF-β’. Two mechanisms of TGF-β activation have 
been shown definitively to be important in vivo: interaction with the secreted protein 
thrombospondin 1 [113] and activation by the integrin αvβ6 [106]. LAP is a high 
affinity ligand for αvβ6, but requires an intact cytoskeleton for TGF- β activation. 
However, because mice lacking both thrombospondin 1 and αvβ6 are born alive and 
manifest phenotypes considerably more mild than the phenotypes of mice 
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homozygous for null mutations of TGF-β 1, 2, or 3, it is clear that additional 
mechanisms of TGF-β activation must play important roles in vivo [114]. 
 
 
 
 
Figure 18 Schematic representation of organisation of latent complexes of 
transforming growth factor-β (TGF- β). Taken and adapted from Sheppard D 
[115]. 
 
 
 
 70 
 
 
Once activated, all TGF-β isoforms have the ability to bind to transmembrane serine 
/ threonine kinase receptors (TβR) [116]. The binding initiates a cascade of cytosolic 
kinase phosphorylation and involves signal transduction though the activation of the 
SMAD family of proteins. In mammalian cells, SMAD4 forms complexes with 
SMAD2 and SMAD3 after activation with TGF-β [117]. In the resting cell, SMADs 
are localised in the cytoplasm. Stimulation with TGF-β leads to translocation of 
SMADs to the nucleus, binding (indirectly or directly) to DNA and thus can affect 
transcription of various genes [118]. However, SMAD6 and SMAD7 function as 
inhibitors of TGF-β – ‘Inhibitory SMADs’. They bind to TβRs and interfere with the 
phosphorylation of the pathway-restricted SMADs (see Figure 19). Consequently, 
active heteromeric SMAD complexes are not formed. Inhibitory SMADs may act as 
autoregulatory negative-feedback signals in the signal transduction of the TGF- β 
family. 
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Figure 19 SMAD Protein and Signalling. Agonistic and antagonistic SMAD 
proteins in TGF-β signalling. a, A hypothetical signal transduction pathway for TGF-
β. TGF-β binding leads to the assembly of a heterotetrameric receptor complex in 
which the type II receptor phosphorylates and activates the type I receptor. Pathway 
restricted SMADs (Smad2 and Smad3), which may be anchored in the cytoplasm in 
homotrimeric forms, are phosphorylated, which leads to heteromerisation with 
Smad4, a common-mediator SMAD. The hetero-oligomeric complex is then 
translocated to the nucleus, where it binds, directly or in complex with other 
component(s), to DNA and affects transcription of specific genes. Note that it is not 
known if the hetero-oligomer between Smad2, Smad3 and Smad4 is a hexamer or 
has another stoichiometry. b, Inhibitory SMADs (Smad6 and Smad7) bind to the 
receptors, and prevent the phosphorylation and signalling activity of pathway-
restricted SMADs. Whether inhibitory SMADs occur as monomers or multimers is 
not known. Taken from Heldin, Miyazono and ten Dijke [109]. 
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1.4.2.2 Foot-And-Mouth Disease Virus (FMDV) 
Foot-And-Mouth Disease Virus is a member of the Aphthovirus genus in the 
Picornaviridae family. It is a highly contagious, and sometimes fatal, viral disease 
which commonly affects cloven-hoofed animals [119]. Foot-and-mouth virus has 
been shown to infect cells, in culture, via αvβ1 [120], αvβ3 [121], αvβ6 [108] and 
αvβ8 [122]. However, Monaghan et al provided evidence that αvβ6 is the major 
FMDV receptor, in vivo [123]. Berryman et al showed that αvβ6-mediated infection 
of SW480 cells by FMDV is dependent on an RGD interaction [108], a clathrin-
dependent endocytosis and active endosomal acidification [124]. 
 
1.4.2.3 Fibronectin 
Fibronectin is a high-molecular-weight glycoprotein and is a major component of the 
ECM. It binds cell surfaces (via integrins) and various ECM compounds including 
collagen, fibrin, and heparan sulphate [125]. Fibronectin has several isoforms and 
has been implicated in cell adhesion, cell migration [99], opsonisation, wound 
healing, and maintenance of cell shape. Fibronectin is an important ligand for αvβ6, 
and therefore their interaction can influence a wide variety of essential functions. 
Busk et al described the formation of ‘focal contacts’, upon interaction of v6 with 
fibronectin [99]. The authors performed immunoprecipitation and affinity 
chromatography on pancreatic cancer cell line lysates and showed that fibronectin 
binding was cation-dependent.  
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1.4.2.4 Vitronectin 
Vitronectin is an extracellular glycoprotein and is a member of the pexin family. 
Vitronectin is found abundantly in serum and the extracellular matrix; promoting cell 
adhesion and spreading, inhibiting the membrane-damaging effect of the terminal 
cytolytic complement pathway, and binding to several serpin serine protease 
inhibitors [126]. These functions have implicated vitronectin to be important in 
homeostasis regulation and tumourigenesis. Vitronectin contains an RGD sequence 
and is thus recognized by certain members of the integrin family. Huang et al 
initially described keratinocyte migration to vitronectin [127]. Huang utilized 
keratinocytes expressing a null mutation in the subunit, ‘6-/-‘. Both adhesion 
and migration of these keratinocytes to vitronectin-coated membranes were reduced 
dramatically, as compared to cells from wild-type mice. Furthermore, adhesion and 
migration of keratinocytes from wild-type mice was decreased to the same extent, 
when in the presence of antibody 10D5 (function-blocking monoclonal to v6). 
Their data suggest that v6 plays a critical role in keratinocyte adhesion and 
migration on vitronectin, probably though the protein kinase C pathway [127]. 
 
1.4.2.5 Tenascin-C 
Tenascins are a highly conserved family of ECM glycoproteins, in vertebrate 
organisms [128]. Tenascin-C is one of at least five members of the tenascin family, 
and currently is the best understood [129]. Tenascin-C is detectable only in small 
amounts in normal adult tissues, but is abundantly detected during embryogenesis 
and in tissue re-modelling processes (e.g. wound healing, neovascularisation and 
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tumourigenesis) [129]. Tenascin-C has been implicated in foetal lung development 
[129], the guidance of migrating neurons during embryogenesis, synaptic plasticity 
as well as neuronal regeneration [128, 130]. Many of these proposed functions of 
tenascin-C may be via its modulation of cellular adhesion and migration. Indeed, 
Prieto et al demonstrated that tenascin-C is able to mediate cellular attachment 
through αvβ6, using monoclonal antibodies and RGD-sequence-containing peptide 
experiments [131]. 
 
1.5 αvβ6 and Cancer 
The epithelial-specific integrin αvβ6 is not usually detectable on normal, 
human, adult tissue but is upregulated during inflammation, development and on 
many different types of carcinoma [101, 132-138].  Indeed, Breuss et al reported that 
expression is strongest at the invasive edge of such expressing cancers [134]. Data 
from this and other laboratories have shown αvβ6 promotes carcinoma migration and 
invasion in vitro and in vivo.  This may explain the data of Bates and colleagues 
[101] who reported that the hazard of dying was 60% higher in colon cancer patients 
with strong expression of αvβ6. Together these data could suggest that αvβ6 actively 
promotes cancer progression, possibly explaining the poor prognosis associated with 
expression.  
Overexpression of αvβ6 has been reported in a broad spectrum of epithelial 
cancers. Oral, cutaneous, lung, breast, ovarian, pancreatic and other gastrointestinal 
cancers have all been associated with increased αvβ6 expression (see Table 2, page 
75).  
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Carcinoma Reference 
Numbers of 
Carcinomas 
% of 
Positive 
Tumours 
Evidence Comment 
O
ra
l 
S
q
u
a
m
o
u
s
 C
e
ll
 C
a
n
c
e
r 
Breuss et 
al (1995) 
 
30 
 
90 
 
ISH 
Absent αvβ6 
expression in 
normal oral mucosa 
from same patients 
 
Jones et al 
(1997) 
 
 
17 
 
100 
 
IHC 
 
 
Hamidi et 
al (2000) 
 
5 80 IHC 
41% expression in 
oral leukoplakia 
peri-tumoural 
dysplasia also 
αvβ6 +ve 
 
Impola et al 
(2004) 
 
11 100 ISH 
Expression 
maintained in LN 
mets 
Regezi et 
al (2002) 
 
40 
 
100 
 
IHC 
αvβ6 expression 
colocalised with 
TN-C peri-tumoural 
dysplasia also αvβ6 
+ve 
Colon 
 
Bates et al 
(2005) 
 
488 37 IHC 
Poor prognostic 
marker, avb6 
expression 
maintained in mets 
Pancreas 
 
Sipos et al 
(2004) 
 
34 100 IHC 
Well differentiated 
tumours expressed 
more than poorly 
differentiated 
Gastric 
 
Kawashima 
et al (2003) 
 
38 47 
 
IHC , 
RT-PCR 
94% αvβ6 +ve 
carcinomas had LN 
mets 
NSCLC 
 
Smythe et 
al (1995) 
 
51 50 IHC 
αvβ6 +ve 
carcinomas well-
differentiate and 
node negative;  
? Good 
prognostic marker 
Breast 
 
Arihiro et 
al. (2000) 
 
90 18 IHC, WB 
No grade 1 
tumours αvβ6 +ve 
Ovary 
 
Ahmed et 
al (2002) 
 
45 
 
100 
 
IHC 
 
Staining correlated 
with grade; Benign 
mucinous tumours 
also αvβ6 +ve 
 
Table 2 αvβ6 expression in carcinomas. Adapted from [104]. 
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αvβ6 seems to be implicated in playing a key role in all parts of the metastatic 
cascade:- 
 
1.5.1 Proliferation 
Agrez et al revealed evidence that αvβ6 enhances the proliferative capacity of cancer 
cells [139]. The human colon carcinoma cell line, SW480, normally does not express 
the β6 subunit. The authors transfected the cell line with cDNA encoding for wild-
type or truncated forms of β6, or the expression plasmid only.  Cells were plated onto 
collagen-coated, three-dimensional culture systems with thymidine incorporation 
utilised as a means of quantifying proliferation at pre-arranged time-points. Results 
revealed that αvβ6 augments cell proliferation; at least when recipient cells were 
cultured in three dimensional collagen gels. Furthermore, this promotion of 
proliferation correlated with the presence of the unique 11 amino acid carboxy-
terminal extension of the β6 tail [139]. Agrez et al showed that the proliferative 
advantage of wild-type β6-transfected cells was not simply a function of clonal 
variation, but related directly to the expression of this integrin sub-unit.   
 
1.5.2 Invasion 
Thomas et al [140] created a panel of squamous cell carcinoma (SCC) cell lines 
expressing various levels of αvβ6. Cells were resuspended in α-MEM and added to 
Matrigel-coated Transwell filters. Keratinocyte Growth Medium (KGM) was placed 
in the lower chamber and invasion measured after 72 hours. Results indicated that 
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increased expression of αvβ6 in malignant keratinocytes promoted invasion towards 
fibronectin [140]. This increased invasion was not due to differences in growth rates 
of cells in Matrigel, which were similar for all the SCC cell lines. Furthermore, 
invasion by the high αvβ6-expressing cell lines could be reduced dramatically using 
anti-αv or anti-αvβ6 antibodies. 
The mechanisms for the increased invasion, seen with αvβ6-expressing 
cancer cell lines, involve increased protease secretion. 
 Thomas et al also demonstrated that increased expression of αvβ6, in the 
aforementioned panel of malignant keratinocytes, upregulates the type IV 
collagenases (MMP-9 and MMP-2), as shown by zymographic examination and 
ELISA [141].  Both MMP-9 and MMP-2 expression were reduced when high αvβ6-
expressing SCC lines were incubated with αv or αvβ6 blocking antibodies. 
Furthermore, high αvβ6-expressing SCC invasiveness could be reduced significantly 
by anti-MMP-9 antibody, suggesting that MMP-9-dependent activities were the main 
drivers of invasion. Additionally, indirect immunochemistry revealed that MMP-9 
localises to the terminal aspect of αvβ6-positive filopodia, suggesting a cellular 
mechanism for targeting MMP activity. 
  Similarly, Niu et al performed gelatin zymography experiments on SW480 
colon carcinoma cells transfected with wild-type or truncated forms of β6, or the 
expression plasmid only [142]. The authors reported that neo-expression of αvβ6 in 
the cell line induces MMP (gelatinase B) secretion through the C-terminal 
cytoplasmic extension unique to the β6 integrin subunit, and that this ligand-
independent event involves activation of the protein-kinase-C pathway. Furthermore, 
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this effect could not simply be explained by the relative amounts of αvβ6 present on 
cells expressing full-length β6 compared with truncated β6 transfectants [142].  
Furthermore, Li et al studied a different β6-transfected SCC line [143]. 
Immunoprecipitation and in vitro kinase assays were performed. Upon fibronectin 
stimulation, Fyn (a member of Src family kinases) was activated and formed a 
complex with FAK and β6. A cascade of activation occurred involving FAK and the 
Shc adaptor protein. Thus Shc recruited the Grb2-mSOS complex and thereby 
activated the Raf-MAPK pathway. Luciferase assays revealed that β6-mediated Fyn 
signalling up-regulates the expression of the MMP-3 gene, via MAPK [143].   
 
1.5.3 Migration 
 Huang et al apparently demonstrated a critical role for αvβ6 in cell migration 
(comparing murine wild-type keratinocytes with mouse β6-/- keratinocytes) on both 
fibronectin and vitronectin [127]. However, Thomas et al looked specifically at 
carcinoma cell migration and αvβ6 expression [140]. Haptotactic SCC migration 
assays were performed using fibronectin-coated Transwell filters. The results 
indicated that increased expression of αvβ6 promoted migration towards fibronectin. 
Again, for these cell lines, differing proliferation rates did not seem to confound the 
results. Furthermore, antibodies against αvβ6 could significantly inhibit migration 
towards fibronectin. This implies that high αvβ6 expression is associated with a more 
migratory phenotype. 
Li et al’s experiments (described above [143]) also demonstrated increased 
SCC migration towards fibronectin, in vitro. The authors showed that Fyn activation, 
by β6 adhesion to fibronectin, correlated with this increased migration [143]. 
 79 
1.5.4 Dissemination 
Mutations in the various TGF-β signalling components have been implicated 
in the spread of cancer. TGF-β has a bi-phasic role in tumourigenesis. At early 
stages, when cells still respond to its anti-mitogenic effect, TGF-β may act as a 
tumour suppressor. However, during malignant progression, when cells acquire 
insensitivity to growth inhibition by TGF-β, it may function as a tumour promoter by 
stimulation of angiogenesis, immunosuppression and synthesis of extracellular 
matrix, which provides an appropriate microenvironment for rapid tumour growth 
and metastasis [144].  
The transition of epithelia into mesenchyme occurs during embryogenesis, 
tissue remodelling and wound repair by a process known as the epithelial-
mesenchymal transition (EMT) [145]. This multi-step process has also been 
hypothesised to occur during neoplasia and tumour progression (see Figure 20) 
[146]. The mechanism involves loss of cell-to-cell junctions and reorganisation of 
the cytoskeleton, which together result in the loss of apical-basal cell polarity and the 
acquisition of spindle-shaped morphology [146]. Accordingly, it is associated with a 
decrease in epithelial-specific gene expression, notably E-cadherin, and the accrual 
of a mesenchymal-specific gene expression. The transition permits epithelial 
neoplastic cells to acquire a more migratory and aggressive phenotype. Eventually 
the mesenchymal cells may regain their epithelial phenotype, allowing settlement at 
a secondary site, through a mesenchyme-to-epithelium transition (MET). TGF-β has 
been proposed as an inducer of EMT [147, 148]. Therefore TGF-β, and its αvβ6-
mediated latent activation, could play a central role in tumour progression.  
However, there is not a consensus agreement on the theory of EMT, since it 
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primarily has been inferred from highly artificial, two-dimensional, in vitro 
environments [149, 150]; with no dynamic vascular, endocrine or neurological 
contribution [151]. These studies presume that epithelial cells acquire spindle-cell 
morphology and neo-express mesenchymal markers, but the morphology of these 
cells is histologically indistinguishable from normal stromal cells. Furthermore, 
direct in vivo evidence for EMT in cancer is lacking and hence the occurrence of 
EMT in cancer remains speculative. 
 
 
 
 
Figure 20 Epithelial to Mesenchymal Transition and a proposed mechanism for 
carcinoma progression. Taken from Thiery JP [146]. 
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1.5.5 Survival mechanisms during Invasion and Metastasis 
 Oral keratinocytes naturally switch from αvβ5 to αvβ6 expression, at their 
cell surface, when they transform from normal to malignant phenotypes [133]. Jones 
and Watt initially transduced an αv-negative human SCC line with a retroviral vector 
containing the cDNA encoding the αv integrin subunit; and later created a further 
cell line by infecting with a second vector that contained cDNA which encoded the 
β6 subunit. β6 was weakly detectable in cells transduced with αv alone and was 
strongly expressed in cells transduced with both αv and β6, using Western Blot 
analysis [133]. Conversely, cells transduced with both αv and β6 no longer expressed 
surface αvβ5 (αvβ5 previously was readily detectable in cells transduced with αv 
alone). Flow cytometry indicated that all of the αv on the cell surface was now in an 
heterodimer with the β6 subunit. Western blot on proteins isolated from the double-
transduced line was consistent with intracellular accumulation of β5 and incomplete 
glycosylation. Interestingly, the authors reported that de novo expression of αvβ6 
seems to protect oral SCC from suspension-induced anoikis and that resistance to 
anoikis correlated with PKB/Akt activation [152]. The authors proposed that 
upregulation of αvβ6 in SCCs allows growth of tumour cells in the absence of a 
basement membrane [152].  
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In summary, αvβ6 has the potential to influence in vivo tumour growth in a 
variety of ways. Agrez et al showed that the β6 cytoplasmic domain (specifically an 
11-amino acid region at the COOH terminus) is required for in vivo tumour 
xenograft growth, for the αvβ6-neo-expressing SW480 cancer cell line, within 
athymic mice [139]. Ahmed et al reported that the β6 cytoplasmic domain binds 
directly to ERK, and deletion of the ERK2 binding site on this domain inhibits 
tumour growth [153]. Li et al confirmed that expression of β6 promotes oral SCC 
tumour growth in nude mice. However, they also retrovirally over-expressed, KD-
Fyn in β6-expressing SCC cell lines. KD-Fyn is a specific competitor for 
endogenous Fyn (Src family kinase). These murine experiments revealed that both 
local and metastatic tumour growth is dependent on Fyn activation, for β6-positive 
oral SCC cells [143]. 
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Chapter II: Introduction to Imaging 
 
2.1 Medical Imaging 
Medical imaging is the scientific field in which non-invasive techniques are used to 
create internal and external images of the (human) body. There are a variety of 
imaging techniques, each with certain advantages and disadvantages over each 
other:- 
 
2.1.1 Radiography: X-rays and Computed Tomography 
Plain film radiography is the process of creating two-dimensional images using x-ray 
radiation. X-rays (a.k.a. Röntgen radiation) are a form of electromagnetic radiation, 
discovered by the Nobel prize-winning physicist, Wilhelm Conrad Röntgen, in 1895 
[154, 155]. X-rays are emitted by electrons from outside of the nucleus and are forms 
of ionising radiation; that is, there is sufficient energy to potentially remove electrons 
from an atom, thus giving it a charge and making it an ‘ion’. Ionising radiation has 
sufficient energy to penetrate human tissue and will be absorbed differentially 
according to its energy and to the density of the object [156]. If a ‘cassette’ is placed 
behind the object, which contains photographic film and two fluorescent intensifying 
screens, penetrating x-rays can produce a photochemical reaction [157]. However, 
areas of the object which have completely absorbed the x-rays will not permit a 
photochemical reaction in the corresponding area of the cassette. Therefore, the 
developed film will be a representation of the absorption pattern of the x-rays, and 
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thus a reflection of the different densities within the object (see Figure 21). This 
property of x-rays is used to differentiate areas of bone and soft-tissues within the 
human body. Consequently, plain film radiography can detect fractures and tumours, 
owing to differences in density from the surrounding tissue.  
 
Figure 21 Plain chest radiograph showing a lesion in the apex of the right lung, 
later confirmed to be an adenocarcinoma. 
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One disadvantage of a plain radiograph is that it results from an image which 
presents x-ray absorption in one plane only. That is, structures that are in the same 
plane as the x-ray beam will be superimposed; thereby creating problems in 
differentiating these mono-planar entities. Therefore, the solution is to create a 
radiograph in a different plane, so that these structures no longer are in the same 
plane and thus not superimposed. Computed Tomography (CT) involves moving the 
x-ray source around the patient to create multiple radiographs at different angles, and 
replacing photographic films with digital images. Computers help reconstruct the 
multitude of radiographic absorption information into detailed cross-sectional images 
(see Figure 22). In other words, the pictorial arrangement of x-ray absorption values 
constructs the final CT image. Sir Godfrey Hounsfield conceived this idea of CT 
scanning in 1967 [158], and shared the Nobel Prize with Allan McLeod Cormack for 
their work on the conception and implementation of this approach [159]; to this day 
its scale for radiodensity (absorption values) is expressed in Hounsfield units. This 
technology enables a detailed study of closely-related structures within the body. 
Furthermore, the use of intravenous or oral contrast agents also facilitates distinction 
of anatomical boundaries and differentiation of tissue densities. Modern scanners 
allow absorption data to be reformatted into volumetric (3D) representations of 
structures [160]; giving highly detailed and several views of complex structures e.g. 
tumour deposits within organs. These detailed views can help guide surgeons with 
pre-operative decisions i.e. whether successful tumour resection is possible or 
potentially hazardous. However, this superior image quality and detail is at the 
expense of increased radiation exposure.  
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Figure 22 A cross-sectional CT image delineating a lesion in the upper zone of 
the right lung, subsequently confirmed to be cancer. 
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2.1.2 Ultrasonography 
This procedure creates an internal image of the body, by analysing the manner in 
which high frequency sound waves are reflected back from organs [161]. Sound 
‘echoes’ are produced whenever there is a mismatch between densities in two 
adjacent tissues; a phenomenon termed ‘acoustical impedance’ [161], e.g. interfaces 
between fluid-filled cysts and solid parenchymal tissue within an organ. Part of the 
sound wave usually is reflected back as ‘echoes’ to a transducer, whereas the residual 
wave will continue to penetrate tissues beyond the interface (with the potential for 
later reflection) [161]. Analysis of the time it takes for an echo to return to the source 
of the sound wave helps with the calculation of the depth of an interface, and 
measurement of the strength of the returning echo determines the mismatch in 
density of the interface [162]. These data are analysed by a computer and digitised 
into grey-scale images. Therefore, solid organs materialise as white, echogenic 
structures since they consist of tissues with multiple acoustic interfaces; while fluids 
emerge as black, anechoic areas owing to their absence of internal acoustic 
reflectors. 
Ultrasonography does not utilise ionising radiation and thus minimises the potential 
for biological injury. Ultrasound scanners tend to be less expensive than CT and are 
more mobile. This portability enables the ultrasound machine to be taken to patients, 
who are too unwell to be moved from their clinical area. Furthermore, the use of the 
Doppler Effect helps with the real-time visualisation of moving objects e.g. blood 
and estimates its speed and direction. However, the clarity and detail of the image is 
inferior to that of CT. Indeed the quality of the image is much more dependent on the 
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ultrasound operator than for CT. Additionally, ultrasonography may take longer to 
acquire than CT scanning, depending on the difficulty of the examination. 
 
2.1.3 Magnetic Resonance Imaging (MRI) 
Paul Lauterbur and Sir Peter Mansfield were awarded the 2003 Nobel Prize for their 
"discoveries concerning magnetic resonance imaging". Lauterbur published the first 
MR image in 1973 [163]; however Mansfield pioneered the mathematical analysis 
and techniques required for fast imaging. Magnetic resonance imaging (a.k.a. 
Nuclear Magnetic Resonance) employs powerful magnets to polarise hydrogen 
nuclei (single proton) in fat and water molecules, within human tissue. When a 
further radiofrequency magnetic field is applied, it ‘excites’ the protons and alters 
their alignment. However, removal of this radiofrequency signal will allow the 
protons to return to their previous equilibrium, with emission of the absorbed 
radiofrequency wave.  These emitted radiofrequency waves can be detected by 
antennae and hence computers are able to determine the spatial localisation of 
protons within the body. Furthermore, tissues of differing molecular composition 
(e.g. tumours) may also be distinguished from each other, since protons of differing 
tissues return to their equilibrium state at dissimilar rates [164]. These data enable a 
grey-scale (2D or 3D) image of the body to be constructed (see Figure 23). 
Intravenous contrast agents (e.g. gadolinium) may also be injected to enhance the 
appearance of blood vessels and tumours [165]. 
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Figure 23 A sagittal MRI image of a head, with excellent soft-tissue 
differentiation. 
 
The MRI technique gives greater soft-tissue differentiation than CT scanning and, 
unlike plain film radiography and CT, MRI does not use ionising radiation. 
However, MRI does have some disadvantages: Patients with implants, made from 
ferromagnetic metals, must not be in close proximity to an operational MRI 
instrument. The powerful magnets of the MRI machine would impose on these 
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implants; potentially causing significant harm. Furthermore the magnetic field and 
radiofrequency pulses, generated by an MRI scanner, can alter programmable 
implants e.g. cardiac pacemakers or attached infusion pumps. Consequently, all of 
the aforementioned patient groups cannot be examined by an MRI instrument.  
Furthermore, owing to the construction of some MRI scanners, the scanning 
procedure may be unpleasant for the patient. Older models of MRI scanners have a 
long and narrow tunnel, in which the patient must lie still for up to 40 minutes. This 
scanning setting, together with the noisy procedure, may precipitate claustrophobia 
and is intolerable for some patients. Consequently there is a higher risk of motion 
artefact, compared with a 90-second CT scan. Additionally, motion artefact inhibits 
the image quality of thorax and abdominal MRI scans, owing to respiratory and 
cardiac movements. Finally, CT currently is more widely available and less 
expensive than MRI.  
 
2.1.4 Nuclear Medicine 
Nuclear imaging uses specific radioactive isotopes (radionuclides) to visualise 
organs, through exploitation of the tissue’s metabolism, blood supply or protein 
expression. The radionuclide is administered internally (orally, intravenously or 
inhaled) to the subject and a time interval is permitted to allow it to reach its target 
organ. Since these radionuclides decay with resultant emission of gamma rays, the 
location of the radionuclide within the body can be calculated using external gamma 
cameras and computer analysis. 
The isotopes chosen for nuclear medicine are those that have half-lives of hours or 
days. Consequently the emission of gamma rays will be limited in time and thus 
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minimise the patient’s radiation exposure. Usually the isotopes are ‘tagged’ to 
another molecule (radiopharmaceutical), and it is the property of this molecule that is 
exploited to image the organ. 
 
2.1.4.1 Scintigraphy and Single Photon Computed Tomography (SPECT) 
Technetium diphosphonates can be used to image bone turnover and are usually 
displayed as a planar representation of the skeleton (scintigram). The data used to 
create the scintigram usually are obtained from a single gamma camera and at one 
projection angle. This 2D image can help identify bone metastases; but areas of 
positive uptake are not cancer-specific and sometimes may represent diseases or 
entities of non-malignant aetiology e.g.  arthritis.  
However Single Photon Computed Tomography (SPECT) uses data, taken from 
multiple gamma cameras at several projections, to construct a 3D tomographic 
representation of the radionuclide’s biological distribution within the body. 
Positional information is obtained through the placement of collimators in front of 
the gamma cameras, which only permit detection of γ-rays travelling in certain 
directions. Consequently, detailed images can be obtained using this technique and 
this has advantages over other nuclear medicine techniques in certain situations 
[166]. SPECT and the radiopharmaceutical, 
99m
Tc-sestamibi, can be important in the 
clinical assessment of left ventricular volume and function, following an ischaemic 
cardiac event [167]. The accuracy of the measurements obtained from SPECT 
analysis is sufficient to risk-stratify patients and guide further interventions. 
Many different gamma-emitting radioisotopes could be used for SPECT or 
scintigraphy.  However, ideally, the isotope should be a pure γ-emitter with 
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negligible particulate emissions and minimal toxicity. Furthermore, it should have a 
suitable emission-energy (100-300-keV) for in vivo studies i.e. an energy level 
appropriate for photoelectric absorption by NaI crystals (gamma camera), but also 
appropriate to have minimal interaction with human tissue [168]. Additionally, the 
isotope should be chemically reactive, permitting combination with other molecules 
and thus forming a radiopharmaceutical. However, this reactive combination ideally 
should not change the pharmaceutical’s ability to recognise its target. Additionally, if 
the isotope’s location is to be used as a surrogate for the location of the 
radiopharmaceutical, the biological half-life of the radioisotope should be 
comparable or less than the half-life of the radiopharmaceutical, and the isotope 
should also be ‘carrier free’. That is, a radiopharmaceutical, with the correct physical 
properties, should be able to represent the pharmaceutical’s (not combined to the 
radioisotope) biological property accurately, in position and time. Technetium-99m 
is a frequently used isotope, since it can easily be manufactured using portable 
generators, has a 6-hour half-life and is relatively inexpensive. Table 3 (below) lists 
the properties of radioisotopes commonly applied in SPECT:- 
 
 
ISOTOPE 
 
HALF-LIFE (T½) 
IN HOURS 
GAMMA EMISSION 
ENERGY (KEV) 
MANUFACTURE 
 
99M
TC 
 
6 140 PORTABLE GENERATOR [169] 
 
123
I 
 
13 159 CYCLOTRON [170] 
 
111
IN 
 
67 172 & 247 CYCLOTRON [171] 
 
Table 3 Physical properties of SPECT radioisotopes 
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2.1.4.2 Positron Emission Tomography (PET) 
This nuclear medicine technique employs the internal administration of 
radioisotopes, which possess proton rich nuclei. These types of radioisotopes decay 
to form a daughter product with the conversion of the proton into a neutron; the 
ejection of a positron (beta plus decay) and a neutrino. A positron is a positively 
charged electron (i.e. the anti-matter counterpart of an electron), which moves a short 
distance (0.6 - 5 mm) before colliding with an electron. It is this collision which 
results in their annihilation, the conversion of mass to energy with the emission of 
two simultaneous gamma rays (180
o
 to each other and both 511 keV). These 
simultaneous rays are able to be ‘coincidence detected’, using opposing gamma 
cameras (see Figure 24). Consequently, computers are able to use time of flight data 
to determine the location of the annihilation; approximating the source of the 
radioisotope within the body and generating images which represent this location.  
 
 
 
Figure 24 Schematic of imaging with positron emission tomography (PET). 
Taken from Shokeen M and Anderson CJ [172]. 
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Since the positron has to travel a short distance before annihilation, and it is the 
location of the annihilation which is calculated (rather than the source of the 
positron), it is this short distance which limits the accuracy / resolution of PET 
imaging. Although the 0.6 – 5 mm ‘blur’ usually is not clinically significant to 
humans, it is a factor for smaller species (e.g. rodents) with tumours under 1 cm. In 
this situation, the higher resolution offered by the SPECT technology may be more 
appropriate. However, since time of flight (instead of collimator-limited) data are 
used for location calculation, more events potentially can be measured using PET in 
a shorter period of time. That is, the collimators in SPECT are necessary to calculate 
source, but also reduce the data / events travelling to the gamma cameras. Clearly, 
more events are preferable to improve statistical accuracy and ensure a valid 
representation of the radiopharmaceutical’s biological distribution.  
A range of positron-emitting radioisotopes could be used for PET. However an ideal 
PET isotope shares many of the same properties listed above for an ideal SPECT 
isotope; with the exception that a pure positron-emitting substance is desirable. 
Unfortunately these ideal radionuclides are difficult to obtain, have short half-lives 
and thus mostly are expensive to manufacture, owing to the requirement for an on-
site cyclotron. Table 4 (page 95) lists the properties of radioisotopes commonly 
applied to PET. 
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ISOTOPE 
 
HALF-LIFE (T½) IN HOURS 
 
ELECTRON-POSITRON 
ANNIHILATION 
ENERGY (KEV) 
 
MANUFACTURE 
 
15
O 
 
0.03 (OR 2 MINS) 511 CYCLOTRON [173] 
 
13
N 
 
0.17 (OR 10 MINS) 511 CYCLOTRON [174] 
 
11
C 
 
0.33 (OR 20 MINS) 511 CYCLOTRON [175] 
 
68
GA 
 
1.13 (OR 68 MINS) 511 GENERATOR[176] 
 
18
F 
 
1.82 (OR 109 MINS) 511 CYCLOTRON [177] 
 
64
CU 
 
12.70 (OR 762 MINS) 511 
GENERATOR OR 
CYCLOTRON 
[172] 
Table 4 Physical properties of PET radioisotopes 
 
Therefore, there are numerous advantages and disadvantages to both PET and 
SPECT technologies. 
 
A number of the aforementioned imaging modalities are able to help with the 
diagnosis, staging, treatment assessment and follow-up of cancer patients. These 
modalities can be divided, broadly, into two groups: anatomical and functional. The 
anatomical group includes Computed Tomography (CT) and Magnetic Resonance 
Imaging (MRI) and gives structural and positional information of tumour masses. 
The functional group includes Positron Emission Tomography (P.E.T.) and Single 
Photon Emission Computed Tomography (S.P.E.C.T.) and has the potential to give 
information regarding metabolism, vascular supply and tissue viability, presence or 
absence of cell surface markers and response to particular treatments. The latter 
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group utilises biomarkers, probes and is part of a growing field of Molecular 
Imaging. 
 
2.2 Molecular Imaging 
Molecular imaging relies on the use of biological markers (biomarkers), which are 
molecules used as indicators of a biological state [178]. Biomarkers, in medicine, 
usually reflect a disease state [179], and so should be either absent or expressed in 
very low concentrations within normal cells. Many tumours, in humans and animals, 
express distinct cell surface molecules that distinguish them from non-malignant 
tissues [180]. Owing to the clonal nature of cancers [181], these cell surface 
molecules tend to be maintained from the primary site to their metastases; marking 
areas of malignant disease. Therefore, molecular imaging has the potential to detect 
minimal residual disease throughout the body, which presently cannot be resolved by 
conventional anatomical scanning [182]. That is, if a known marker of malignant 
cells can be targeted by a probe and its signal detected by a functional imager, then 
the presence of disease can be identified, even if morphologically undetectable. 
Furthermore, many of these distinct markers may be involved in the processes of 
maintaining and progressing malignancy [183]. Consequently, these biological 
markers have the potential to deliver prognostic information (prognostic / surrogate 
marker); be predictive in terms of tumour response and patients’ side-effect profile to 
a given drug (predictive); and may also reveal if a given drug is activating a desirable 
molecular pathway (pharmacodynamic) [184]. Predictive markers are particularly 
important when using drugs with narrow ‘therapuetic windows’ and where there are 
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no acceptable or available surrogate markers for survival. This information could 
help in drug selection when alternative therapies are available [185]. Hence, the 
detection of these molecules, using radiolabelled ligands, allows tailored targeted 
therapy and response monitoring [184].  
The use of radiolabelled small molecules (probes), to target biological markers, 
enables their tracing within the body scintigraphically. Radioactivity to label ligands, 
hence identifying biological markers, is ideal since low dose radiation has little effect 
on normal tissue [186]. Levine et al first described the use of monoclonal antibodies 
and Iodine-131 to image high density targets scintigraphically on tumour cells [187]. 
Consequently, P.E.T. and S.P.E.C.T. have the potential to track a given radiolabelled 
probe in four dimensions. New targeted radiolabelled ligands allow the sensitivity 
and specificity necessary for diagnosis and patient management. This improved 
diagnostic information has the potential to reduce the numbers of diagnostic biopsies 
and thereby reduce potential morbidity [184, 188]. Ideally the imaging technique 
would also identify distant metastases. Furthermore, future developments of targeted 
therapy and translation into clinical studies could be greatly facilitated by non-
invasive techniques that allow serial studies of the proposed target [184, 188]. 
Molecular imaging has the potential to document target expression within tumours 
before the administration of prospective targeted antagonists, thus allowing 
appropriate selection of patients entering clinical trials [184]. 
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2.2.1 Probe Design 
For targeting, the affinity of the probe has to be high enough to generate a 
rapid and significant (i.e. easily measurable) signal to background ratio in order to 
discriminate the target tissue. A probe typically comprises three main components: a 
targeting ligand (such as antibody or peptide) that binds to the desired receptor; a 
radionuclide with an appropriate emission for the selected imaging modality; and in 
some cases, a chelating agent (such as diethylenetriamene pentaacetate (DTPA) and 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)) and a spacer, 
which facilitates attachment of the radionuclide to the targeting moiety [189].  
Correct radioisotope selection is essential for successful tumour imaging and 
this already has been discussed (section 2.1.4) with the associated imaging technique 
e.g.  SPECT and PET. However, Table 5 (page 99) further summarises the 
advantages and disadvantages of the common radionuclides, used for radiolabelling. 
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Advantages Limitations 
 
Technetium-99m 
 Easily available and low cost 
 Easy to handle 
 Reasonable T½ of 6 hours 
 140 keV γ-emission 
 Excellent imaging characteristics 
 Absence of α and β radiations 
 Favourable dosimetry 
 
 
 Not suitable for delayed imaging 
studies 
 
Iodine-123 
 159 keV γ-emission 
 T½ of 13 hours 
 Good imaging characteristics 
 
 
 High cost 
 Limited availability 
 Cyclotron-produced radionuclide 
 
Indium-111 
 172 and 247 keV γ-emission 
 T½ of 2.8 days 
 Useful for acquiring delayed imaging  
 
 
 High cost 
 Limited availability 
 Cyclotron-produced radionuclide 
 Relatively high radiation burden to 
patients 
 Sub-optimal nuclear characteristics 
 
Copper-64 
 Emissions of β
-
(573 keV) and β
+
(655 
keV) 
 Suitable for both imaging and 
radiotherapy 
 T½ of 12.7 days 
 Can be produced using a generator 
system or biomedical cyclotron 
 
 
 Limited availability 
 Costly production and shipment 
 Sub-optimal characteristics for PET 
imaging due to low abundance of β
+ 
(19%) 
 
 
Gallium-66/67/68 
 Suitable for γ-scintigraphy and PET 
imaging 
 T½ of 
66
Ga(9.5 hours), 
67
Ga(78.3 
hours) and 
68
Ga(68 minutes) 
 Useful physical characteristics 
 
 
 High cost 
 Limited availability 
 Cyclotron-produced radionuclides 
(
66
Ga, 
67
Ga) 
 
 
Fluorine-18 
 Can be produced in high quantity 
(i.e. Ci) 
 Low positron energy of 0.635 MeV 
 High resolution and sensitivity 
 Low radiation dose to patients 
 T½ of 110 minutes permits both 
radiophamaceutical preparation and 
imaging studies. 
 
 
 High cost 
 Limited availability 
 Cyclotron-produced radionuclide 
 
 
Table 5 Characteristics of Different Radionuclides Used for Radiolabelling. 
Adapted from Okarvi S.M. [190]. 
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Notably, when a choice of radioisotopes is available, it should not be 
assumed that the results of one tracer will be similar to another. That is, the spatial 
and chemical relationship of the radionuclide to the targeting ligand may influence 
the radiopharmaceutical’s overall pharmacokinetics. Indeed, de Jong et al studied the 
binding of DOTATOC to somatostatin receptors and compared the biodistribution of 
90
Y-labelled DOTATOC to that of 
111
In-labelled DOTATOC, in rats bearing the CA 
20948 tumour [191]. Interestingly, the authors discovered that uptake of 
90
Y-labelled 
DOTATOC (into the somatostatin receptor-positive organs) was significantly higher 
than that of the 
111
In-labelled compound. Marion de Jong et al suggested that the 
DOTA chelator was more appropriate for the complexation of 
90
Y than for 
111
In 
[191]. This phenomenon may be due to differing groups of the DOTATOC molecule 
interacting with the different radioisotopes. The relationship of the targeting ligand, 
chelator and radionuclide will be discussed further in Section 2.2.3. 
There are many potential biopharmaceuticals which could be used as targeted ligands 
for imaging. However radiolytic resistance of the targeting ligand is an essential 
requirement, owing to its proximity with a radionuclide. That is, chemical stability 
can be a problem with certain radioisotopes, possibly resulting in diminished tumour 
targeting efficiency [192]. Although, free-radical scavenging may reduce radiolysis 
[193], this further step can complicate proceedings. Common targeting ligands 
include modified substrates for a cell’s enzymatic processes, monoclonal antibodies, 
single chain Fv antibodies (scFv), peptides and viral vectors; each has advantages 
and disadvantages. Of note, probe-based imaging modalities also permit the targeting 
of cell surface markers, within tumours and associated ‘normal’ tissues [189]. That 
is, as well as targeting biological markers on cancer cells, biological markers can 
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also be sought out on tissues which are not themselves transformed but which are 
required for tumour growth. For example, new vessel formation is required to deliver 
blood nutrients to a growing tumour mass [194]. In order to achieve this need, 
tumours secrete a variety of factors to promote angiogenesis. Therefore, the receptors 
on newly-formed blood vessels can be targeted and used as a surrogate for tumour 
activity. The use of an RGD sequence-containing peptide [194] to image αvβ3 over-
expression on neo-vascularisation will be described in Section 2.3. 
 
2.2.1.1 
I8
F-FDG substrate 
In 1980, Som et al described a fluorinated glucose analogue, 2-fluoro-2-deoxy-D-
glucose (
I8
F-FDG), and its potential for detecting transplanted and spontaneous 
tumours in animals [195]. Certain cancer cells have an increased metabolic demand 
compared to normal tissues, in part due to their increased cell division. In 1978, 
Monakhov et al showed that the hexokinase activity was raised significantly in 
certain malignant tumours, in contrast to normal tissues [196]. 
I8
F-FDG competes 
with glucose in the hexokinase reaction, in which glucose is phosphorylated at the 6- 
position to form glucose-6-phosphate. Once phosphorylated, FDG-6-phosphate 
escapes the usual glucose metabolism and is not released from the cell; trapping it 
within these cells after initial absorption. 
I8
F-FDG’s tumour uptake was maximal at 
30 minutes and remained relatively constant up to 60 minutes, post injection. 
Tumour-to-normal tissue and tumour-to-blood ratios ranged from 2.10-9.15 and 
2.61-17.82, respectively, depending on the type of tumour [195]. However, it should 
be noted that the % dose / gram was quoted at just 0.43 ± 0.07 at 60 minutes post-
injection, for a melanoma rabbit model. Nonetheless, the authors showed 60 minute 
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% dose / gram ranging from 0.4 – 18 in different tumour models, and published 18F-
FDG scintagrams in a dog with a seminoma (see Figure 25).  
 
Figure 25 In vivo scintigram with 
18
F-FDG 2 hours post injection (1); and excised 
tumour (2), in a dog with spontaneous seminoma. A = visible tumour; A' necrotic. 
Taken from Som  et al [195]. 
 
Tumour visualisation was described as ‘excellent’, owing to low blood and tissue 
background. Nevertheless, the dog required catheterisation in order to eliminate 
urinary activity; a considerable amount of 
l8
F-FDG metabolite is excreted in the 
urine and thus could hinder image interpretation [197]. Toxicological studies in mice 
using 1000x human tracer dose per week (for 3 weeks) did not show any evidence of 
acute or chronic toxicity; determined by routine observations, changes in body 
weight, and gross and histopathology of the internal organs. This and subsequent 
studies have established 
l8
F-FDG as a surrogate for tumour viability; through its 
accumulation in areas of high glycolytic activity [198]. Indeed the new staging 
criteria for Hodgkin’s disease now incorporates P.E.T. and l8F-FDG analysis [199].  
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2.2.1.2 Antibody vs. Peptide 
While monoclonal antibodies display high affinity and specificity, they suffer 
from clinical limitations when used as a targeting ligand.  
Peptides can be synthesised in large quantities relatively inexpensively and 
are more amenable to ‘derivatisation’ [200]. Peptide synthesis techniques can be 
divided broadly into two main groups: solution-phase peptide synthesis and solid-
phase peptide synthesis (SPPS) [190]. Although solution-phase synthesis is useful 
for large-scale peptide production and for specialised laboratory applications, it is 
time-consuming and requires complex purification procedures. Consequently, SPPS 
is the method of choice for small and medium-scale peptide synthesis. Furthermore, 
this method of synthesis permits relatively easy derivatisation. For example, 
biotinylation of the peptide is possible; this biotin ‘tag’ allows the peptide to be 
tracked and is useful in the analysis of certain cell binding assays. The addition of a 
bifunctional chelating agent (described later) may also be added to the peptide during 
SPPS, facilitating future radiolabelling. 
Peptides seem to be more accessible to solid tumours. That is, the relatively 
larger antibodies (approximately 150 kDa) may penetrate tumour vasculature poorly, 
limiting delivery of the ligand to the tumour and thus slowing localisation and 
binding kinetics [201]. Other physiological barriers may also inhibit access of the 
larger antibody to its target e.g. blood-brain-barrier. 
The binding of an ideal probe to its desired target would be stable and long-
lived; possibly exhibiting receptor-mediated internalisation into tumour cells. 
Internalisation results in accumulation of the probe within the target tissues, 
providing an increased signal for imaging. Smaller molecules, such as short peptides, 
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may have the advantage in their potential to be internalised and, therefore, 
accumulated.  
Integrins are known to bind some ligands more stably than others [202]. This 
property permits greater clearance of non-specifically bound probe, and is thus 
important for target-to-background ratio. Reduction of the background signal helps 
contrast the target signal. As well as more rapid localisation within the target tissue, 
low molecular weight peptides have the potential for faster blood clearance from 
blood and non-target tissues. Small peptides tend to be degraded quickly / 
metabolised in vivo, by e.g. proteases, and renally excreted; resulting in a relatively 
short biological half-life. These processes take longer for the ‘bulkier’ monoclonal 
antibody structures and therefore also permit non-specific binding to persist. 
Furthermore, this slower clearance (monoclonal antibodies) from the circulation 
results in greater radiation exposure to normal organs. 
However, the targeting ligand must have sufficient stability to reach its 
biological target. Therefore, a fine balance is required between clearance 
(background signal) and target localisation (target signal) for maximal contrast. The 
relative ease of peptide modification can also help shift this balance for improved 
efficacy. That is, peptides can be modified, using certain techniques (see Table 6, 
page 105), to enhance resistance against proteolysis and hence improve in vivo 
stability. Conversely, knowledge of these techniques could be utilised to decrease in 
vivo stability, improving clearance and thus reduce background signal. 
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 Introduction of appropriate D-amino acids 
 Substitution of peptide bonds 
 Replacement of amino moieties with imino groups 
 Use of unusual amino acids or side chains 
 Use of non-peptide molecules with similar configurations 
 Terminal capping process( by acetylating the N-terminus or by converting the C-
terminus carboxylic acid into an amide) 
 Cyclisation 
 Introduction of non-cleavable isotere bonds 
 Peptide mimetics (group reduction) 
 
Table 6 Methods of Inhibiting Proteolysis of Peptides. Adapted from Okarvi 
[190]. 
 
Murine monoclonal antibodies are also immunogenic, generating human anti-
mouse antibody (HAMA) responses [203]. These responses create allergic-like 
reactions to the mouse antibody and rapid removal of the mouse antibody from the 
body, thus limiting efficacy [204]. This problem can be minimised by 
immunosuppression, the use of chimeric antibodies or even ‘humanising’ the 
antibody in order to reduce the immunogenic components. However, 
immunosuppression may not be desirable in some patients, and could cause other 
troublesome side-effects [205]. Furthermore, the process of humanisation involves 
the mimicking of a protein sequence of a human antibody; producing an 
immunoglobulin framework in which non-human hypervariable complementarity-
determining regions (CDRs) can be inserted. These CDRs potentially could contain 
inherently antigenic determinants, which would initiate an immune response – 
‘human anti-human antibodies (HAHA) production [206].  On the other hand, small 
peptide molecules tend to have low antigenicity and therefore minimise this issue 
[200].  
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Single-chain Fv recombinant proteins are prepared by connecting genes 
encoding heavy chain and light chain variable regions of immunoglobulins at the 
DNA level using an oligonucleotide linker. Since these fragments are approximately 
25 kDa in size, they do have the potential for better tumour penetration and faster 
clearance compared to whole immunoglobulins [207]. However, owing to their 
monovalency, they do have lower avidity. This problem can be overcome by 
generating multivalent forms of scFv molecules and optimising their affinity. 
Nevertheless, scFv development is still in its infancy for clinical use. 
All of the aforementioned properties must be accounted for in the design of 
an imaging probe; maximising target-to-background efficiency and safety. It, 
therefore, has been suggested that small synthetic receptor-binding peptides are the 
agents of choice for diagnostic imaging of cancers due to their favourable 
pharmacokinetics and flexibility in chemical modification facilitating radiolabelling 
[190]. 
 
Notwithstanding the above, monoclonal antibodies have been relatively 
successful, when incorporated within an imaging probe. Prostascint® is an 
111
In-
labelled monoclonal mouse antibody specific for the prostate-specific membrane 
antigen and has been FDA-approved for the detection of recurrence in prostate 
cancer patients [208]. Indeed Ellis et al have been able to detect cancer foci in the 
prostate, with 79% sensitivity and 80% specificity when correlated with histology, 
using this reagent [209]. Furthermore, an increasing body of evidence indicates that 
radiolabelled trastuzumab is able to identify HER2-positive tumours within advanced 
breast cancer patients [210]. 
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However, the archetypal radiopharmaceutical is 
111
In-DTPA-D-Phe
1
-
octreotide (OctreoScan, 
111
In-pentetreotide) – a targeted cyclic radiopeptide. It was 
approved by the FDA in 1994 for scintigraphy of patients with neuroendocrine 
tumours [183]. Octreotide is an eight-amino acid, somatostatin-analogue and its 
DTPA-D-Phe
1
 modification transfers enhanced resistance to in vivo enzymatic 
degradation and reduced hepatobiliary excretion; thereby allowing good imaging of 
abdominal tumour sites. Somatostatin (a cyclic neuropeptide via a disulphide bond 
interaction) physiologically acts as a neurotransmitter in the brain with resultant 
inhibition of hormone release [211]. However, somatostatin receptors are expressed 
additionally in tumours of neuroendocrine origin e.g. carcinoids [211]. The over-
expression of these receptors can serve as a potential target within the tumour for 
111
In-DTPA-D-Phe
1
-octreotide. Imaging is permissible within hours of injection of 
this radiolabelled peptide [212]. Furthermore, the availability of 
68
Ga-labelled 
octreotide analogues now opens the field to PET imaging of neuroendocrine tumours 
[213]. 
 
 
2.2.2 Radiolabelling Techniques 
Generally, radiolabelling techniques can be divided into either ‘direct’ or ‘indirect’ 
categories. Direct labelling usually involves a reaction with the radioisotope and the 
targeting ligand; whereas indirect labelling requires a conjugate or coupling method. 
The choice of labelling technique is determined by biological, chemical and 
structural consequences of the reaction and resulting radionuclide attachment. 
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Iodine (
131
I and 
125
I) labelling of proteins may be performed using electrophilic 
substitution, in which positively charged iodine attacks a system with high electron 
density e.g. an aromatic ring or a double bond; resulting in a covalent carbon-iodine 
bond formation. When hydrogen is replaced by a radioiodine atom (radioiodo-
deprotonation) in an arene (activated for electrophilic substitution), direct 
radiolabelling occurs. However, this method involves strong oxidising conditions, 
which may be problematic for the native protein [214]. Consequently, the iodogen 
method™ is preferred for clinical applications. This technique involves a reaction 
vessel coated with 1,3,4,6-tetrachloro-3α, 6α-diphenylglycouril (iodogen), which 
‘mildly’ oxidises iodine isotopes. If this oxidation occurs in the presence of a protein, 
which contains tyrosine, there is subsequent incorporation of the radioiodine into the 
tyrosine; that is, a substitution of iodine for hydrogen atoms (in the phenolic ring of 
tyrosine) within the protein [215]. Therefore, this direct labelling method is limited 
to proteins which contain an accessible tyrosine. 
Alternatively, if a tyrosine residue is not available or if any oxidation is undesirable 
to the native protein, indirect radioiodination via prosthetic groups is possible. Here 
the protein is treated with an iodine-labelled acylating agent, e.g. iodinated 3-(4-
hydroxyphenyl)propionic acid N-hydroxysuccinimide ester (iodine-labelled Bolton–
Hunter reagent), which reacts with free amino groups in a protein molecule; 
attaching the iodine-labelled groups by amide bonds [216]. That is, an activated 
aromatic compound (Bolton–Hunter reagent) is first radioiodinated, and this 
subsequently is coupled to the native protein, via acylation of a free amino group e.g. 
lysine. In this way, the native protein escapes the harsh conditions required for 
iodination [216]. 
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Technetium-99m (
99m
Tc) is the most frequently used radioisotope in nuclear 
medicine [217]. Direct labelling involves the chelation of 
99m
Tc to the reactive 
sulphide-groups within a compound. The direct labelling reaction usually involves a 
reducing agent which converts disulphide bridges into free thiols; the free thiols are 
able to chelate with 
99m
Tc [218]. However, direct 
99m
Tc labelling methods are limited 
to compounds containing disulphide bonds and the resultant products also have poor 
in vivo stability; the radiometal can dissociate during imaging [217]. Therefore 
different approaches are required to provide a range of stable radiolabelled 
compounds with minimal toxicity. One such approach is via an indirect method, 
using a bifunctional chelating agent (BFCA). The BFCA initially is attached to the 
peptide to form a BFCA-peptide conjugate. The attachment can occur to the C, or N 
terminus, or to a branch chain or even to the peptide backbone. However, since the 
attachment of any molecule has the potential to affect the targeting ligand’s affinity 
for its receptor, the choice of attachment site is not only dependent on ease of 
attachment, but also on its resultant effect on the receptor binding affinity [219]. If 
necessary, ‘spacers’ can be used to increase the distance between the conjugation site 
and the receptor binding site. Once the conjugate has been selected, subsequent 
radiolabelling can be attained either by direct reduction of 
99m
TcO4
-
, or by ligand 
exchange using an intermediate 
99m
Tc complex (e.g. [
99m
Tc] glucoheptonate) [217]. 
This indirect labelling technique is the most practical approach for the development 
of peptide-based target-specific radiopharmaceuticals. 
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Indium-111 and gallium-67 are found in group 13 (post-transition metal category) of 
the periodic table. These trivalent metal radionuclides have physical properties 
suitable for radioisotope imaging. 
111
In is produced by a charged particle accelerator 
(cyclotron) that creates proton-rich radionuclides by bombardment of a cadmium 
target with positively charged particles (proton irradiation). 
111
In has a sixty-seven 
hour half-life and decays by electron capture; emitting γ-photons at 172 and 247 
keV, with 55 to 72 percent yield factors for the two peaks [168, 171]. These 
characteristics are suitable for γ-scintigraphy and SPECT imaging. Gallium 
radionuclides have decay characteristics that are suitable for γ-scintigraphy, PET 
imaging, and receptor-mediated radiotherapy. However, to obtain an indium or 
gallium radiolabelled biomolecule (probe) with the required stability, a biomolecule-
chelator conjugation also is required in order to complex the metal [219]. 
Furthermore, 
111
In(III) does not cross the cell membrane readily and must first be 
chelated with a lipophilic chelating agent [168]. Chelators will be discussed further 
in Section 2.2.3. 
At pH > 6, many metals form insoluble hydroxide complexes and thus become 
unavailable for binding to the chelator [219]. Therefore, radiolabelling with 
111
InCl3 
(dissolved in dilute HCl) requires buffering, at pH 4–6. Furthermore, the presence of 
weakly chelating ions in the buffer (such as acetate or citrate) will also reduce the 
likelihood of hydrolysis [219]. The radiolabelling mixture may also contain 
antioxidants (such as ascorbic or gentisic acid) to prevent radiolysis of the peptide 
[193]. To ensure that labelling will be almost 100% efficient, the peptide conjugate is 
usually in excess in comparison with the radionuclide. The most effective incubation 
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conditions are dependent on the chelator choice (see Section 2.2.3), as well as on the 
peptide structure [219]. However, since chelators facilitate metal attachment, it is 
important to eliminate metal impurities from the indium radiolabelling mixture. The 
presence of other metals could lead to the chelation of impurities, rather than indium. 
Therefore, performing the radiolabelling reaction in polypropylene vessels (instead 
of glass), using polypropylene weighing spatulas, and acid-treating vials and pipette 
tips should all be considered [219]. 
 
Although direct electrophilic fluorination of peptides is possible, this method is 
unsuitable for medical applications [220]. Therefore, prosthetic groups are required 
for stable fluorine-18 radiolabelling [220], such as N-succinimidyl-4-[
18
F]-
fluorobenzoate ([
18
F] SFB). However, there are usually three major steps involved in 
([
18
F] SFB synthesis: (i) [
18
F]-fluorination of a suitable aromatic precursor, (ii) 
formation of 4-[
18
F]-fluorobenzoic acid ([
18
F] FBA), and (iii) activation of [
18
F] FBA 
to form the [
18
F] SFB reagent [220]. That is, peptides are usually radiolabelled with 
18
F by first converting [
18
F] FBA into a corresponding active ester, which is then 
isolated, purified, and coupled to a free amino group (via acylation) on the 
biomolecule e.g. lysine residue.  The addition of O-(N-succinimidyl)-N,N,N’,N’-
tetramethyluronium tetrafluoroborate (TSTU) helps with the activation / 
esterification of [
18
F] FBA (see Figure 26), reduces synthesis time and achieves a 
higher yield of purity [220].  
 
 112 
 
 
Figure 26 A general scheme for the preparation of 
18
F-labelled peptides via N-
succinimidyl-4-[
18
F]-fluorobenzoate (O-(N-succinimidyl)-N,N,N’,N’-
tetramethyluronium tetrafluoroborate)-mediated esterification of 4-[
18
F]-
fluorobenzoic acid. Taken from Okarvi [190]. 
 
 
2.2.2.1 Pre-labelling vs. Post-labelling 
The previous section described some examples in which the radiometal was 
introduced to its chelator, after the chelator already had been attached to its targeting 
ligand; a process termed ‘post-labelling’. ‘Pre-labelling’ occurs when the 
radionuclide-chelator complex is formed prior to activation and undergoes 
substitution into the targeting ligand. The choice of  labelling strategy is influenced 
by a variety of considerations [221]. A direct one-step post-labelling may be 
appropriate if the radionuclide is not abundantly available, or if the labelling 
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efficiency is reduced with multiple stages of conjugation. However, if complex 
formation between the radionuclide and chelator can be achieved only under ‘harsh’ 
conditions (i.e. damaging to the targeting ligand), then clearly a pre-labelling strategy 
is indicated [221]. 
 
2.2.3 Bifunctional chelating agents (BFCAs) 
If a metal radionuclide (e.g. 
64
Cu) and targeting ligand have been selected for 
imaging, the subsequent step is to select a bifunctional chelating agent, consisting of 
a coordination site for metal complexation and a linking site for covalent coupling to 
an available functional group within the targeting ligand. The choice of complexation 
site not only is dependent on ease of attachment, but also on its resultant effect on the 
receptor binding affinity [219].  
The first BFCAs to be described were analogues of ethylenediaminetetraacetate 
(EDTA) and diethylenetriaminepentaacetic acid (DTPA). The polyamino-
polycarboxylic ligand, DTPA, provides linkage and coordination sites to “simple” 
aquo-ions, such as 
111
In(III), without the necessity for derivatisation [221]. DTPA 
can be synthesised in a monoreactive state with regards to peptide conjugation: one 
free terminal carboxylic acid and four carboxylates protected with tert-butyl ester 
(see Figure 27).  This DTPA derivative now affords a degree of site-specific 
attachment control to its biomolecule [222]. 
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Figure 27 Chemical Structure of DTPA-tetra (t-Bu ester) 
 
However, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a 12 
member tetraaza macrocycle and is a modern BFCA (Figure  28) [223]. DOTA can 
complex a broad range of radioisotopes, suitable for use in nuclear medicine. DOTA 
complexes tend to be more thermodynamically and kinetically stable than the DTPA 
complexes [219]. An unstable complex may result in deposition of the radionuclide 
in normal tissue; producing false positive imaging data and unnecessary radiation 
exposure. Nevertheless, DOTA complexes require a degree of heating to aid their 
formation, whereas the less-stable DTPA complexes can form at room temperature 
(19–25 oC) [219]. 
 
Figure 28 Chemical Structure of DOTA-tris (t-Bu ester) 
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Nevertheless, the choice of chelator for any given nuclide also may be influenced by 
the metabolic fate of the free radionuclide and its chelated form [221]. The ideal 
chelated radionuclide would be excreted rapidly via the urinary tract. Intact 
conjugate should accumulate and be retained intracellularly and selectively at tumour 
sites, but not in normal tissues [221]. However, this ideal is not always possible and 
persistent and unwanted non-target retention of metallic radionuclides (possibly still 
in their chelated forms) may occur.  
Forrer et al compared the pharmacokinetics of somatostatin analogues (
111
In-
DOTATOC vs. 
111
In-DOTATATE) in five patients with neuroendocrine tumours 
[224]. Both analogues showed high specific uptake in somatostatin receptor-positive 
tissue, although better visualisation of some liver metastases was found with 
111
In-
DOTATOC. Furthermore, dosimetry showed a significantly higher mean absorbed 
dose to the liver for 
111
In-DOTATATE, and a favourable tumour-to-kidney ratio 
(P=0.065) for 
111
In-DOTATOC. The amount of 
111
In-DOTATOC excreted into the 
urine was significantly higher than for 
111
In-DOTATATE. It was suggested that the 
difference in charge (positive overall charge of 
111
In-DOTATOC and neutral charge 
of 
111
In-DOTATATE) could lead to differing kidney absorbed doses.  
Furthermore, chelator choice may alter the sensitivity and specificity of the targeting 
ligand. Marion de Jong et al studied the binding of 
111
In-DOTATOC to somatostatin 
receptors and compared the biodistribution of 
90
Y- and 
111
In-labelled DOTATOC 
with that of 
111
In-DTPAOC, in rats [191]. The authors found that the specific uptake 
of both 
90
Y- and 
111
In-labelled DOTATOC in octreotide receptor-expressing tissues 
was significantly (2 – 6 times) higher than that of 111In-DTPAOC [191].  
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In addition, transferrin (the iron transport protein found in plasma) has a high affinity 
for 
111
In(III) and may cause the 
111
In(III) to detach from its chelate; thus de-
stabilising the targeting ligand radiolabel. Therefore, Indium-peptide complexes 
(within radiopharmaceuticals) should not only be stable to proteolysis, but ideally 
should also be more stable than Indium-transferrin complexes [168] 
Therefore, the spatial and chemical relationships of the chelator, radionuclide and 
targeting ligand are highly important to achieve maximal imaging efficiency. Table 
7 (below) lists some common radionuclides and their most favourable corresponding 
chelating agents.  
 
 
 
Chelators 
 
Radionuclides 
 
Diethylenetriamine pentaacetic acid (DTPA) 
 
Indium, Yttrium, Lutetium, Iodine 
Tetraazacyclododecane tetraacetic acid (DOTA) 
 
Gallium, Indium, Yttrium, Lutetium, 
Copper 
 
 
Hydrazino nicotinamide (HYNIC) 
 
Technetium 
 
Tricarbonyl Core 
 
Technetium, Rhenium 
 
Triethylenetetramine (TETA) 
 
Copper 
 
Table 7 Complexing Agents and Corresponding Radionuclides 
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2.2.4 Combined Functional and Anatomical Imaging 
Despite the advances in functional imaging and radiochemistry, conventional 
anatomical imaging still can add valuable positional information (see Table 8, page 
118) to the data accrued from molecular imaging and biomarkers. Positional 
information is still necessary to guide certain treatments e.g. surgery. Therefore, 
SPECT data could be overlaid onto the corresponding CT images i.e. ‘mapping’ 
functional information onto anatomical imaging. This combined approach to imaging 
is increasing molecular imaging’s profile in diagnostic medicine. Enhanced 
diagnostic and prognostic information can be achieved by this combined approach. It 
is for this reason that the experiments described in this thesis used Bioscan’s 
combined NanoSPECT/CT.  
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Table 8 Overview of imaging technologies. Adapted from Weissleder R and Pittet 
MJ [188]. 
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However, prior to use in humans, biological markers must be selected using in vitro 
characterisation and validated in pre-clinical models. These investigations will 
quantify non-specific binding, biodistribution, pharmacokinetics and 
pharmacodyamics as well as establish if tumour access of the targeted molecule is 
possible; that is, if the tumour is poorly perfused the targeted molecule may not be 
able to reach the biological marker and therefore may give false negative results. 
Furthermore, a concern of using cell lines for identification of potential biomarkers is 
that the cell surface expression profile in culture may not reflect the state of the 
cancer cells in a tumour. Therefore, pre-clinical models can answer many valuable 
questions prior to human trials. My analysis of αvβ6 expression suggests quite 
strongly that it could serve as an appropriate target for molecular imaging of a range 
of human carcinomas. Nevertheless, careful consideration should be made as to the 
choice of the most appropriate pre-clinical model. 
 
The phylogenetic expression of cellular integrins and their tissue distribution appear 
to be universal from fungi to mammals. Indeed, the sequences and genes of the 
Drosophila integrins are about as closely related to chordates as are those which 
comprise the most divergent of the vertebrate subunits [12]. There is 92.33% αv 
similarity and 90.71% β6 similarity of the mouse to the human genes (comparison 
based on amino acids). This high degree of similarity is important, especially when 
dealing with mouse models which could spontaneously develop αvβ6-expressing 
tumours. However, integrin diversity varies widely among species; for example, in 
mammals, 19 alpha and 8 beta subunit genes encode polypeptides that combine to 
form 25 different receptors, whereas the Drosophila and Caenorhabditis genomes 
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encode only five and two integrin alpha subunits, respectively [20]. It should be 
noted that although the pattern of αvβ6 staining has been documented in primates 
[134], the baseline αvβ6 expression in mice has not been established. Therefore, this 
baseline expression must be ascertained prior to any targeting experiments. 
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αv Sequence Homology  
 
Murine MAAPGRLLLRPRPGGLLLLLPGLLLPLADAFNLDVESPAEYAGPEGSYFGFAVDFFEPST 60 
Human  MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSA 60 
       ** * *  **  * ** ***.******. ******:*****:************** **: 
 
Murine SSRMFLLVGAPKANTTQPGIVEGGQVLKCECSSSRRCQPIEFDSTGNRDYAKDDPLEFKS 120 
Human  SSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS 120 
       *****************************: **:*********:**************** 
 
Murine HQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSKNIDAD 180 
Human  HQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDAD 180 
       ******************************************************::**** 
 
Murine GQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIISKYDPNVYSIKYNNQLAT 240 
Human  GQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLAT 240 
       *****************************************:****************** 
 
Murine RTAQAIFDDSYLGYSVAVGDFNGDGIEDFVSGVPRAARTLGMVYIYDGKNMSSLHNFTGE 300 
Human  RTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE 300 
       **************************:***************************:***** 
 
Murine QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRAVGDFQTTK 360 
Human  QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTK 360 
       **************************************************** ******* 
 
Murine LNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGLVYIFNGRSTGLNSVPSQI 420 
Human  LNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI 420 
       *****************************************:************:***** 
 
Murine LEGQWAAQSMPPSFGYSMKGATDVDRNGYPDLVVGAFGVDRAVLYRARPVVTVNAGLEVY 480 
Human  LEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY 480 
       *******:***************:*:******:*********:*******:********* 
 
Murine PSILNQDNKICPLPGTALKVSCFNVRFCLKADGKGTLPRKLHFQVDVLLDKLKQKGAIRR 540 
Human  PSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRR 540 
       ********* *.***********************.*****:***::************* 
 
Murine ALFLHNRSPVHSKTMTVFRGGQMQCEELVAYLRDESEFRDKLTPITIFMEYRLDQRTAAD 600 
Human  ALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD 600 
       ****:.*** ***.**: *** ******:************************* ***** 
 
Murine ATGLQPILNQFTPANVSRQAHILLDCGEDNVCKPKLEVSVNSDQKKIYIGDDNPLTLTVK 660 
Human  TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVK 660 
       :**************:************************:**************** ** 
 
Murine AQNQGEGAYEAELIVSIPPQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG 720 
Human  AQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG 720 
       ****************** ***************************************** 
 
Murine TQLLAGLRFSVHQQSEMDTSVKFDLKIQSSNSFDNVSPVVSYKVDLAEKAAVEIRGVSSP 780 
Human  TQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP 780 
       *************************:***** **:******:*****  *********** 
 
Murine DHIFLPIPNWEYKENPETEEDVGPIVQHIYELRNNGPSSFSKAILNLQWPYKYNNNTLLY 840 
Human  DHIFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLY 840 
       ***********:************:******************:*:************** 
 
Murine ILHYDIDGPMNCTADTEINPLRIKTP-----EKNDTGAAGQGERSHLITKRGLTLREGDV 895 
Human  ILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDT-VAGQGERDHLITKRDLALSEGDI 899 
       *************:* ******** .     ***** .******.******.*:* ***: 
 
Murine HTLGCGIAKCLQITCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNII 955 
Human  HTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVI 959 
       ******:*:**:*.********************************************:* 
 
Murine EFPYKNLPIEDLFNSTLVTTNITWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMG 1015 
Human  EFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMG 1019 
       ***********: ********:************************************** 
 
Murine FFKRVRPPQEEQEREQLQPHENGEGNSET 1044 
Human  FFKRVRPPQEEQEREQLQPHENGEGNSET 1048 
       ***************************** 
 
Figure 29 αvβ6 amino acid homology between mice and humans. 
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β6 Sequence Homology {Accession numbers  NP_000879.2, human; NP_067334.1, murine} 
 
Murine MGIELVCLFLLLLGRNDHVQGGCAWGGAESCSDCLLTGPHCAWCSQENFTHLSGAGERCD 60 
Human  MGIELLCLFFLFLGRNDHVQGGCALGGAETCEDCLLIGPQCAWCAQENFTHPSGVGERCD 60 
       *****:***:*:************ ****:*.**** **:****:****** **.***** 
 
Murine TPANLLAKGCQLPFIENPVSRIEVLQNKPLSVGRQKNSSDIVQIAPQSLVLKLRPGREQT 120 
Human  TPANLLAKGCQLNFIENPVSQVEILKNKPLSVGRQKNSSDIVQIAPQSLILKLRPGGAQT 120 
       ************ *******::*:*:***********************:******  ** 
 
Murine LQVQVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLAKEMSKLTSNFRLGFGSFVEK 180 
Human  LQVHVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLSKEMSKLTSNFRLGFGSFVEK 180 
       ***:***********************************:******************** 
 
Murine PVSPFMKTTPEEITNPCSSIPYFCLPTFGFKHILPLTDDAERFNEIVRKQKISANIDTPE 240 
Human  PVSPFVKTTPEEIANPCSSIPYFCLPTFGFKHILPLTNDAERFNEIVKNQKISANIDTPE 240 
       *****:*******:***********************:*********::*********** 
 
Murine GGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDHRNE 300 
Human  GGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDSKNE 300 
       ******************************************************** :** 
 
Murine YSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNI 360 
Human  YSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNI 360 
       ************************************************************ 
 
Murine LQLIISAYEELRSEVELEVLGDTEGLNLSFTALCNNGVLFPHQKKCSHMKVGDTASFNVT 420 
Human  LQLIISAYEELRSEVELEVLGDTEGLNLSFTAICNNGTLFQHQKKCSHMKVGDTASFSVT 420 
       ********************************:****.** ****************.** 
 
Murine VSVSNCEKRSRNLIIKPVGLGDTLEILVSAECDCDCQREIETNSSKCHNGNGSFQCGVCT 480 
Human  VNIPHCERRSRHIIIKPVGLGDALELLVSPECNCDCQKEVEVNSSKCHHGNGSFQCGVCA 480 
       *.:.:**:***::*********:**:***.**:****:*:*.******:**********: 
 
Murine CNPGHMGPHCECGEDMVSTDSCKESPGHPSCSGRGDCYCGQCICHLSPYGSIYGPYCQCD 540 
Human  CHPGHMGPRCECGEDMLSTDSCKEAPDHPSCSGRGDCYCGQCICHLSPYGNIYGPYCQCD 540 
       *:******:*******:*******:*.***********************.********* 
 
Murine NFSCLRHKGLLCGDNGDCDCGECVCRDGWTGEYCNCTTNRDSCTSEDGVLCSGRGDCVCG 600 
Human  NFSCVRHKGLLCGGNGDCDCGECVCRSGWTGEYCNCTTSTDSCVSEDGVLCSGRGDCVCG 600 
       ****:********.************.***********. ***.**************** 
 
Murine KCVCRNPGASGPTCERCPTCGDPCNSKRSCIECYLSADGQAQEECADKCKAIGATISEE- 659 
Human  KCVCTNPGASGPTCERCPTCGDPCNSKRSCIECHLSAAGQAREECVDKCKLAGATISEEE 660 
       **** ****************************:*** ***:***.****  *******  
 
Murine DFSKDTSVSCSLQGENECLITFLITTDNEGKTIIHNINEKDCPKPPNIPMIMLGVSLAIL 719 
Human  DFSKDGSVSCSLQGENECLITFLITTDNEGKTIIHSINEKDCPKPPNIPMIMLGVSLAIL 720 
       ***** *****************************.************************ 
 
Murine LIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKH 779 
Human  LIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKQ 780 
       ***********************************************************: 
 
Murine KAGLSSDG 787 
Human  KVDLSTDC 788 
       *..**:*  
 
 
Figure 30 αvβ6 amino acid homology between mice and humans. 
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2.3 αvβ6 as a Biological Marker 
Neoplastic cells are characterised by genetic, epigenetic, cytoplasmic, cell surface 
and extracellular matrix changes. During the stages of carcinogenesis, certain 
molecules may become expressed ectopically, whereas others may be down-
regulated, on the cell surface of malignant cells. Such tumour markers often present a 
useful tool for cancer diagnosis and sometimes prognosis. The difference in the 
surface profile between cancerous cells and their non-malignant counterparts can 
serve as a molecular address for targeting reagents to deliver a molecule of choice to 
the desired cell type. As αvβ6 is 1) a cell surface molecule 2) expressed on cancers, 
but weak or absent on normal tissue and 3) associated with cancer progression, 
targeting αvβ6 represents a potential approach to detection and therapy of many 
types of cancer.  
 
The concept of αv integrin targeting and imaging has been reported previously. For 
example, αvβ3 is found at much higher levels on activated, as opposed to resting, 
endothelial cells [225, 226]. It also is over-expressed in certain tumours, such as 
melanomas, and weakly expressed on most normal organ systems. Haubner et al 
[226] 
18
F-labelled RGD-containing cyclo-glycopeptides to image αvβ3, using 
positron emission tomography (PET) in vivo. The authors used a melanoma 
xenograft model, M21, which expresses αvβ3, and M21-L which has weak 
expression and served as a negative control. Biodistribution studies were performed 
initially to prove that in vivo αvβ3 targeting had been achieved. Results revealed a 
tumour to blood ratio of 27.5 and a tumour to muscle ratio of 10.2, at 120 minutes 
post-injection (p.i.). At 120 minutes p.i. the % injected dose per gram (% I.D./g) in 
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the M21 xenograft was approximately 1.5. Higher % I.D./g for the tumour was 
achieved at earlier timepoints p.i., but this was at the expense of much smaller 
tumour to background ratios. Furthermore at 120 minutes p.i., the liver, colon and 
kidneys revealed a similar activity concentration to the αvβ3-expressing tumour. I 
also note that the lungs and spleen also had a relatively higher tracer uptake 
compared to blood and muscle. For their negative control M21-L xenograft mouse 
model the authors discovered a tracer uptake 3.8 times lower than that in the αvβ3-
positive tumour, between 60 and 120 minutes p.i.. Although the study showed αvβ3-
expressing tumour uptake of the radiolabelled peptide, it did not show that this 
specifically was αvβ3-dependent. Furthermore, αvβ3 receptor density was not 
determined quantitatively for the tumour models, e.g. immunohistochemistry or 
Western blot. Nonetheless the authors proceeded to PET studies and visualised the 
αvβ3-expressing tumour in the left flank of the mouse. This visualisation was in 
contrast to the negative control melanoma M21-L xenograft. Of note, only one 
mouse was imaged in each group. Haubner et al concluded that 
18
F-labelled peptides 
were suitable compounds for the non-invasive determination of αvβ3 integrin status 
and could be used for monitoring of therapy [226].  
In a later study, Haubner did correlate tracer uptake with αvβ3, as detected by 
immunohistochemistry and Western Blot [227]. At 90 min after tracer injection, their 
small-animal PET scanner showed increasing tracer uptake in the tumour 
corresponding with the percentage of receptor-positive cells. However, the full % 
I.D./g for each organ was not reported in this article. Furthermore, the % I.D./g for 
the M21 xenograft was now reported at only 1.07. Nevertheless, the authors 
proceeded to a human study and reported heterogeneous detection of αvβ3-
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expressing tumours [227]. The authors have suggested many possible reasons for this 
heterogeneous result. These include poor vascular access (perfusion and 
permeability) to some of the tumours, potential necrotic areas within tumours and 
sampling error confounding correlation. 
Hausner et al [228] have recently published initial results of our group’s lead peptide 
(A20FMDV2) radiolabelled with 4-[
18
F]fluorobenzoic acid and imaged on a PET 
scanner. In vitro sensitivity and specificity was documented for αvβ6. Male athymic 
nude mice were inoculated subcutaneously, on opposite shoulder areas, with either 3 
x 10
6
 αvβ6-expressing, or 3 x 106 αvβ6-non-expressing cells. Initially biodistribution 
experiments revealed uptake in the αvβ6-expressing tumour was 0.66% ID/g at 1 h, 
dropping to 0.28% and 0.06% ID/g at 2 and 4 h, respectively. In contrast, uptake in 
the control tumour stayed at less than one third of the αvβ6-expressing tumour at all 
time points (0.21%, 0.07%, and 0.02% ID/g at 1, 2, and 4 h, respectively). Other 
background measurements included blood (0.27%, 0.06%, and 0.03% ID/g at 1, 2, 
and 4 h, respectively) and muscle (0.56%, 0.22%, and 0.08% ID/g at 1, 2, and 4 h, 
respectively). Therefore, αvβ6-expressing tumour to blood and muscle ratios were 
around 3:1 and close to 1:1, respectively. Relative high levels of activity were also 
detected in the gall bladder (1 h, 15.1%I.D./g; 4 h, 1.97% ID/g) and stomach (1 h, 
1.33% ID/g; 4 h, 0.22% ID/g). The uptake of the lungs was not published. Despite 
the disappointing tumour to background ratios, PET images with good positive 
tumour/negative tumour and positive tumour/background ratios generally were 
obtained 30 to 90 min after injection [228]. Based on PET volume-of-interest 
analysis, the ratio of accumulated activity in the αvβ6-expressing tumour versus 
background improved steadily over time (1 h, 2.2:1; 3 h, 3.5:1). The authors showed 
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that the differences in tumour uptake were not caused by differences in tumour 
viability; utilising the metabolic tracer [
18
F]FDG as a surrogate for tissue viability. 
The similar uptake of the metabolic radiotracer in both tumours suggested 
comparable blood supplies and metabolic rates in both xenografts. 
  
The above studies all serve as a proof-of-principle for targeting and imaging of 
integrins within cancers. 
 
 
  We therefore have developed αvβ6-specific peptides for in vivo targeting of 
αvβ6. This project will describe the coupling of these peptides to γ-emitting 
radioisotopes and the use of SPECT to localise the peptide-isotope complex, in vivo. 
The advantages of the NanoSPECT system, (e.g. improved resolution; relative ease 
of availabilty of the SPECT radionuclides - see Table 8, page 118) in comparison to 
microPET, lend the former system to be more favourable for murine experiments. 
Initially, the characterisation of linear peptides will be illustrated. However later 
studies will demonstrate the use of cyclic peptides. Cyclisation and use of D-amino 
acids can be used to stabilise peptides whilst maintaining (and sometimes improving) 
their biological activity [190]. This increased stability aims to retard protease 
degradation and increase serum viability. This allows greater time for the ligand to 
bind to its target. 
 
 
 
 127 
 
 
 
2.4 Overview Of Project 
Previous work in the Tumour Biology Laboratory synthesised a panel of short 
peptides, which contained the known tripeptide integrin–binding motif, RGD [12]. 
Linear peptides were generated, screened and selected on their ability to inhibit 
αvβ6-dependent adhesion competitively on known high affinity ligands e.g. LAP. 
Results revealed that the lead peptide was A20FMDV2 [229]. It was derived from 
the GH loop of the viral surface protein VP1 of Foot and Mouth Disease Virus 
(FMDV). The NMR solution structure of A20FMDV2 is consistent with the X-ray 
crystallography data of the reduced, stabilised sequence in the VP1 protein of FMDV 
O1 BFS [230]. Nuclear Magnetic Resonance imaging demonstrated, and confirmed, 
that A20FMDV2 binds to αvβ6 via its RGDLXXL motif. Furthermore its extended 
carboxy α–helical structure is supportive to ligand binding. 
Therefore, A20FMDV2 and other candidate peptides were selected to be 
radiolabelled for pre-clinical validation of their potential use as in vivo targeted 
agents for imaging.  
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2.5 Project Objectives 
 
 To radiolabel A20FMDV2 and other candidate (v6-specific) ligands 
 To confirm in vitro specificity of the aforementioned probes and measure 
their affinity to v6-expressing cells  
 To establish whether the v6-specific probes are internalised and retained 
within cells 
 To examine the stability of  v6-specific probes upon purification 
 To determine the biodistribution and kinetics of v6-specific probes in vivo.  
 To establish optimal conditions for SPECT imaging of v6-expressing 
tumours in vivo.  
 To validate the v6-specific probes on other tumour models 
 To compare the targeting capacity of different v6-specific ligands as 
imaging modalities. 
 To translate the benchwork into clinical benefit, by developing a potential 
human trial design. 
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 Chapter III:  Materials and Methods 
 
3.1 Saline and Media Formulations 
The following were supplied by Cancer Research UK (CR-UK) Media Services 
(South Mimms, Herts): Dulbecco’s Modification of Eagle’s Medium (DMEM), 
Ham’s-F12 media and isotonic Phosphate Buffered Saline (PBS). 
 
3.2 Antibodies 
Several murine (unless stated otherwise) monoclonal antibodies (mAbs) were used in 
this study: FB12 (anti-α1 integrin subunit; Chemicon, Hampshire, UK), P1E6 (anti-
α2 integrin subunit; Chemicon), P1B5 (anti-α3 integrin subunit; Chemicon), 7.2 
(anti-α4 integrin subunit; CR-UK), P1D6 (anti-α5 integrin subunit; Chemicon), 
GOH3 (rat anti-α6 integrin subunit; Serotec), Y9A2 (anti-α9β1 integrin subunit; 
Chemicon), 3E1 (anti-β4 integrin subunit; Chemicon), LM609 (anti-αvβ3 integrin 
subunit; Chemicon), 10D5 (anti-αvβ6 integrin subunit, Chemicon), 14E5 (anti-β8 
integrin subunit, kind gift of Dr. S. Nishimura, UCSF, San Francisco, USA). P1F6 
(anti-αvβ5 integrin subunit, gift from Dr D. Sheppard, UCSF, San Francisco, USA) 
and AIIB2 (rat anti-β1 integrin subunit) were prepared in-house from hybridomas. 
62G2, 68G6 and 63G9 were supplied by Biogen Idec (Cambridge, MA, USA) [231]. 
Control mouse and rat IgG1 was purchased from DAKO (DAKOCytomation Ltd., 
Ely, UK). 
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3.3 Radioisotopes 
Indium chloride (
111
InCl3) was supplied by Tyco Healthcare UK Commercial Ltd. 
(Hampshire, UK). 
 
3.4 HPLC solvents 
HPLC solvents were sourced from Sigma-Aldrich (Dorset, UK) and were all ‘HPLC 
grade’. Ultra High Purity (UHP) water was obtained from an Elga Purelab Maxima 
water purification system (Buckinghamshire, UK). 
 
3.5 Cell Lines 
Table 9 (page 131) lists the cell lines used in this study. All cells grew as adherent 
monolayers, in 100% humidified atmosphere of 8% (v/v) carbon dioxide / air at 37
o
C 
(mouse keratinocytes at 33
o
C). The tumour cell lines routinely were tested for and 
found free of Mycoplasma and were grown in Falcon tissue culture flasks. 
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Cell Line Tissue of Origin Growth Media
§
 Reference 
A375P puro Skin melanoma DMEM Generated in-house [232] 
A375P β6 Skin melanoma DMEM Generated in-house [232] 
Mouse Keratinocytes Mouse Skin KGM DiPersio et al [233] 
MCF-10A Breast DMEM/F12 (1:1) DiPersio et al [233] 
MCF-10AneoT Breast DMEM/F12 (1:1) Santner et al [234] 
AT1K.c12 Breast DMEM/F12 (1:1) Santner et al [234] 
Ca1h Breast DMEM/F12 (1:1) Santner et al [234] 
CA1a Breast DMEM/F12 (1:1) Santner et al [234] 
MCF-10 DCIS.com Breast DMEM/F12 (1:1) Santner et al [234] 
 
Table 9 Summary of cell lines tested within this project. 
§
 Media supplements are described within text. 
 
 
3.5.1 Melanoma cell line as a model for β6 targeting  
Human melanoma cancer cell lines were obtained from the CR-UK stocks and 
maintained according to standard protocols. The A375P β6 and A375P puro cells 
were generated in-house, as follows: The A375P human melanoma cell line [232] 
was retrovirally infected with the full-length gene for the human β6 integrin subunit 
and the puromycin resistance gene, or solely the puromycin resistance gene; 
generating A375P β6 and A375P puro, respectively [141, 229, 235]. Cells were 
selected in puromycin (1.25 μg/ml) and then αvβ6-expressing cells were selected by 
magnetic bead sorting, using 10D5 (anti-αvβ6; Chemicon International), according to 
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the manufacturer’s instructions (Invitrogen). Clone 10D5 was also used in flow 
cytometry and function-blocking (see below).  
 
Cells were maintained on DMEM supplemented with 10% foetal calf serum (FCS; 
Biowest, Nuaille, France), 4mM glutamine (CR-UK Media Services) and 1.25µg/ml 
of puromycin.  
 
3.5.2 Breast Cell Lines 
A panel of human breast cell lines, all derived from the immortal MCF-10A 
line, were provided by the Barbara Ann Karmonos Cancer Institute (Detroit, 
Michigan, USA). MCF-10A, MCF-10AneoT and AT1K.c12 belonged to the MCF-
10A and MCF-10AneoT series. Ca1h, CA1a and MCF-10 DCIS.com belonged to the 
MCF-10CA1 series [234]. The culture medium for the MCF-10CA1 series of lines 
comprised DMEM/F12 with 5% horse serum (Invitrogen, Paisley, UK) and 4mM 
glutamine (CR-UK Media Services). The culture media for the MCF-10A and MCF-
10AneoT lines is similar, but supplemented with 20 ng/ml epidermal growth factor 
(Upstate Biotechnology Inc, Lake Placid, NY), 10μg/ml insulin (Sigma Chemical, St 
Louis, MO), 100 ng/ml cholera enterotoxin (Sigma Chemical), and 0.5μg/ml 
hydrocortisone (Sigma Chemical). 
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Figure 31 The MCF-10A cell series [234] 
. 
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Figure 32 The MCF-10AneoT cell series [228]. 
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Figure 33 The MCF-10CA1 cell series [234]. 
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3.5.3 Mouse Keratinocyte cell line 
Immortalised wild-type mouse keratinocytes were prepared from the temperature-
sensitive SV40 large T mouse (Immortomouse) as described previously [233]. 
Briefly, primary mouse keratinocytes were immortalised from mouse skin and grown 
in KGM, at 33
o
C. KGM consisted of low Ca
2+
 FAD (Cancer Research UK, London, 
UK), 10% FCS (chelated), 10
-10
M cholera toxin, 0.4 µg/ml hydrocortisone, 5 μg/ml 
insulin (all from Sigma Chemical), 10 ng/ml EGF (Life Technologies), but omitting 
the interferon-γ. The omission of interferon-γ switches off the temperature-sensitive 
mutant of the SV40 large T antigen (tsA58) immortalisation gene and therefore the 
keratinocytes have a primary cell phenotype. Immortalised keratinocytes were used 
for all experiments.  
Prior to seeding the keratinocytes, tissue culture plastic was pre-incubated with 
‘coating media’, at 37oC for at least one hour. The coating media comprised BSA 
(0.09 mg/ml; PAA Laboratories GmBH, Pasching, Austria), HEPES (18.5 mM; 
Sigma Chemical), calcium chloride (0.9 mM; Fisher Scientific UK Ltd, 
Leicestershire, UK) and Type 1 collagen (PureCol; diluted 1:100; Nutacon, The 
Netherlands) diluted in DMEM. After this period, the coating medium was removed 
and replaced with keratinocytes resuspended in KGM.[236] 
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3.5.4 Maintenance of cell lines 
 The A375P derived cells were sub-cultured approximately twice weekly by 
incubation with 0.25% (w/v) trypsin,  followed by centrifugation and neutralisation 
of the trypsin with growth medium, and distribution of the cell suspension to fresh 
tissue culture flasks together with fresh growth medium. 
The MCF-10CA1 series of lines were sub-cultured approximately twice 
weekly by incubation with 0.25% (w/v) trypsin  followed by centrifugation and 
neutralisation of the trypsin with growth medium, and distribution of the cell 
suspension to fresh tissue culture flasks with fresh growth medium. 
The MCF-10A and MCF-10AneoT series of lines were sub-cultured, 
approximately three times a week, using the following regime: three 8-10 minute 
incubations with 0.02% (w/v) versene, followed by differential trypsinisation with 
0.5% (w/v) stock trypsin solution. This procedure was followed by centrifugation 
and neutralisation of the trypsin with growth medium, and distribution of the cell 
suspension to fresh tissue culture flasks with fresh growth medium. 
The mouse keratinocytes were sub-cultured, approximately twice weekly, 
using differential trypsinisation with 0.25% (w/v) trypsin, at 37
o
C. The incubation 
was followed by centrifugation and neutralisation of the trypsin with growth 
medium, and distribution of the cell suspension to ‘coated’ tissue culture flasks with 
fresh growth medium. 
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3.5.5 Long-term Storage of Cell Lines in Liquid Nitrogen 
A375P derived cells in logarithmic-phase growth were detached as described above, 
the trypsin centrifuged off and neutralised by addition of growth media, and a single-
cell suspension of cells generated by pipetting. The cells were then re-pelleted by 
centrifugation, re-suspended in DMEM supplemented with 20% foetal calf serum 
and 10% dimethyl sulphoxide (DMSO; BDH, distributed by VWR UK), transferred 
to 2ml cryovials (Falcon) and stored overnight within insulated polystyrene boxes 
(Eprak, Scotlab, Scotland) at -80
o
C. The vials were then relocated to liquid Nitrogen 
for long-term storage. Vials subsequently were defrosted at 37
o
C and the cells 
washed once in warm growth media before plating. 
The breast cell lines in logarithmic-phase growth were detached as described above, 
the trypsin centrifuged off and neutralised by addition of growth media, and a single-
cell suspension of cells generated by pipetting. The cells were then re-pelleted by 
centrifugation and re-suspended in DMEM/F12 medium containing 20% calf serum 
supplemented with 10% dimethyl sulphoxide (DMSO; BDH, distributed by VWR 
UK). Aliquots of this cell suspension were transferred to 2ml cryovials (Falcon) and 
stored overnight within insulated polystyrene boxes (Eprak, Scotlab, Scotland) at -
80
o
C. The vials were then transferred to liquid Nitrogen for long-term storage. Vials 
subsequently were defrosted at 37
o
C and the cells washed once in warm growth 
media before plating. 
The mouse keratinocytes in logarithmic-phase were detached as described above, the 
trypsin centrifuged off and neutralised by addition of growth media, and a single-cell 
suspension of cells generated by pipetting. The cells were then re-pelleted by 
centrifugation and re-suspended in Calcium-depleted FBS containing 10% dimethyl 
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sulphoxide (DMSO; BDH, distributed by VWR UK). Aliquots of this cell suspension 
were transferred to 2ml cryovials (Falcon) and stored overnight within insulated 
polystyrene boxes (Eprak, Scotlab, Scotland) at -80
o
C. The vials were then 
transferred to liquid Nitrogen for long-term storage. Vials subsequently were 
defrosted at 37
o
C and the cells washed once in warm growth media before plating. 
 
 
3.6 Peptides 
All peptide sequences used in this report are given in Appendix I. Peptides B-DBD1 
and B-Ran were supplied by Bachem (Merseyside, UK). All other peptides were 
synthesised by Cancer Research UK Peptide Synthesis Laboratory using the 
following solid-phase peptide synthesis protocol (provided by Ms Rebecca Black). 
Protected amino acids and pre-loaded Wang resins were obtained from Calbiochem-
Novabiochem (Nottingham, UK). Solvents and HBTU [2-(1H-benzotriazol-lyl)-1, 1, 
3, 3-tetramethylironium hexafluorophosphate] were obtained from Applied 
Biosystems (Warrington, UK). The peptides were synthesised on a Model 433A 
Applied Biosystems Solid Phase Synthesiser on preloaded Wang resin using basic 
feedback monitoring cycles and HBTU as a coupling reagent. 9-
fluoroenylmethylcarbonyl was used for temporary α-amino group protection and 
removed using piperidine. Side-chain protecting groups were tert-butloxycarbonyl 
for Lys; trityl for His, Asn and Gln; 2, 2, 4, 6, 7-pentamethyldihydro-benzofuran-5-
sulfonyl for Arg; tert-butylester for Glu and Asp and tert-butyl ether for Thr, Ser and 
Tyr. 
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Cleavage of the resin and deprotection of the peptides was achieved by treating the 
peptidyl-resin with 10 mls of a mixture containing 9.25mls trifluoroacetic acid, 
0.25mls ethanedithiol, 0.25mls tri-isopropylsilane and 0.25mls water at 20
o
c (room 
temperature) for 4 hours. The peptide was precipitated using ice-cold di-ethylether 
and then filtered on a fine sintered glass filter funnel under light vacuum. The 
peptide precipitate was dissolved in 10% acetic acid / water solution and freeze-
dried. 
 
The crude peptides were analysed by Agilent 1100 reverse phase HPLC and 
electrospray mass spectroscopy. Peptides were purified by reverse phase HPLC to 
greater than 90% pure, on an Aquapore ODS 20 micron 250 x 10 mm column. 
Peptides were supplied lyophilised and stock solutions prepared in 0.1% 
Trifluoroacetic acid (TFA; Sigma Chemical).  
 
Standard concentrations were confirmed spectrophometrically using absorption at 
215nm, as follows: A 10 l 0.1% TFA reconstituted sample was diluted to 1000 l 
with UHP water. A blank was created using similar ratios of 0.1% TFA and UHP 
water. The absorbancies of the samples were measured at 215 nm, on a Beckman DU 
600 general purpose UV/Vis spectrophotometer, with a 1250 ml quartz micro-
cuvette. The concentration of the sample is thus calculated using the Beer-Lambert 
Law. 
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To a selection of peptides, the chelating agents diethylenetriamene pentaacetate-tetra 
(DTPA t-Bu ester; Macrocylcics, Texas, USA) or 1,4,7,10-Tetraazacyclododecane-
1,4,7-tris-tert-butyl acetate-10-acetic acid (DOTA-tris t-Bu ester; Macrocylcics) 
were added to the N-terminus, and a lysine residue biotinylated. These peptides 
essentially were synthesised using the method described above. However, the DTPA 
/ DOTA addition was carried out between synthesis and cleavage, when the final 
Fmoc had been removed but all the other protecting groups were still present. 
Furthermore, during cleavage the peptides were centrifuged for 10mins at 3700rpm, 
instead of filtering them in a sinter funnel to avoid contact with glass.  
 
3.7 Flow Cytometry Experiments 
3.7.1 Analysis Of Integrin Expression Using Flow Cytometry  
Single cell suspensions were generated as described above and collected by 
centrifugation at 4
o
C. All of the following steps occurred at 4
o
C. The supernatant 
was removed, and cells were re-suspended in a buffer consisting of 20mM Tris pH 
7.5, 150mM NaCl, 20mM EDTA, 0.1% azide, 0.1% BSA and distilled water (EDTA 
0.1/0.1). The cells were washed (by centrifugation and pellet resuspension) a further 
two times in the aforementioned cation chelating buffer. Finally, the cells were 
washed three times, pelleted and resuspended in MgCa 0.1/0.1 buffer consisting of 
20mM Tris pH 7.5, 150mM NaCl, 0.5mM MgCl2, 1mM CaCl2, 0.1% sodium azide, 
0.1% BSA and distilled water. Cells were counted, and 100,000 cells were placed 
into each well of a Falcon 353911 flexible plate. Cells were then incubated for 40 
min with the desired integrin-specific antibody (10 μg/ml) antibody, isotype IgG1 
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(10 μg/ml) control (DAKOCytomation Ltd., Ely, UK), or diluent alone [141]. All 
dilutions were made using MgCa 0.1/0.1 buffer. After washing, cells were incubated 
for 20 min with a 1:200 dilution of Alexa-488 conjugated goat anti-mouse IgG 
(Molecular Probes). Samples were again washed in MgCa 0.1/0.1 wash buffer. 
Finally, the cells were resuspended in 400µL of wash buffer and transferred to a 
Falcon 2054 tube. Cells were analysed on a Becton Dickinson FACS LSR1. Analysis 
was performed using Cell Quest (v3.3), measuring 10,000 events per sample and 
gating performed to exclude cell debris and apoptotic cells. 
 
3.7.2 Confirmation of Biotinylated Peptide binding to Cells by Flow 
Cytometric Analysis 
The method was similar to that for integrin profiling, but the integrin-specific 
antibody was substituted with biotinylated peptide, diluted to the desired 
concentration in MgCa 0.1/0.1 wash buffer. Furthermore, after the peptide 
incubation, the cells were washed and incubated for 30 min with a 1:120 dilution of 
mouse anti-biotin IgG (Jackson ImmunoResearch, Stratech, Soham, Cambridgeshire, 
UK). Once this incubation had been completed, the cells were washed and incubated 
for 20 min with a 1:200 dilution of Alexa-488 conjugated goat anti-mouse IgG 
(Molecular Probes). The protocol then continued as described above for the Analysis 
Of Integrin Expression. 
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3.7.3 Anti- αvβ6 Competition Assay to Confirm Binding Specificity of 
Peptide 
Murine keratinocytes in suspension were washed three times with EDTA 0.1/0.1 
cation chelating buffer and then three times with the TBS-Mn 0.1/0.1 wash buffer. 
TBS is Tris-Buffered-Saline and was prepared by CR-UK Media Services, using 
25mM Trizma base, 15mM NaCl, 3mM KCl, 0.7mM NaH2PO4, 5.6 mM D-glucose 
and 0.04mM phenol red. The addition of 1mM manganese chloride, 0.1% azide and 
0.1% BSA to TBS produced TBS-Mn 0.1/0.1 wash buffer. All of the following steps 
occurred at 4
o
C. Cells (2x10
5
/50µl) were resuspended in TBS-Mn 0.1/0.1 
supplemented with either 10μg/ml 68G6 (mouse anti-αvβ6, Biogen Idec) or non-
immune control IgG1. After a 30 minute incubation, biotinylated peptide was added 
to the aforementioned cell-antibody suspensions (final peptide concentration 10 nM). 
After a further 40 minute incubation, cells were washed three times in TBS-Mn 
0.1/0.1. Bound biotinylated peptide was detected by incubation for 30 minutes with 
10 μg/ml polyclonal rabbit anti biotin (Abcam, Cambridge, UK). After two washes 
with TBS-Mn 0.1/0.1, wells were designated to be incubated with either a 1:250 
dilution of Alexa-647 goat anti-rabbit IgG (Molecular Probes) or a 1:200 dilution of 
Alexa-488 conjugated goat anti-mouse IgG (Molecular Probes), or both were added 
to the cells. Dual colour allowed differential detection of bound anti-αvβ6 antibody 
from bound biotinylated peptide. Following this 20 minute incubation, cells were 
washed three times with TBS-Mn 0.1/0.1 wash buffer, resuspended in 400µL of 
wash buffer and transferred to a FACS Falcon 2054 tube. Cells were analysed on a 
Becton Dickinson FACS LSR, using FL-1H, FL-5H and FL-3H channels. Analysis 
 144 
was achieved using Cell Quest (v3.3), measuring 10,000 events per sample and 
propidium iodide gating performed to exclude dead cells. 
A similar method was employed to confirm peptide binding specificity on the A375P 
derived cells. However, the use of EDTA 0.1/0.1 cation chelating buffer was not 
required and the TBS-Mn 0.1/0.1 wash buffer was substituted for DMEM 0.1/0.1 
wash buffer. DMEM 0.1/0.1 comprises DMEM, 0.1% azide and 0.1% BSA. 
 
 
3.8 Transwell® Invasion Assays 
Cell invasion assays utilised Transwell® plates (Costar®, Corning Incorporated, Life 
Sciences, Corning NY, USA) in which an upper and lower chamber are divided by a 
polycarbonate insert. The polycarbonate membrane, incorporated for these assays, 
was 6.5 mm in diameter and penetrated by 8µm pores. Furthermore, these inserts 
were coated with 70 µL of diluted Matrigel® (Becton Dickinson) and allowed to 
polymerise at 37
o
C, for 1 hour. Single cell suspensions were generated as described 
above and collected by centrifugation at 4
o
C. However, the cells were re-suspended 
in serum-free media. Following Matrigel® polymerisation, 5 x 10
4
 cancer cells were 
plated in the upper chamber and the appropriate ‘complete’ media dispensed in the 
lower chamber, acting as a chemoattractant. The Transwell® plate was incubated for 
24-72 hours in 100% humidified atmosphere of 8% (v/v) carbon dioxide / air, at 
37
o
C. 
After incubation, the cells which invaded the Matrigel® and passed through the 
membrane into the lower chamber were counted. This counting procedure involved 
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collection of the complete media from the lower chamber and dispensing the cell 
suspension into a prepared counting tube containing a known volume of CASY®ton 
solution (Schärfe System GmbH, Reutlingen, Germany). The transfer of cells from 
the lower chamber and lower surface of the membrane was facilitated by trypsin / 
versene incubation for 1 hour, at 37
o
C. Subsequent careful washing of the insert and 
lower chamber ensured maximal transfer of harvested cells from chamber to the 
counting tube. The cell counts were quantified using a CASY automated cell counter 
(Schärfe System GmbH). Each condition was replicated at least in triplicate and 
individual experiments were repeated at least three times. 
Blocking experiments additionally used one of the anti-αvβ6 antibodies (68G6 or 
63G9) which were pre-mixed with the cancer cells, 30 minutes prior to plating, and 
these treatments were compared to pre-mixing with a control antibody (e.g. 7.2) 
. 
3.9 Radiolabelled Peptide Studies 
3.9.1 Peptide Radiolabelling  
Lyophilised peptide preparations were reconstituted in 0.1% TFA and further diluted 
to desired concentrations (0.1-20 μg/μl). 111InCl3 was added to the peptide at the 
desired specific activity, within a cryogenic vial (Corning, New York, USA), and 
buffered with ammonium acetate, pH 5.5 (20% of indium volume added). Precise 
specific activities were determined using a CRC-15 Beta dose calibrator (Capintec, 
New Jersey, USA). Sealed cryovials were vortexed briefly and incubated for thirty 
minutes, either at room temperature (DTPA peptides) or 100
o
C (DOTA peptides). 
Following incubation the reaction was quenched with 0.1M Sodium EDTA (5% of 
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reaction volume) and buffered with PBS to the desired injection volume. 
Radiopeptides prepared for saturation assays also had 1µL of 1mg/ml cold InCl3 
added to the reaction mixture, prior to EDTA quenching. 
Radiolabelling efficiency and purity of the radiolabelled compound were analysed by 
reverse phase high-performance liquid chromatography (RP-HPLC). Analysis was 
performed using a Beckmam system Gold HPLC (166 NM detector; Beckman, High 
Wycombe, UK), its proprietary software and a Jupiter 300A column (5μm C18, 259 
x 4.60 mm; Phenomenex, Macclesfield, UK) with a flow rate of 1 ml/minute. The 
mobile phase consisted of a linear gradient of increasing acetonitrile in 0.1% aqueous 
TFA, according to the following schedule: 0-5 minutes, 0% acetonitrile; 5-25 
minutes, 0-60% acetonitrile; 35-37 minutes, 100-0% acetonitrile. Radioactivity was 
detected via a sodium-iodide detector (Raytest ‘Gabi’; Raytest UK Ltd, Chesterfield 
UK) interfaced to a multichannel analyser. 
 
 
3.9.2 Radioligand binding studies:  Saturation Assays 
A375Pβ6 cells were incubated at 37oC for 24-48 hours and grown to 60-80% 
confluency within six-well plates (Falcon, Tissue Culture treated, Becton Dickinson).  
After the desired confluency was reached, wells were washed with DMEM media in 
order to remove unbound cells. To each well was added a volume of 150 l of 111In-
DTPA-A20FMDV2 (varying from 200nM to 1nM concentrations, diluted in 
PBS/1%BSA) together with 1.2 l of DMEM/1% BSA /0/1% azide.  To determine 
background non-specific binding, selected wells also had 150 l of non-radiolabelled 
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DTPA-A20FMDV2 (10µM) added. To those wells not selected for the addition of 
non-radiolabelled DTPA-A20FMDV2, 150 l of PBS/1%BSA was added to keep 
reaction volumes and concentrations comparable. The plates were incubated at 37
o
C 
for ninety minutes, after which the wells were washed twice with ice-cold 
DMEM/1% BSA /0/1% azide, and then cells were lysed with 1ml of 1M NaOH for 
15 min. Transfer of lysates into labelled scintillation tubes was facilitated by twice 
washing with PBS. Three 150 μl aliquots of 111In-DTPA-A20FMDV2, at each 
prepared molarity, were placed in three scintillation tubes to provide standards and a 
method to relate radioactivity counts to molarity, for the assay. The radioactivity 
associated with lysates and standards was measured on a Gamma Counter (LKB 
Compugamma, Victoria, Australia). Each radioligand molarity was analysed in 
triplicate and the respective mean amount of bound radioactivity determined.  The 
specific binding of the radiopeptide was calculated by subtracting the non-specific 
binding from the total cell-radioligand binding. After counting the radioactivity, 
protein was measured in cell lysates using a commercial kit (BioRad DC Assay, 
Netherlands). Using non-linear regression analysis with GraphPad Prism version 
4.00 for Windows (GraphPad Software, San Diego California USA), Kd and BMAX 
were determined. 
 
3.9.3 Radioligand binding studies: Cell Internalisation Assay 
The extent and rate of internalisation of the 
111
In-DTPA-A20FMDV2 was studied 
with A375P β6 cells. Cells were grown to 60-80% confluency in six-well plates and 
washed with DMEM. A volume of 150 l of 111In-DTPA-A20FMDV2 (20 ng/ml, 
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diluted in PBS/1%BSA) was added together with 1.2 l of ice-cold DMEM/1% BSA 
to each well, either in the absence or presence of 150 l of unlabelled DTPA-
A20FMDV2 (10µM). To those wells not selected for the addition of non-
radiolabelled DTPA-A20FMDV2, 150 l of PBS/1%BSA was added to keep 
reaction volumes and concentrations comparable. The plates were incubated at 37
o
C 
for various time points after which triplicate wells were analysed as follows:- 
Internalisation was interrupted (at pre-selected time points) by removing the medium 
and washing twice with ice-cold DMEM/1% BSA. Surface-bound radioactivity was 
removed by a 25 minute treatment of intact cells with 1 ml DMEM-HCl acid buffer 
at pH 4, on ice. Please note, that the acid wash buffer and its duration was tested in 
separate optimisation experiments (see below). The transfer of the membrane-bound 
radioligand fraction into labelled scintillation tubes was facilitated by a further 30 
second wash with the acid wash buffer. Following this, the internalised activity was 
collected after lysing the cells with 1 ml 1M NaOH and washing twice with PBS. 
Three 150 μl aliquots of 111In-DTPA-A20FMDV2 were placed in three separate 
scintillation tubes to provide standards and a measure of the total radioactive counts 
for the assay. The radioactivity content of collected fractions and standards were 
measured on a gamma counter, and the specific internalised fraction expressed as a 
percentage of the initial radioactivity added per milligram of cell protein. In addition, 
the specific internalised fraction was expressed in relation to the total activity bound 
to cells i.e. the sum of the internalised and membrane bound fractions equates to the 
total cell-bound activity. After counting the radioactivity, protein was measured in 
cell lysates using a commercial kit (BioRad DC Assay, Netherlands). 
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3.9.3.1 Optimisation of Cell Internalisation Assay 
In order to determine the most efficient acid wash buffer, to remove the membrane-
bound radioligand fraction, optimisation experiments were carried out. A375P β6 
cells were grown to 60-80% confluency in six-well plates and washed with DMEM. 
All of the following procedures were performed ‘on-ice’ (unless stated) to minimise 
internalisation. A volume of 150 l of 111In-DTPA-A20FMDV2 (20 ng/ml, in 
PBS/1%BSA) was added together with 1.2 l of ice-cold DMEM/1% BSA to each 
well, either in the absence or presence of 150 l of unlabelled DTPA-A20FMDV2 
(10µM). To those wells not selected for the addition of non-radiolabelled DTPA-
A20FMDV2, 150 l of PBS/1%BSA was added to keep reaction volumes and 
concentrations comparable. The plates were incubated on ice for 30-60 minutes to 
permit radioligand and receptor interaction, but minimal internalisation. After this 
incubation, triplicate wells were analysed as follows:- 
Radioligand and receptor interaction was interrupted (at pre-selected time points) by 
removing the medium and washing twice with ice-cold DMEM/1% BSA. Surface-
bound radioactivity was removed by different acid wash buffers and at varying 
incubation times. The transfer of the membrane-bound radioligand fraction into 
labelled scintillation tubes was facilitated by a further 30 second wash with the acid 
wash buffer. Following this, the residual, undisplaced, membrane-bound radioligand 
activity was collected after lysing the cells with 1 ml 1M NaOH and washing twice 
with PBS. This assumes that minimal internalisation took place on ice. Three 150 μl 
aliquots of 
111
In-DTPA-A20FMDV2 were placed in three separate scintillation tubes 
to provide standards and a measure of the total radioactive counts for the assay. The 
radioactivity content of collected fractions and standards were measured on a gamma 
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counter. The acid wash removed fraction was expressed as a percentage of the total 
membrane-bound radioligand .  
 
3.9.3.2 Cell Viability Check  
It is necessary to determine whether acid wash buffer exposure initiates membrane 
permeabilisation; thus potentially invalidating subsequent internalisation assay 
calculations. A375P β6 cells were grown to 60-80% confluency in six-well plates 
and washed with DMEM. Selected wells were subjected to the optimal duration of 
incubation of each acid wash buffer, on ice. Furthermore, selected wells were also 
subjected to the optimal durations with the addition of three minutes, on ice. After 
each incubation period, 0.25% trypsin was added to the well and incubated at 37
o
C, 
followed by centrifugation and neutralisation of the trypsin with serum-free medium. 
A sample of the cell suspension was aspirated off and added to 0.08% trypan blue. 
After standing for 5 min at room temperature, a sample of the cell suspension and 
trypan blue was introduced into a haemocytometer and examined under a light 
microscope. The percentage of viable cells in each acid wash buffer condition was 
compared to control wells, which simply had DMEM incubation, followed by 
trypsinisation. Each condition was replicated at least in triplicate and individual 
experiments were repeated at least three times. 
 
3.9.3.3 Correlation of Cell Protein with Cell Number 
Single cell suspensions of A375P β6 were generated as described above using 
centrifugation, trypsinisation and re-suspension with serum-free growth medium. 
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The cells were washed (by centrifugation and pellet re-suspension) a further two 
times in PBS. The cell concentration was quantified on a Casy™ Counter (Schärfe 
System GmbH), using a sample of the suspension. Protein was measured in a further 
sample, after pellet formation, careful supernatant aspiration and cell lysis, using a 
commercial kit (BioRad DC Assay). 
 
3.10 In vivo studies 
Specific-pathogen-free mice were either purchased from Charles River or Harlan or 
bred at Clare Hall, South Mimms and housed in the Biological Services Unit, at 
Charterhouse Square, London. Food and water were available ad libitum. Animal 
care and treatment followed guidelines approved by the Home Office (United 
Kingdom). 
 
Cells for injection were harvested by trypsin detachment (described above), then 
either washed three times in serum-free DMEM (A375P line), or in serum-free 
DMEM/F12 (MCF-10A descendants). Cells were then counted and the concentration 
adjusted to 2 x 10
7
 cells/ml.  
In one grouping of experiments, athymic mice were given subcutaneous injections of 
2 x 10
6
 A375Pβ6 cells (right shoulder) and 2 x 106 A375P puro cells (left shoulder). 
In a separate category of experiments, 2 x 10
6
 cells of the desired breast cancer line 
were injected subcutaneously into athymic mice (right shoulder only); either in 
serum-free media alone or mixed in 50% Matrigel. Depending on the experiment, 
CD1 nu/nu, Balb C nu/nu or ICRF nu/nu strains were used. Two to four weeks later, 
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once the tumours had reached at least 5-7 mm diameter, biodistribution and imaging 
experiments took place. 
 
 
3.10.1 Plasma Stability Studies 
To investigate stability in plasma, mouse plasma was collected from nu/nu mice and 
incubated with the radiolabelled peptide, at 37
oC. Simultaneously, a ‘control’ 
incubation in 0.1 M PBS (pH 7.2) also occurred, at 37
o
C. At pre-selected time-
points, samples of both incubation mixtures were mixed with an equal volume of 
acetonitrile, and solids were removed by centrifugation followed by RP-HPLC 
analysis of the supernatant. 
 
3.10.2 Biodistribution 
Tumour-bearing mice were given intravenous injections of between 1-10 MBq of 
Indium-labelled peptide, formulated as described above and in a volume of 
approximately 100μL. Exact injection quantities were determined for each mouse by 
recording the syringe mass before and after injection, on an electronic balance. At 
pre-selected timepoints, mice were killed and major organs removed by dissection. 
Organs were rinsed briefly in PBS and sealed in pre-weighed scintillation tubes. 
These tubes were then re-weighed to calculate the net tissue weight, and the 
associated radioactivity was quantified by analysis in a Gamma Counter (LKB 
Compugamma, Victoria, Australia).  
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‘Standards’ were created by adding a 10 ml mixture of PBS and BSA (concentration 
1mg/ml) to a labelled 15 ml polypropylene centrifuge tube (Corning). To this 
mixture, a known volume of radiopeptide was injected using a syringe and needle, 
mimicking the method used for the intravenous murine injections. Once equilibrium 
within the mixture was attained, one millilitre samples were dispensed into separate 
scintillation tubes. Furthermore, a 1 mL sample was diluted 1 in 10 with PBS and 
mixed. Samples from the diluted mixture were taken and also dispensed into separate 
scintillation tubes. Simultaneous gamma measurement of the standards with tissue 
samples enabled calculations of the potential injected dose activities / counts. Thus, 
data could be recorded as the percentage injected dose per gram of tissue (%I.D./g). 
A375P β6 tumours to background ratios were calculated and a paired t test was used 
for statistical analysis between both xenografts. 
 
 
 
3.10.2.1 Peptide Mass Studies 
The ideal mass of DTPA-A20FMDV2 for injection was investigated by estimating 
the biodistribution of 
111
In-DTPA-A20FMDV2 in tumour-bearing mice, at varying 
specific activities. A range of peptide masses (from 0.1µg to 20µg), each 
radiolabelled with the same amount of radioactivity (10 MBq), was injected into 
different cohorts of mice. Biodistribution was determined as described above, at 1-hr 
post-injection. The tumour-to-background ratios and %I.D./g were compared for 
each specific activity. 
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3.10.2.2 Co-injection Studies in vivo 
The receptor(αvβ6)-mediated uptake of 111In-DTPA-A20FMDV2 was investigated 
by estimating the biodistribution of 
111
In-DTPA-A20FMDV2 (4μg / 1 MBq) injected 
into  tumour-bearing mice, in the presence or absence of 100-fold excess (400μg) of 
non-radiolabelled DTPA-A20FMDV2. Biodistribution was determined as described 
above, at 1-hr post-injection.   
To determine the effect of an excess of non-targeting peptide on the uptake of 
A20FMDV2, 
111
In-DTPA-A20FMDV2 (4μg / 1 MBq) was co-injected into tumour-
bearing mice with 400μg of non-radiolabelled DTPA-A20FMDVran. Biodistribution 
was determined as described above, at 1-hr post-injection. 
 
3.10.2.3 NanoSPECT /CT 
Mice bearing subcutaneous tumours were anaesthetised with isofluorane and each 
given intravenous injections of either 
111
In-DTPA-A20FMDV2 (4µg/10-30 MBq), 
111
In-DOTA-A20FMDV (4µg/10-30 MBq) or 
111
In-DTPA-DBD2 (2µg/10-30 MBq);  
formulated as described above and in a volume of around 100μL. The animals were 
placed in a tail-first, prone position on the scanner bed, in an air-warmed animal 
chamber. Mice were imaged at half, one, two and four hour timepoints, using a CT-
NanoSPECT small animal imager (Bioscan, Washington, D.C., USA). A typical 
SPECT study designed for 50,000 – 100,000 counts for 16 - 24 projections; resulting 
in a 20 – 60 minute scan time (dependent on injected activity). Images were analysed 
using In Vivo Scope software (Bioscan, Washington, D.C., USA). 
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3.11 Immunohistochemical staining and evaluation. 
Murine tissues from three ICRF nu/nu mice were formalin-fixed and paraffin-
embedded. Five-micron-thick, formalin-fixed and paraffin-embedded tissue 
histology sections were deparaffinised, hydrated, incubated at 37
o
C with 3 Digest-All 
3 Pepsin Solution (Invitrogen Corporation, Carlsbad, CA) for 5 minutes for antigen 
retrieval, and washed in phosphate buffer (PBS). Endogenous peroxidase was 
neutralised with 0.45% hydrogen peroxidase in methanol for 15 minutes. Avidin-
biotin pre-treatment (Vector Laboratories, Burlingame, California, USA) was 
incorporated to block endogenous biotin. The slides were incubated, at room 
temperature, with mouse anti-αvβ6 (Biogen™ antibody - 6.2G2) at 2µg/ml for 30 
min (n.b. later 62G2 batches required higher concentrations [6µg/ml] overnight 
incubations, at 4
o
C). After washing, bound antibody was detected using a Mouse-on-
Mouse kit (Vector BMK-2202 M.O.M Kit). The tissues were stained with 3, 3'-
diaminobenzidine tetrahydrochloride (DAB) freshly prepared using the Dako K-3468 
system, and then counterstained with Mayer’s haematoxylin (1-2 minutes), 
dehydrated, and mounted in DPX. Formalin-fixed, paraffin-embedded, mouse 
keratinocyte specimens were used for antibody optimisation, and later as positive 
controls. Isotype-matched antibodies were used as negative controls. 
Cell membrane staining was quantified by a pathologist, blinded to the sample 
identity. Staining in each sample was quantified from sections using an eight-value 
membrane Quick score (0 to 7+) based on algorithms developed and standardised for 
oestrogen receptor immunohistochemistry, in breast cancer [237]. The staining 
intensity was scored out of three (1, weak; 2, moderate; 3, strong), and the proportion 
of epithelial cells staining positively was scored out of four (1, <25%; 2, 25-50%; 3, 
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51-75%; 4, 76-100%). The score for intensity was added to the score for proportion 
to give a score in the range of 0 to 7 and grouped as - (score = 0), + (score = 1-3), ++ 
(score = 4-5), or +++ (score = 6-7) [238]. 
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Chapter IV 
 Results: Characterisation and Optimisation of αvβ6 
Targeting Agents 
 
 
 
 
 
4.1 Melanoma Cell Model for Targeting αvβ6 
The A375P puro and A375Pβ6 cell lines were tested for their surface integrin 
expression, using flow cytometry. The integrin subunit antibody was tested and 
compared with the appropriate isotype control (black line). Figure 34 shows that 
A375P puro and A375Pβ6 both express four different RGD-binding integrins, but 
only A375P β6 expresses αvβ6 [235]. Therefore, this model is ideal for testing the 
sensitivity and specificity of RGD peptides against αvβ6. 
 
 
 
Figure 34 Integrin Expression Profiles of A375P puro and A375Pβ6, using flow 
cytometry 
αvβ6 αvβ8 αvβ5 αvβ3 α5β1 
A375Pβ6 
 
A375Ppuro 
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4.2 Assessment of Peptide Sensitivity and Specificity by Flow 
Cytometry  
A20FMDV2 was tested at a range of concentrations (10µM-1nM; 30 mins 
incubation) on the melanoma cell model, described above. As A20FMDV2 was 
biotinylated, bound peptide was detected by antibody detection of the biotin. Results 
revealed a relationship between concentration of peptide and resultant binding to 
A375Pβ6 cells. 
 
 
Figure 35 Peptide Affinity to the A375Pβ6 cell line, using flow cytometry. 
 
 
The black lined histogram (see Figure 35) represents the negative control for the 
system, using mouse IgG. The grey shaded histogram represents clone 10D5 
(commercial antibody to αvβ6) and serves as a positive control for the system, as 
well as a comparison for peptide binding. Clearly, the A375P β6 cell line expresses 
αvβ6 at its surface, as demonstrated by the approximate two log difference (median 
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fluorescence intensity) in binding compared with the negative control. Furthermore, 
an overlapping pattern of binding for the peptide was shown at a concentration of 
10nM (red line). Although, the pattern is overlapping, this experiment cannot 
confirm whether the peptide is binding to the same molecule as the anti-αvβ6 clone - 
this will be tested in later competition assays. Nevertheless, there was a 
concentration-dependent relationship between varying amounts of peptide and 
constant levels of αvβ6; with even some binding occurring at 1nM (lowest 
concentration tested, violet line). 
 
The specificity of A20FMDV2 was examined by analysing binding to the (non-β6 
expressing) A375P puro cell line. 
 
 
Figure 36 Peptide specificity using A375P puro (non-β6 expressing) cell line and 
flow cytometry. 
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The black lined and the grey shaded histograms (see Figure 36) again represent the 
mouse IgG negative and 10D5 positive controls for the system, respectively. The 
10D5 overlap with the negative control confirms the absence of surface αvβ6 on the 
A375P puro cell line. With respect to the A20FMDV2, even at the highest 
concentration tested (10 μM), there was an absence of significant binding to the 
(non-β6 expressing) A375P puro cell line. That is, A20FMDV2 is at least 1000-fold 
(and maybe 10,000 fold) more specific for A375Pβ6 than for A375P puro. In 
summary, A20FMDV2 is specific and has good affinity for the β6 expressing cell 
line. 
 
 
 
4.3 Peptide Derivatisation and Effects on Affinity and Specificity 
Molecular modification techniques permit the synthesis of a variety of bioactive 
peptides with chelating groups, without necessarily compromising biological 
properties. A20FMDV2 was synthesised with the DTPA (diethylenetriamine penta-
acetic acid) chelating agent on the N-terminus (DTPA-A20FMDV2). The DTPA 
chelating agent would facilitate future radiolabelling (see later). However, this 
modification had the potential to interfere with binding efficacy. Therefore studies 
comparing the affinity and specificity on the A375P cell lines were carried out.  
Again, both peptides were biotinylated, and so bound peptide was detected by 
antibody detection of the biotin.   
 161 
 
Figure 37 Comparing the affinity and specificity of A20FMDV2 with DTPA-
A20FMDV2, using flow cytometry. 
 
Figure 37 reveals a ‘side-by-side’ comparison of the original peptide and its 
derivative. Essentially, identical patterns of A375Pβ6 binding are seen with the 
peptide and the derivative. That is, at equal concentrations of peptide, both DTPA-
A20FMDV2 and A20FMDV2 bound to almost identical levels to A375P6 cells 
suggesting that both bind with similar affinity. Furthermore, identical absence of 
binding is seen with the peptide and its derivative, for the A375P puro line. That is, 
the addition of DTPA to A20FMDV2 did not result in any increased binding to other 
RGD integrins (51, v3, v5, and v8). Therefore, the comparison assays 
reveal that the DTPA modification did not alter the specificity and affinity 
significantly for the A375Pβ6 cell line. Additionally, the experiments were 
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performed in magnesium- and calcium-containing buffers and so it is highly likely 
that the derivative bound the cations; therefore chelate formation also did not seem to 
affect sensitivity or specificity. 
We also tested the ability of our control, scrambled peptide (A20FMDV2ran), both 
as DTPA-modified and non-modified variants, to bind to A375P6 and A375Ppuro 
cells. Figure 38 shows that, even at the highest concentration (10µM), neither 
peptide bound to either cell line; confirming that scrambling the RGD motif in the 
peptide was sufficient to destroy any integrin-specific binding, but also did not 
generate any novel binding activity.  
Figure 38 Comparing the affinity and specificity of A20FMDV2ran with DTPA-
A20FMDV2ran, using flow cytometry. 
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4.4 Competition with αvβ6-Function Blocking Antibody in the A375P 
β6 cell line 
The data in Section 5.3 suggested that DTPA-A20FMDV2 bound specifically  to 
v6 but, to prove this, A375P6 cells were pre-incubated with the v6-blocking 
antibody 68G6 (10µg/ml; Biogen Idec) [231] or control IgG1, for 30 minutes before 
adding 10nM DTPA-A20FMDV2 for an additional 40 minutes.  After washing off 
unbound material and labelling cells with anti-biotin antibody, bound 68G6 was 
detected on the FL1-H channel, using Alexa-488 conjugated goat anti-mouse IgG 
(Molecular Probes). However, bound peptide (or absence of binding) was detected 
on the FL5-H channel, using Alexa-647 goat anti-rabbit IgG (Molecular Probes). 
Results revealed that, whereas the presence of IgG1 (light-blue shaded histogram and 
dark-blue lined histogram of inset) had not changed the binding capacity of DTPA-
A20FMDV2 (compared with nil antibody treatment), the presence of 68G6 (green 
shaded histogram and green-lined histogram of inset), however, had suppressed 
binding of the peptide completely.  The complete abrogation of binding is signified 
by the essential overlap of the 68G6 green-shaded histogram with that of the 
negative control (black line). Thus DTPA-A20FMDV2 binds in an v6-dependent 
manner to A375P6 cells (Figure 39).  
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Figure 39 αvβ6-dependent adhesion of A20FMDV2 to A375P β6 cells, using flow 
cytometry (description within text). 
 
 
4.5 Competition with αvβ6-Function Blocking Antibody in Mouse 
Keratinocytes 
Since the DTPA-A20FMDV2 peptide was planned to be used for imaging v6 in 
mice, the specificity for mouse αvβ6 integrin (as well as to human αvβ6 within the 
A375P line) had to be established.  To prove that the binding of the peptide to mouse 
cells was αvβ6-dependent, a similar competition assay to that used in Section 5.4 was 
incorporated. In these assays, the αvβ6 ligand docking site was again inhibited by the 
ligand–mimetic 68G6, but now mouse keratinocytes were pre-incubated with either 
non-immune IgG or 68G6. This was followed by further incubation with 10nM of 
biotinylated A20FMDV2. Of note, all reagents and incubations were buffered with 
TBS-Mn
2+
, to avoid terminal differentiation of the keratinocytes (see Discussion) 
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[239]. After a series of washes and incubations, bound 68G6 was detected on the 
FL1-H channel, using Alexa-488 conjugated goat anti-mouse IgG (Molecular 
Probes). However, bound peptide (or absence of binding) was detected on the FL5-H 
channel, using Alexa-647 goat anti-rabbit IgG (Molecular Probes). 
 
Figure 40 αvβ6-dependent adhesion of A20FMDV2 to mouse keratinocytes, 
using flow cytometry (description within text). 
 
The competition assays (see Figure 40) revealed that 10nM of A20FMDV2 bound 
effectively to mouse keratinocytes (filled blue histogram, FL5-H), in the presence of 
non-immune IgG (dark blue line histogram, inset FL1-H). However, this binding was 
abolished totally (filled green histogram, FL5-H), when 68G6 was bound to mouse 
keratinocytes (light green line histogram, inset FL1-H). Of note, the black line 
histogram in FL5-H represents absence of peptide in the presence of non-immune 
IgG; that is, it represents the negative control. In summary, the binding of 
A20FMDV2 to mouse keratinocytes is αvβ6-dependent. 
 166 
 
4.6 Immunohistochemical staining and Evaluation of Murine Tissues. 
As stated above, the radiolabelled peptides were to be used for imaging v6 in mice 
and although the expression of 6 mRNA had been documented in primates [134], 
the baseline levels of αvβ6 expression in mice had not been established. This 
expression profile is particularly important, given that A20FMDV2 recognises 
murine αvβ6, described in Section 5.5. Therefore, ICRF nude mice (n=3) bearing 
double subcutaneous xenografts of A375P β6 and A375P puro tumours were killed 
approximately two to three weeks after inoculation (see Methods). Subsequently, 
organs were harvested, fixed and paraffin-embedded for histological examination. 
The following section describes staining patterns of the αvβ6-expressing organs and 
exhibits representative images. All the harvested organs were tested for αvβ6 
expression (right-sided image) and compared with an isotype negative control 
antibody (left-sided image). 
 
4.6.1 Skin 
The majority of the skin essentially is negative. However, there is focal staining of 
the outer root sheath of a number of hair follicles. The intensity is moderate and is 
scored at 3+, using the eight-value membrane score. 
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Figure 41 Murine skin staining for αvβ6. Left image is negative control and right 
is 62G2 staining. 
 
4.6.2 Uterus 
The uterus has occasional glands which stain for αvβ6. This positive staining is 
usually discovered in endometrium of a secretory phase uterus. Nevertheless, this 
staining is weak to moderate and scored only 2+, using the eight-value membrane 
scoring system.  
 
 
Figure 42 Murine uterine staining for αvβ6. Left image is negative control and 
right is 62G2 staining. 
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4.6.3 Gallbladder 
The entire epithelilum of the gallbladder stained positively for αvβ6. The intensity 
was moderate-to-high and scored 6 to 7+, the highest levels of intensity. 
 
Figure 43 Murine gallbladder staining for αvβ6. Left image is negative control 
and right is 62G2 staining. 
4.6.4 Urinary Bladder 
There was moderate staining of the entire urinary bladder epithelium. It scored 6+, 
indicating a high level of αvβ6 expression. 
 
Figure 44 Murine urinary bladder staining for αvβ6. Left image is negative 
control and right is 62G2 staining. 
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4.6.5 Stomach 
The entire epithelium of the stomach stained for αvβ6. All of the gastric glands were 
strongly positive and this tissue scored 7+, on our scoring system. 
 
 
Figure 45 Murine gastric staining for αvβ6. Left image is negative control and 
right is 62G2 staining. 
 
 
4.6.6 Duodenum 
There was strong staining at the tips of the villi of the duodenum, with obvious 
membrane localisation between the individual enterocytes. However the intensity 
decreased as the villus was followed down to the crypts. As a result the overall score 
for the duodenum was assigned at 5+. 
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Figure 46 Murine duodenal staining for αvβ6. Left image is negative control and 
right is 62G2 staining. 
 
 
4.6.7 Ileum 
There was strong staining at the tips of the villi of the ileum, as can be seen in the 
‘honeycomb’ type of appearance in the presented image. However the intensity 
decreased as the villus was followed down to the crypts. As a result the ileum scored 
4+ overall. 
 
Figure 47 Murine ileal staining for αvβ6. Left image is negative control and right 
is 62G2 staining. 
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4.6.8 Colon 
There is strong staining at the tips of the villi of the colon. However the intensity 
decreases as the villus is followed down to the crypts. As a result the colon scores 
4+.  
 
 
Figure 48 Murine colonic staining for αvβ6. Left image is negative control and 
right is 62G2 staining. 
 
 
In summary, the entire GI tract stains for αvβ6. However, the strongest intensity was 
seen in the stomach, and in general this intensity was decreased as the GI tract was 
followed down its length, from proximal to distal portion. 
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4.6.9 Xenografts 
The A375Pβ6 tumours revealed strong staining throughout the tumour and scored 
7+.  
 
Figure 49 Murine A375P β6 xenograft staining for αvβ6. Left image is negative 
control and right is 62G2 staining. 
 
As expected, the A375P puro tumours showed an absence of β6 expression, scoring 
0. These results indicate that the A375P tumours maintained their β6 (or lack of) 
expression, in vivo and that growth within the animal did not result in de novo 
expression of this integrin subunit. 
 
Figure 50 Murine A375P puro xenograft staining for αvβ6. Left image is negative 
control and right is 62G2 staining. 
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Therefore, these results demonstrate that murine keratinocytes, gallbladder, urinary 
bladder, secretory endometrium and GI tract normally express detectable levels of 
v6 expression (see Table 10, page 174). This normal or baseline expression 
appears to be very different from that reported for primates [240] and this positivity 
of murine tissue has to be borne in mind, whilst using the mouse as a model for 
targeted imaging.  
 
Immunohistochemistry using biotinylated A20FMDV2 was attempted on paraffin 
sections, but unfortunately did not yield any specific staining for v6 and thus these 
results were not incorporated in this thesis. 
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Organ system and tissue Score Comment 
 
Digestive System 
 
 
Salivary Glands 0  
Stomach 7 Entire epithelium stains strongly 
Pancreas 0  
Liver 0  
Gallbladder 6-7 Moderate staining of entire epithelium 
Duodenum 5 Strong staining at the tips of the villi. 
However the intensity decreases as the 
villus is followed down to the crypts. 
Ileum 4 
Colon 4 
 
Urinary System 
 
 
Urinary Bladder 6 Moderate staining of entire epithelium 
Kidney 0  
 
Female Reproductive System 
 
 
Uterus 
2 
Weak to moderate focal staining in 
glands, of secretory phase endometrium. 
Mammary Glands 0  
 
Lymphatic system 
 
 
Residual Thymus 0  
Lymph Nodes 0  
Spleen 0  
 
Cardio-respiratory system 
 
 
Heart 0  
Lungs 0  
 
Nervous System 
 
 
Brain 0  
Eyes 0  
 
Endocrine System 
 
 
Thyroid 0  
 
Musculoskeletal System 
 
 
Bone 0  
Skeletal Muscle 0  
Skin 
3 
Focal staining of the outer root sheath of 
a number of hair follicles. 
 
Xenografts 
 
 
A375P B6 tumour 7 Strong staining throughout the tumour 
A375P Puro tumour 0 Complete absence of staining 
 
Table 10 Pattern of v6 expression in murine tissues, as detected by 
immunohistochemistry. 
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4.7 Peptide Radiolabelling and Quality Control 
To create a γ-emitting probe, DTPA-A20FMDV2 was radiolabelled with indium to 
generate 
111
In-DTPA-A20FMDV2. Reverse-phase HPLC was used to analyse the 
labelling efficiency and to evaluate the structural integrity of the radiolabelled 
targeting ligand. 
111
In-DTPA-A20FMDV2 was eluted in a single peak, with a 
retention time of around 20 minutes (see Figure 51). The radiochemical purity of the 
radiolabelled 
111
In-DTPA-A20FMDV2 was over 99%, according to this analysis. 
Furthermore, there was no evidence of fragmentation or aggregation during the 
labelling process, as indicated by the sharp single peak. 
 
 
Figure 51 Reverse phase HPLC trace measuring 
111
In-DTPA-A20FMDV2 
radiolabelling efficiency. 
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Secondly, the scrambled peptide, DTPA-A20FMDV2ran also was radiolabelled with 
indium to generate 
111
In-DTPA-A20FMDV2ran.  It too was analysed by reverse-
phase HPLC and found to elute in a single peak, with a retention time which also 
was around 20 minutes (see Figure 52). The radiochemical purity of the 
radiolabelled 
111
In-DTPA-A20FMDV2ran approached 100%, with no evidence of 
fragmentation or aggregation of the compound.  
 
 
 
 
Figure 52 Reverse phase HPLC trace measuring 
111
In-DTPA-A20FMDV2ran 
radiolabelling efficiency 
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4.8 Radioloigand binding studies 
4.8.1 Saturation Binding Assays 
Use of v6-blocking antibodies revealed that the binding of DTPA-A20FMDV2 to 
the A375P β6 cell line is αvβ6-dependent i.e. single receptor binding (see Section 
4.4). To determine the affinity of DTPA-A20FMDV2 binding to v6 on A375P 6 
cells, saturation binding assays were performed. These experiments involved 
incubating a range of concentrations of 
111
In-DTPA-A20FMDV2 with adherent 
A375P 6 cells, in the presence and absence of 10,000-fold excess of non-
radiolabelled peptide.  Results of binding assays confirmed that, after labelling with 
Indium-111, DTPA-A20FMDV2 retained the ability to bind to its specific receptor 
and showed a dose-dependent binding to A375P 6 cells (Figure 53). After 
subtracting the non-specific background binding (that occurred in the presence of the 
excess cold peptide) the calculated mean affinity constant (Kd) was 1.73×10
−9
M, 
ranging from 1.27×10
-9
 to 2.19×10
−9
 (95% confidence interval). 
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Figure 53 Saturation binding assay of 
111
In-DTPA-A20FMDV2 to adherent 
A375P 6 cells. TB=Total Binding.  Non-specific (NS) binding was determined by 
co-addition of excess non-radiolabelled DTPA-A20FMDV2.  Specific-binding (SB) 
was calculated by the following formula: TB-NS = SB. 
 
 
 
4.8.2 Internalisation Assays  
v6 mediates virus binding and internalisation, and thus infection of foot-and-
mouth disease, via its RGD-containing capsid protein [108]. It was therefore 
hypothesised that 
111
In-DTPA-A20FMDV2 also may be internalised. To confirm this 
hypothesis, internalisation assays of DTPA-A20FMDV2 on A375P 6 cells were 
performed.  
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4.8.2.1 Optimisation of Cell Internalisation Assay 
However, in order to perform the calculations necessary for an accurate 
internalisation assay, an efficient acid wash buffer is required. An efficient acid wash 
buffer should remove the membrane-bound radioligand fraction, but without 
disrupting the cell’s structural integrity and its internalised radioligand fraction.  
Therefore, optimisation experiments on a range of commonly used acid wash buffers 
were carried out. Firstly, Cell Viability experiments (see Methods) were performed 
to determine the maximum exposure time of A375P β6 cells to the different acid 
buffers, prior to membrane permeabilisation and significant percentage of cell death. 
Membrane permeabilisation was determined using the trypan blue reagent, with the 
percentages of viable cells counted and compared to control buffer incubations. 
Secondly, using ‘near-confluent’ A375P β6 cells set ‘on-ice’ conditions (minimising 
internalisation); 
111
In-DTPA-A20FMDV2 was added, either in the absence or 
presence of unlabelled DTPA-A20FMDV2. After a 30-60 minute ‘ice-incubation’ 
(permitting radioligand and receptor interaction, but minimal internalisation) the 
unbound radioligand was washed and decanted. Subsequently, the surface-bound 
radioactivity was removed by different acid wash buffers used at maximal exposure 
times. Finally, the residual, undisplaced, membrane-bound radioligand activity was 
collected after lysing the cells. The acid wash removed fraction was expressed as a 
percentage of the total membrane-bound radioligand (see Table 11, page 180). It 
should be noted that the exposure time for each buffer (documented in parentheses) 
is the maximum permitted, prior to significant numbers of A375P β6 cell 
permeabilisation / death, as determined in the Cell Viability experiments. 
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Removed Surface 
Fraction 
Residual Surface 
Fraction  
% Surface Removal 
Efficiency 
E4 / BSA  
‘Control’ Media  
(30 minutes) 
6186 9037 40.64% 
Glycine pH 2.8  
(5 minutes) 
6752 12137 37.75 
Acetate pH 5  
(12 minutes) 
16289 5980 73.15% 
E4/HCl pH 4  
(25 minutes) 
26652 1637 94.21% 
Table 11 Comparison of Different Acid Wash Buffer Efficiencies. 
 
 
Table 11 (above) reveals that E4/HCl (pH 4), at an exposure time of 25 minutes, is 
the most efficient acid wash buffer, without causing significant cell permeabilisation. 
 
4.8.2.2 Internalisation Assay with 
111
In-DTPA-A20FMDV2 on A375P 6 cells, 
using E4/HCl (pH 4) 
Having established the optimal conditions, internalisation assays of DTPA-
A20FMDV2 on A375P 6 cells were performed. These assays involved variable 
incubation periods of a set concentration of 
111
In-DTPA-A20FMDV2 with adherent 
A375P 6 cells, in the presence and absence of 10,000-fold excess of non-
radiolabelled peptide.  Experiments compared surface-bound radioactivity to 
internalised activity. Results revealed that the internalisation of 
111
In-DTPA-
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A20FMDV2 in A375P β6 cells was rapid, reaching a plateau after about 60 minutes 
(see Figure 55). A similar experiment was performed and analysed by confocal 
microscopy, detecting the internalising DTPA-A20FMDV2 by labelling the biotin 
tag.  It can be seen that at time 0 minutes most of the peptide remained at the 
membrane of A375P 6 but by 45 minutes, most of the peptide was located in the 
cytoplasm (see Figure 56). In contrast, almost no peptide bound to, or was 
internalised by, A375P puro, suggesting that internalisation into A375P 6 is v6-
dependent (see Figure 54). 
 
 
Figure 54 Internalisation Assay: 
111
In-DTPA-A20FMDV2 (20 ng/ml) was added to 
adherent A375P6 cells and incubated at 37oC. Acid washes removed the surface-
bound fraction. The residual radioactivity represented the internalised fraction. 
Internalisation is represented as a proportion of the added dose, per milligram of 
cellular protein for both A375P 6 and A375P Puro cell lines.  
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Figure 55 Internalisation Assay: Results for 
111
In-DTPA-A20FMDV2 expressed as 
percentage of bound ligand, rather than  added dose, for A375P 6 cells only. 
 
Figure 56 Internalisation Assay: Pictures are confocal images which reveal initial 
membrane localisation of the peptide, but this is followed by cytoplasm translocation 
at 45 minutes in A375P6 cells. Note: DAPI nuclear staining was performed only 
with A20FMDV2 (lower panel). 
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4.9 In vivo studies  
4.9.1 Plasma Stability Studies 
Plasma stability is an important parameter to consider in drug discovery and 
development. Peptides are exposed in plasma to enzymatic processes (proteinases, 
esterases), which may result in intra-molecular rearrangement, aggregation or 
degradation. Therefore, the stability of a compound in plasma can strongly influence 
its in vivo efficacy. Plasma stability assays were thus performed on 
111
In-DTPA-
A20FMDV2, using RP-HPLC to measure structural integrity of the labelled peptide. 
111
In-DTPA-A20FMDV2 was incubated at 37
o
C in either PBS or murine plasma for 
various periods of time.  Firstly, incubation in PBS showed high stability, with only 
around 10% loss of purity at 24 hours. This result was considered to be a favourable 
point with regard to chemical storage and transport. In contrast, and as expected for a 
linear peptide, there was degradation of the radioligand in plasma. Figure 57 shows 
that at 2 hours, 63% of the radiopeptide remained intact whereas by 4 hours only 
46% remained undegraded.  The RP-HPLC trace, after 4 hours plasma incubation, 
displays obvious fragmentation and aggregation of the peptide (see Figure 57, inset).  
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Figure 57 Plasma Stability Study: 
111
In-DTPA-A20FMDV2 was incubated at 37
o
C 
in either PBS or murine plasma for various periods of time.  After the selected time 
periods, samples of the incubation mixture were analysed on an RP-HPLC. Stability 
was preserved in PBS up to 24 hours after initation of incubation; whereas plasma 
stability was affected considerably after only 4 hours incubation. 
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4.9.2 Biodistribution 
Preclinical biodistribution studies are designed to investigate the dissemination of a 
test compound within an appropriate animal model. The resulting pattern of 
dissemination can inform on the likely efficacy of in vivo targeting and from such 
results, it may be possible to infer potential toxicity from the non-target tissue data. 
111
In-DTPA-A20FMDV2 was injected intravenously into each ‘bi-xenografted’ 
mouse (described in Methods). Mice were killed at the pre-selected time-points, 
dissected and major organs were harvested. The associated radioactivity of each 
organ was quantified (expressed as percentage of injection dose per unit mass of 
tissue) and used as an indirect measure of peptide uptake and organ retention. 
 
4.9.2.1 Post-Injection Interval Studies  
Initially, 10 MBq of 
111
Indium was radiolabelled onto 2μg of DTPA-A20FMDV2 
and the peptide uptake in the xenografts was compared at various time points (see 
Figure 58). A combination of properties (maximal differential uptake between the 
A375P β6 and the A375P puro tumours and high %I.D./g in the A375P β6 tumour) 
occurred between 1 to 2 hours p.i. (post-injection). The ratio of A375P β6 tumour 
uptake and retention to that of A375P puro consistently was around 7:1. At 1 hour 
post-injection, the mean % injected dose per gram was around 2.1% ± 0.25 for the 
A375P β6 tumour, compared with 0.31% ± 0.07 for the A375P puro tumour. An 
interval of 1 hour post-injection was therefore chosen for further analyses. 
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4.9.2.2 Peptide Mass Studies  
To determine the optimal peptide mass for biodistribution and imaging, ranges of 
peptide masses (from 0.1µg to 20µg) of DTPA-A20FMDV2, but labelled with 
similar  amounts of radioactivity (
111
In), were injected into different cohorts of mice; 
tumour retention at 1-hour post-injection was then measured. Figure 59 reveals that 
the maximum %I.D./g tumour occurred with an injection mass of 2 µg peptide; 
attaining  1.72%+/-0.41 %I.D./g and a retention 5.6-fold more in the A375P6 
tumour than in the A375Ppuro tumour. Subsequent experiments showed that a 4 µg 
peptide injection could also deliver excellent, and sometimes superior, results. Thus 
subsequent experiments used peptide injection masses in the range of 2 to 4 µg.  
 
 
4.9.2.3 Species Generalisation Experiments  
To be certain that our findings could be generalised to other athymic mouse models,  
uptake of radiopeptide in xenografts grown in ICRF nu/nu mice were compared with 
xenografts grown in CD1 nu/nu and Balb/C nu/nu mouse strains. The results at 1h 
post-injection showed (see Figure 60) that uptake and retention ratios of 
A375P6:A375P puro were maintained, regardless of the strain of athymic mouse 
studied. Ratio of uptake of A375P6:A375P puro for CD1, Balb/C and ICRF 
athymic mice was 7:1, 8:1 and 9:1, respectively. Furthermore, for CD1 nudes, at one 
hour post-injection, the A375Pβ6 tumour-to-muscle ratio and tumour-to-blood ratio 
was 9:1 (n=3).  
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Figure 58 Determining the optimal parameters for pre-clinical imaging studies 
of v6.  111In-DTPA-A20FMDV2 (10 MBq) was injected into groups of tumour-
bearing mice.  At 0.5, 1, 2 and 4 hours post-injection three mice were killed and 
tumours removed and the % ID/g tissue determined.  Data suggested that examining 
mice 1-2 hours after injection of 
111
In-DTPA-A20FMDV2 would be the optimal time 
point for such assessments.  
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Figure 59 Determining the optimal parameters for pre-clinical imaging studies 
of v6.  To determine the optimal specific activity for studies various different 
masses of DTPA-A20FMDV2, each labelled with 10 MBq of indium-111, were 
injected into tumour-bearing mice.  At 1 hour post-injection three mice were killed 
and tumours removed and the % ID/g tissue determined.   
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Figure 60 A375P6 and A375Ppuro xenografts. CD1, Balb/C and ICRF nu/nu 
athymic mice bearing A375 β6 and A375 puro tumours were injected with 10 MBq 
of 
111
In-DTPA-A20FMDV2 and after 1 hour the tumours removed and the %I.D./g 
tissue determined. Results suggested that the strain of mouse did not affect the ratio 
of uptake in A375P6 versus A375Ppuro tumours. 
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4.9.2.4 Whole body biodistribution 
 
Having optimised the time-frame for analysis, peptide mass for injection, and 
established that all mouse strains tested performed equally well, full tissue 
biodistribution on tumour-bearing mice was undertaken; harvesting organs at 1h 
post-injection of 
111
In-DTPA-A20FMDV2 (1 MBq / 4 µg). Figure 61 indicates that 
several organs retained significant amounts of radioactivity at 1 hour.  In addition to 
the A375P 6 tumour, the lower gastrointestinal (GI) tract, lungs, stomach, skin and 
gall bladder all have retained significantly more radioactivity than either A375P puro 
tumour or skeletal muscle. With the exception of the kidneys and lungs, these 
positive tissues all express v6 endogenously as described in Section 4.6, which 
suggests that 
111
In-DTPA-A20FMDV2 recognises and binds to endogenous vβ6-
expressing tissues.   
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Figure 61 
111
In-DTPA-A20FMDV2 tissue biodistribution. 
111
In-DTPA-
A20FMDV2 was injected into tumour bearing mice. After 1 hour animals were 
killed and tumours and major organs were harvested and the % ID/g tissue 
determined.  Data show that several organs retained significant amounts of 
radiopeptide.   
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4.9.2.5 Co-injection Studies in vivo 
To establish that the measured 
111
In-DTPA-A20FMDV2 retention within organs was 
through a receptor-dependent mechanism, rather than via a peptide-dependent 
increase in vasodilatation and vessel permeability (blood pooling), receptor 
specificity studies were performed. A 100-fold (400µg) excess of non-radioactive 
DTPA-A20FMDV2 peptide was co-injected with 4µg 
111
In-DTPA-A20FMDV2 and 
a full tissue biodistribution performed at 1 hour post-injection. If peptide residence 
within the A375P β6 tumour was solely as a consequence of a vasodilatory 
mechanism then an excess of cold peptide, co-injected with the radiolabelled peptide, 
should increase subsequent hot peptide retention. However, if peptide residence 
within the A375P β6 tumour was as a consequence of a receptor-mediated 
mechanism, an excess of cold peptide co-injected with the radiolabelled peptide, 
would be expected to decrease the subsequent hot peptide retention. The results 
show that the excess cold peptide significantly decreased the uptake of 
111
In-DTPA-
A20FMDV2 in the stomach, lower GI tract, skin and in the A375P β6 tumour (see 
Figure 62). For example, A375Pβ6 tumour uptake of 111In-DTPA-A20FMDV2 was 
reduced from 2.0% ID/g to 0.68% ID/g; whereas, in contrast, there was no 
significant change in uptake into the A375P puro tumour (0.81% to 0.88% ID/g). 
Therefore, these data suggest that the peptide retention in vβ6-expressing tissues is 
a consequence of a receptor-ligand interaction and, therefore they also imply that this 
mechanism potentially is ‘saturable’.  
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Figure 62 100-fold excess of non-radiolabelled DTPA-A20FMDV2 was co-
injected with 4µg/1MBq of 
111
In-DTPA-A20FMDV2. After 1 hour animals were 
killed and tumours and major organs were harvested and the %I.D./g tissue 
determined.  Black shaded histograms represent ‘control’ comparison of 4µg/1MBq 
of 
111
In-DTPA-A20FMDV2, whereas white histograms represent co-injections. The 
data show that ‘cold’ peptide suppressed uptake in all v6-expressing tissues, but 
also within kidneys and lungs; endogenousv6 expression was not detected in 
latter two organs. 
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It should be noted that co-injection of cold DTPA-A20FMDV2 caused a >50%  
reduction in the retention of  
111
In-DTPA-A20FMDV2 within the kidneys (71%+/-29 
to 32%+/-19 I.D./g) and within the lungs (1.8%+/-0.5 to 0.5%+/-1.5 I.D./g). 
However, since kidney and lung expression of v6 were not detected by 
immunohistochemistry, radiopeptide retention in these organs may not be related to 
receptor (v6)-specific binding, but instead may occur via a different saturable 
mechanism. Biodistribution of an indium-111-radiolabelled scrambled peptide (
111
In-
DTPA-A20FMDV2ran), which was composed of the identical amino-acids to 
A20FMDV2 and thus had identical charge and hydrophobicities, was undertaken to 
ensure that these physical properties were not responsible for distribution patterns. 
Figure 38 showed that DTPA-A20FMDV2ran does not recognise β6 in vitro and 
Figure 63 confirms the same activity in vivo.  Thus there was no significant 
difference in uptake by the A375P β6 versus the A375P puro (0.16 +/-0.04% versus 
0.18 +/-0.03% ID/g, respectively) tumour.  
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Figure 63 Biodistribution of 
111
In-DTPA-A20FMDV2ran (scrambled peptide). 
111
In-DTPA-A20FMDV2ran was injected into tumour bearing mice. After 1 hour 
animals were killed and tumours and major organs were harvested and the %I.D./g 
tissue determined.  Data showed no significant radiopeptide uptake in A375P puro or 
A375P 6 tumours, nor in most other tissues (excluding kidney, the site of 
excretion). Inset displays data for xenografts only, with scale adjusted to show the 
minimal % I.D./g of 
111
In-DTPA-A20FMDV2ran in these tumours. Some 
radiopeptide was associated with the lower GI tract. 
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Having established that the DTPA-A20FMDV2ran peptide behaved in vivo as it did 
in vitro, this peptide next was tested to see whether its renal retention was also via a 
saturable recycling mechanism. A 100-fold excess (400µg) of non-radiolabelled 
DTPA-A20FMDV2ran was co-injected with 4µg/1MBq of 
111
In-DTPA-
A20FMDV2, and biodistribution performed at 1 hour post-injection in the normal 
fashion.  
Firstly, Figure 64 shows that co-injection of ‘cold’ DTPA-A20FMDV2ran has had 
no significant effect on radiopeptide uptake and retention in the vβ6-expressing 
tissues, including A375P6 tumours, compared with the control group.  
However there was a moderate, although not significant, reduction in the retention of 
111
In-DTPA-A20FMDV2 in the kidney (70 +/-8% to 47 +/-16% I.D./g) following 
scrambled peptide co-injection; a reduction that was similar to that achieved with the 
wild-type peptide. Since the kidney retention of 
111
In-DTPA-A20FMDV2 can be 
partially suppressed by saturating the retention mechanism with scrambled peptide, 
these results suggest that the mechanism of kidney retention may not be fully RGD-
specific, and thus is not likely to be operating via an v6-dependent system.  
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Figure 64 100-fold excess of non-radiolabelled scrambled peptide (DTPA-
A20FMDV2ran) co-injected with 4µg/1MBq of 
111
In-DTPA-A20FMDV2. Black 
shaded histograms represent ‘control’ comparison of 4µg/1MBq of 111In-DTPA-
A20FMDV2, whereas white histograms represent co-injections. After 1 hour 
tumours and major organs were harvested and the %I.D./g tissue determined.  
Results show that the scrambled peptide had no effect on uptake in v6-expressing 
tissues but brought about a reduced uptake in the kidney. 
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4.9.2.6 Non-Biotinylated 
111
In-DTPA-A20FMDV2 
Although the renal retention of 
111
In-DTPA-A20FMDV2 can be suppressed with 
scrambled peptide and the level of radioactivity retention is acceptable for imaging 
studies, it is desirable to limit the kidney’s exposure further when considering 
potential therapeutic studies and repeated doses of radiopeptide. It was hypothesised 
that the biotinylated lysine may affect renal filtration, reabsorption and secretion of 
the 
111
In-DTPA-A20FMDV2. Therefore, biodistribution experiments, at 1h post-
injection, compared the dissemination of a non-biotinylated form of 
111
In-DTPA-
A20FMDV2 (2µg/1MBq) to the wild-type peptide (2µg/1MBq). Figure 65 shows 
that the renal uptake and retention of the non-biotinylated radiopeptide was over 
double that of the wild-type peptide (160%+/-9 to 71%+/-8 I.D./g). Conversely, the 
lower GI tract and gallbladder had higher uptake and retention values for the wild-
type peptide over the non-biotinylated form. However, the standard deviations were 
relatively large in these organs, making interpretation of these data difficult. 
Fortunately, there did not seem to be any significant differences in uptake and 
retention of the xenografts or remaining vβ6-expressing tissues. Therefore, these 
results suggest that biotinylation of a lysine residue within 
111
In-DTPA-A20FMDV2 
can affect renal handling, but that such a procedure seems not to affect the affinity 
and specificity for vβ6, in vivo. 
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Figure 65 Biodistribution of biotinylated peptide vs. non-biotinylated peptide. 
Both versions of radiolabelled DTPA-A20FMDV2 (2µg/1MBq) were injected into 
separate cohorts of tumour bearing mice. After 1 hour animals were killed and 
tumours and major organs were harvested and the % ID/g tissue determined. Black 
shaded histograms represent biotinylated 
111
In-DTPA-A20FMDV2, whereas white 
histograms represent non-biotinylated 
111
In-DTPA-A20FMDV2.  Data showed that 
biotinylation of a lysine residue within 
111
In-DTPA-A20FMDV2 can affect renal 
handling, but that such a procedure seems not to affect the affinity and specificity for 
vβ6, in vivo. 
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4.9.3 NanoSPECT/CT Small Animal Imaging 
DTPA-A20FMDV2 has been shown, in the studies so far, to exhibit high sensitivity 
and specificity for αvβ6, both in vitro and in vivo. To determine whether 111In-
DTPA-A20FMDV2 (4µg/10-30 MBq per mouse) could be used as a molecular-
specific imaging agent, it was injected intravenously into the aforementioned ‘bi-
xenografted’ athymic mice. The mice were anaesthetised and imaged at pre-selected 
time-points, using a high-resolution single photon emission computed tomography 
small animal imager fitted with a separate, computed tomography scanner 
(NanoSPECT/CT).  
The imaging findings generally were in harmony with the biodistribution results and 
a representative coronal image is shown (see Figure 66). The signals from the 
A375P β6 tumours consistently were found to be higher than those from the non-β6 
expressing control tumours. Moreover, the resolution of the NanoSPECT/C.T 
permitted the observation that the radioligand was not distributed uniformly through 
the tumour but rather appeared to be located in high-activity nodules, which were 
spatially distinct.  Images, with a clearly identifiable β6-positive tumour, routinely 
were obtained as early as 30 min, and as late as 4 hours, post-injection. The best 
images, delineating ideal differentiation between the A375P β6 and the A375P puro 
tumours and other background tissues, occurred at 1 hour post-injection; correlating 
with the biodistribution results already reported. This experiment was repeated (n=9) 
with similar results. High signals were observed from the kidneys and bladder, when 
injected without co-injection of ‘cold’ DTPA-A20FMDV2ran. Figure 66 also shows 
a Maximal Intensity Projection (MIP) which displays uptake in the GI tract, 
corresponding with localisation of endogenous vβ6 expression. Thus 111In-DTPA-
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A20FMDV2 specifically is retained by v6-expressing tissues and this suggests 
strongly that this is a reagent which can be used to identify v6-expressing cancers 
selectively. 
 
 
In summary, the findings reported in this section have shown that 
111
In-DTPA-
A20FMDV2 selectively localises to β6 expressing tissues in a ‘bi-xenograft’ athymic 
mouse model. This selective localisation can be discerned, and visualised, on a 
NanoSPECT/CT and the distribution patterns indicate that there was not 
homogenous distribution throughout the entire tumour mass. 
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Figure 66 Non-invasive imaging of v6-expressing tumour with 111In-DTPA-
A20FMDV2. 10-30MBq of 
111
In-DTPA-A20FMDV2 was injected i.v. into mice 
bearing A375P puro (left-shoulder) and A375P 6 (right-shoulder) tumours.  After 1 
hour the mice were imaged on a NanoSPECT/CT. LEFT:  Coronal slice showing that 
the radiopeptide has accumulated selectively in the A375P 6 tumour.  In contrast 
the A375P puro tumour was negative. RIGHT:  Maximum Intensity Projection (MIP) 
of images from a different mouse; confirming that the A375P 6 tumour, kidneys, 
bladder and lower GI tract all labelled strongly. 
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Chapter V 
 Results: Validation of αvβ6 Targeting on other Models and 
the Study of other Peptide Variants  
 
5.1 Breast Cancer Model for Targeting αvβ6.  
5.1.1 Integrin Expression Profile on Breast Cell Lines.  
 
The panel of human breast cell lines (derived from the immortalised MCF-10A line 
[234]): MCF-10A, MCF-10AneoT, AT1K.c12, Ca1h, CA1a and MCF-10 DCIS.com 
were tested for their surface integrin expression, using flow cytometry. Each integrin 
antibody was tested and geometric mean values were compared with appropriate 
isotype controls. Table 12 (page 204) shows that all of breast cancer cell lines 
endogenously express αvβ6, at varying levels, on their cell surface. Therefore, these 
lines are suitable for validating the targeting efficacy of the 
111
In-DTPA-A20FMDV2 
peptide. It also was noted that the RGD-binding integrin, αvβ3, is not expressed on 
MCF-10A, MCF-10AneoT, AT1K.c12 and CA1a cells.  
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Integrin 
Cell Line 
1 2 3 4 5 6 91 
MCF-10A ++ ++++ ++++ - ++  + 
MCF-10AT1K.c12 + ++++ ++++ - ++  + 
MCF-10AneoT ++ ++++ ++++ - ++  + 
MCF-10A.CA1a + ++++ ++++ - ++  + 
MCF-10A.Ca1h + ++++ ++++ - ++  ++ 
MCF-10.DCIS.com + ++++ ++++ - +  + 
A375P β6 ++ ++ ++ + ++  ++ 
 
Integrin 
Cell Line 
4 v3 v5 v6 v8 
MCF-10A ++++ - + ++++ ++ 
MCF-10AT1K.c12 ++++ - + +++ ++ 
MCF-10AneoT ++++ - + ++ + 
MCF-10A.CA1a ++++ - ++ ++++ ++ 
MCF-10A.Ca1h ++++ + ++ ++++ ++ 
MCF-10.DCIS.com ++++ ++ ++ ++++ ++ 
A375P β6 - ++ + +++ + 
 
 
 
Table 12 Surface integrin expression by breast cancer cell lines in comparison 
with the A375P β6 melanoma line. Measured by flow cytometry. Pluses designate 
the abundance of the integrin, according to a grading system [241] derived from 
geometric mean values relative to isotype negative control antibodies.  
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5.1.2 Invasive Activity of an αvβ6-expressing Breast Cancer Cancer Cell 
Line 
Control antibody v6-blocking antibody
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Figure 67 Transwell Invasion Assay with MCF-10A.CA1a cells, in the presence 
of v6-blocking (63G9) and non-blocking antibodies (7.2). 
 
Owing to Santner et al’s description of MCF-10A.CA1a’s ability to form fast 
growing tumours in all murine subjects [234], and MCF-10A.CA1a’s high 
expression of v6,  but not v3, this cell line was studied in further detail. Its 
ability to invade Matrigel-coated Transwell invasion chambers, in the presence of 
v6-blocking (63G9) and non-blocking antibodies (7.2), was quantified. The 
numbers of invading cells were counted after 72 hours incubation and replicates were 
averaged. Figure 67 shows that MCF-10A.CA1a’s ability to invade was reduced 
significantly (p<0.03) in the presence of an v6-blocking antibody; suggesting that, 
in this assay, this cell line exhibited significant v6-dependent invasion.   
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5.1.3 Maintenance of αvβ6 expression within Tumour Xenografts  
Hu et al also recently reported on Santner’s MCF10.DCIS.com cell line [234, 242], 
as a subcutaneous xenograft, and commented on the importance of αvβ6 in affecting 
tumourigenic behaviour [243]. The MCF10.DCIS.com cell line was injected 
subcutaneously into female nude mice, alone or together with 50% Matrigel, in this 
report [243]. Therefore, it was decided to replicate this model and possibly attempt to 
validate the targeting of 
111
In-DTPA-A20FMDV2, as an addition to the “engineered” 
cell lines that previously were used in this thesis. However, prior to targeting 
experiments, it was important to confirm that tumour xenografts maintained their 
αvβ6 expression, in vivo. Therefore, CD1 nude mice were either inoculated 
subcutaneously with MCF- MCF-10 DCIS.com alone or with MCF-10 DCIS.com / 
Matrigel to determine the effect on xenograft formation. Mice were killed after the 
development of ‘palpable’ tumours (see Methods) and subsequently tumours were 
dissected, fixed and paraffin-embedded for histological examination. Tumour 
sections were stained for αvβ6 expression and the results compared with those 
obtained using an isotype negative control antibody. Figure 68 reveals staining 
patterns of the xenografts and is a representative image.  
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Figure 68 Murine MCF-10 DCIS.com / Matrigel xenograft staining for αvβ6. 
Left image is 62G2 staining and right is Haematoxylin stain. 
 
The MCF-10 DCIS.com / Matrigel xenograft (shown above) revealed strong 
staining, especially at the periphery of the tumour islands. Similar findings were 
discovered in the MCF-10 DCIS.com alone xenograft (data not shown), suggesting 
that the presence of Matrigel had little impact on the level or localisation of αvβ6  
 
5.1.4 Biodistribution Experiments using CD1 mice bearing MCF-10 
DCIS.com / Matrigel Xenografts 
Having established breast cancer xenograft models, with a tumour line which 
endogenously (as opposed to genetically engineered) expressed αvβ6, validation of 
111
In-DTPA-A20FMDV2’s targeting was undertaken. Full tissue biodistribution on 
tumour-bearing mice was performed; harvesting organs / tumours at 1h post-
injection of 
111
In-DTPA-A20FMDV2 (1 MBq / 4 µg). Since the breast cell lines 
were injected with Matrigel, a cohort of animals, in which Matrigel alone was 
injected subcutaneously, was used as a negative control. Although, the constituents 
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of Matrigel were not expected to express αvβ6, and thus an αvβ6-targeting agent 
theoretically should not be retained in the Matrigel-alone plug, Figure 69 indicates 
that the Matrigel alone plug retained significant amounts of radioactivity (1.15 ± 0.28 
% ID/g) at 1 hour. Having proven in vivo specificity for targeting αvβ6 in the 
previous Results section, this unexpected experimental finding suggested that 
Matrigel alone was not a suitable negative control for any future peptide targeting 
experiments. 
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Figure 69 
111
In-DTPA-A20FMDV2 biodistribution in Matrigel xenografts, with 
or without MCF-10 DCIS.com cells. 
111
In-DTPA-A20FMDV2 was injected into 
tumour bearing mice; tumours were harvested after 1 hour and % ID/g tissue 
determined.   
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5.1.5 Biodistribution Experiments using CD1 mice bearing either MCF-10 
DCIS.com or MCF-10A.CA1a Xenografts (No Matrigel) 
Owing to the apparent unsuitability of Matrigel for peptide targeting experiments 
(described section 5.1.4.), it was decided not to continue to use this preparation for 
xenograft models. That is, either MCF-10 DCIS.com or MCF-10A.CA1a tumour 
cells, suspended in serum-free media alone were injected subcutaneously into mice. 
Thereafter, full tissue biodistribution was performed on these tumour-bearing mice; 
harvesting organs / tumours at 1h post-injection of 
111
In-DTPA-A20FMDV2 (1 MBq 
/ 4 µg). ). Figure 70 reveals a similar biodistribution pattern for both cohorts of 
mice. That is, in addition to the tumour xenografts, the lower gastrointestinal (GI) 
tract, lung, stomach, skin, gall bladder, kidneys and lungs all have retained 
significantly more radioactivity than skeletal muscle. This biodistibution pattern is 
markedly similar to that found in the nude mice described in Chapter 4 (see Section 
4.9). Furthermore, both the tumour xenografts retained significant amounts of 
radioactivity, at 1 hour. The MCF-10 DCIS.com. xenograft attained 2.1 ± 0.63 % 
ID/g (19:1 tumour to muscle ratio); whereas the MCF-10A.CA1a xenograft achieved 
2.34 ± 0.35 % ID/g (17:1 tumour to muscle ratio). The tumours to blood ratios for 
both cohorts of mice were 15:1 and 16:1, respectively. 
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Figure 70 
111
In-DTPA-A20FMDV2 biodistribution in mice bearing either MCF-
10 DCIS.com or MCF-10A.CA1a xenografts. 
111
In-DTPA-A20FMDV2 was 
injected into tumour bearing mice; organs and tumours were harvested after 1 hour 
and the %I.D./g tissue determined.   
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5.1.6 NanoSPECT/ CT Small Animal Imaging of Breast Cancer Models 
Results reported in Section 5.1.5 revealed that 
111
In-DTPA-A20FMDV2 was 
retained within tumour xenografts that express αvβ6 endogenously. To determine 
whether 
111
In-DTPA-A20FMDV2 (4µg / 10-30 MBq per mouse) could be used as a 
molecular-specific imaging agent for these breast cancer models, radiolabelled 
peptide was injected intravenously into cohorts of athymic mice bearing either MCF-
10 DCIS.com or MCF-10A.CA1a xenografts. The mice were anaesthetised and 
imaged at pre-selected time-points, using a high-resolution single photon emission 
computed tomography small animal imager fitted with a separate, computed 
tomography scanner (NanoSPECT/CT).  
Once more the imaging findings were in harmony with the biodistribution results and 
representative coronal images are shown in Figure 71. The signals from the MCF-10 
DCIS.com or or MCF-10A.CA1a tumours consistently were found to be higher than 
non-β6 expressing ‘background’ tissues e.g. skeletal muscle. The resolution of the 
NanoSPECT/CT again revealed that the radioligand was not distributed uniformly 
throughout the tumour mass, but appeared rather to be located in nodular regions 
which manifested high-activity.  Images with a clearly identifiable β6-positive 
tumour routinely were obtained as early as 30 min, and as late as 4 hours, post-
injection. However, the best images, delineating optimal differentiation between the 
tumours and other background tissues, occurred at 1 hour post-injection, correlating 
with the biodistribution results. High signals were observed from the kidneys and 
bladder, when injected without co-injection of ‘cold’ DTPA-A20FMDV2ran. 
Additionally, Figure 71 confirms uptake within the GI tract, which corresponds with 
the endogenous vβ6 expression observed in this organ. Therefore 111In-DTPA-
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A20FMDV2 is retained specifically by v6-expressing tissues and its targeting 
capacity has been validated on these v6-expressing breast tumour models. 
 
 
Figure 71 
111
In-DTPA-A20FMDV2 injected i.v. into mice bearing either MCF-
10 DCIS.com or MCF-10A.CA1a breast tumours.  After 1 hour the mice were 
imaged on a NanoSPECT/CT. A: Maximum Intensity Projection (MIP) of images 
from a mouse bearing MCF-10 DCIS.com xenograft on right shoulder.  The MCF-10 
DCIS.com tumour labelled strongly with radiopeptide, again showing that peptide 
does not distribute uniformly. B: MIP of images from a mouse bearing MCF-
10A.CA1a xenograft on right shoulder.  The MCF-10A.CA1a tumour again labelled 
strongly with radiopeptide, together with the kidneys, bladder and the lower GI tract.  
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5.2 Colon Cancer Model for Targeting αvβ6.  
A range of mouse models of colorectal cancer have been developed to study this 
multistage disease:- 
Moser et al described the production of a mouse model where, after ethylnitrosurea 
treatment, a single germline mutation in a gene which was dominantly expressed and 
fully penetrant, resulted in susceptibility to tumour formation [244]. The mutant gene 
was inherited in an autosomal dominant manner and charcterised as ‘multiple 
intestinal neoplasia’ (‘Min’); owing to the development of multiple adenomas 
throughout the entire intestinal tract with progression to adenocarcinomas in the 
intestine in older mice [244]. Consequently, the mice passed bloody faeces and 
became anaemic, eventually these manifestations were so severe that they resulted in 
death of the affected animals [244]. 
Some time later, Marsh et al described a transgenic model involving the combined 
deletion of both PTEN and Apc genes [245]. Inactivation of Apc is the most frequent 
genetic event in colorectal cancer; where it appears to be important for differentiation 
control and cellular migration [246]. On the other hand, mutations of 
phosphatidylinositol 3-kinase (PI3K/Akt) pathway components have been reported in 
almost 40% of all human colorectal cancers [247]. The PI3K/Akt pathway normally 
promotes proliferation and cell survival, and stimulates progression of the cell cycle. 
Conversely, PTEN acts as a tumour suppressor through its antagonism of the 
PI3K/Akt pathway [245]. Marsh et al showed that loss of PTEN, in the context of 
Apc deficiency, accelerates tumourigenesis through increased activation of Akt; 
leading to rapid development of adenocarcinomas [245]. 
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Tumour sections from both these murine models were kindly donated by Professor 
A.R. Clarke’s and Professor Sir N. Wright’s groups. If these tumours also expressed 
αvβ6, then these models, potentially could, be used to validate 111In-DTPA-
A20FMDV2 targeting. Therefore, both sets of sections were derived from mice 
which were killed at time points expected to result in different stages of tumour 
formation. Subsequently, intestines and tumours were harvested, fixed and paraffin-
embedded for histological examination. Representative images taken from several 
mice at different stages of tumour progression,are shown below.  
 
 
 
Figure 72 Min mouse: normal colon staining for αvβ6 (x100). Left image is 
negative control and right is 62G2 staining. 
 
Figure 72 reveals strong αvβ6 staining at the surface of enterocytes, forming the 
mucosa of the colon, similar to that previously described in the immunodeficient 
mice used in earlier experiments (see Section 4.6). Again, the intensity decreases as 
the epithelial layer is followed down to the crypts.  
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Figure 73 Min mouse: adenoma staining for αvβ6 (x100). Left image is negative 
control and right is 62G2 staining. 
 
Marked epithelial dysplasia of the large intestine with glandular growth into the 
muscularis layer is shown in Figure 73. The periphery of the polyp stains strongly 
for αvβ6. 
 
 
 
Figure 74 Apc 
f/+
; Pten 
f/f
 mouse: adenocarcinoma staining for αvβ6 (x100). Left 
image is negative control and right is 62G2 staining. 
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Figure 74 reveals an advanced, ulcerating, invasive adenocarcinoma that has 
penetrated the full thickness of the small intestinal wall, destroying the muscularis 
propria. The dysplastic glandular area, within the main tumour mass, stains strongly 
for αvβ6 expression. Moreover, Figure 75 shows that ‘escaping’ tumour islands 
(x200 magnification), leaving the main tumour mass and invading underlying tissue, 
also stain strongly for αvβ6. 
 
 
Figure 75 Apc 
f/+
; Pten 
f/f
 mouse: adenocarcinoma staining for αvβ6 (x200).  
 
Although there is background expression of αvβ6 on normal intestinal surface 
epithelium, the strong tumour cell expression of αvβ6 suggests that both mouse 
models would be suitable models for validating the suitability of 
111
In-DTPA-
A20FMDV2 for targeting intestinal tumours. Accordingly, collaborative experiments 
are being planned between the involved groups. Unfortunately, the projected 
schedule for these collaborative experiments is beyond the time limits of my training 
degree and such studies will be undertaken by my successors. 
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5.3Peptide Variants and Probe Stabilisation Methods 
5.3.1 Cyclisation: A Method of Inhibiting Proteolysis of Peptides 
Cyclisation already has been mentioned (see Table 6, page 105) as a technique to 
improve peptide stability, whilst maintaining (and sometimes improving) their 
biological activity [190]. Therefore, several peptide variants were designed, using 
disulphide cyclisation and based on A20FMDV’s structure.  
 
5.3.1.1 Assessment of Cyclic Peptides’ Sensitivity and Specificity by Flow 
Cytometry 
Two variants, DBD1 and DBD2, were tested at a range of concentrations (10µM-
1nM; 30 mins incubation) on the A375P melanoma cell model and compared to 
A20FMDV2. Both variants were biotinylated and so bound peptide was detected by 
antibody detection of the biotin. Results revealed a relationship between 
concentration of peptide and resultant binding to A375Pβ6 cells. Figure 76 reveals a 
‘side-by-side’ comparison of the original peptide and its cyclic derivatives. The black 
lined histogram represents the negative control for the system, using mouse IgG. The 
grey shaded histogram represents clone 10D5 (commercial antibody to αvβ6) and 
serves as a positive control for the system, as well as a comparison for peptide 
binding. There were concentration-dependent relationships between varying amounts 
of each peptide and constant levels of αvβ6. Essentially, identical patterns of 
A375Pβ6 binding are seen with the native peptide and its cyclic derivatives. That is, 
at similar concentrations of A20FMDV2, both DBD1 and DBD2 bind at almost 
identical levels to A375P6 cells; suggesting that A20FMDV2 and its cyclic 
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derivatives bind with similar affinity to αvβ6. However, there appears to be some 
binding of the cyclic derivatives (especially DBD1), at higher peptide concentrations, 
to the A375P puro line. That is, cyclisation seems to have reduced the specificity of 
the peptide derivatives to αvβ6.  
 
 
Figure 76 Comparing the affinity and specificity of A20FMDV2 with DTPA-
A20FMDV2, using flow cytometry. 
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Nonetheless, the reduction of specificity mainly was a characteristic of DBD1; 
DBD2 still had relatively good affinity and specificity for v6, and so was selected 
for further evaluation. 
 
5.3.1.2 DTPA-DBD2 Radiolabelling and Quality Control  
DTPA-DBD2 was radiolabelled with indium to generate 
111
In-DTPA-DBD2. 
Reverse-phase HPLC was used to analyse the labelling efficiency and to evaluate the 
structural integrity of the radiolabelled targeting ligand. 
111
In-DTPA-DBD2 was 
eluted in a single peak, with a retention time of around 21 minutes (see Figure 77). 
The radiochemical purity of the radiolabelled 
111
In-DTPA-DBD2 was over 99%, 
according to this analysis. Furthermore, there was no evidence of fragmentation or 
aggregation during the labelling process, as indicated by the sharp single peak. 
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Figure 77 RP- HPLC trace measuring 
111
In-DTPA-DBD2 radiolabelling 
efficiency. 
 
 
 
5.3.1.3 Plasma Stability Studies of 
111
In-DTPA-DBD2 
The aim of cyclisation was to improve peptide stability from the relatively harsh 
enzymatic environment, contained within the plasma. An improvement in probe 
stability of a compound in plasma can strongly influence its in vivo efficacy. Plasma 
stability assays were thus performed on 
111
In-DTPA-DBD2, using RP-HPLC to 
measure structural integrity of the labelled peptide. 
 221 
111
In-DTPA-DBD2 was incubated at 37
o
C in either PBS or murine plasma for 
various periods of time.  Firstly, incubation in PBS showed high stability, with only 
around 10-15% loss of purity at 24 hours. This result was considered to be a 
favourable point with regard to chemical storage and transport. In contrast, and as 
expected for a linear peptide, there was degradation of the radioligand in plasma. 
Figure 78 shows that at 2 hours, 81% of the radiopeptide remained intact whereas by 
4 hours only 64% remained undegraded.  
 
 
0 5 10 15 20 25 30
0
20
40
60
80
100
PBS
Serum
Time (hours)
%
 p
e
p
ti
d
e
 r
e
m
a
in
in
g
 
 
Figure 78 Plasma Stability Study: 
111
In-DTPA-DBD2 was incubated at 37
o
C in 
either PBS or murine plasma for various periods of time.  After the selected time 
periods, samples of the incubation mixture were analysed on an RP-HPLC. Stability 
was preserved in PBS up to 24 hours after initation of incubation; whereas plasma 
stability was affected considerably after only 4 hours incubation. 
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5.3.1.4 Biodistribution of 
111
In-DTPA-DBD2 
The previous experience with A20FMDV2 suggested that the addition of a DTPA 
chlelating agent and 
111
In radiolabelling would not adversely affect DBD2’s affinity 
to αvβ6 (see Sections 4.3 & 4.8). Therefore, 111In-DTPA-DBD2 was injected 
intravenously into each ‘bi-xenografted’ mouse (described in Methods). Mice were 
killed at the pre-selected time-points, dissected and major organs were harvested. 
The associated radioactivity of each organ was quantified (expressed as percentage 
of injection dose per unit mass of tissue) and used as an indirect measure of peptide 
uptake and organ retention. Initially, 1 MBq of 
111
Indium was radiolabelled onto 2μg 
of DTPA-DBD2 and peptide uptakes in the xenografts were compared, at various 
time points (see Figure 79). Of note, this 2μg mass for injection was derived from 
the previous peptide mass experiments with DTPA-A20FMDV2 (see Section 
4.9.2.2).  
Maximal differential uptake between the A375P β6 and the A375P puro (non-vβ6 
expressing) tumours occurred at 1 hour (post-injection). However, good differential 
uptake, although at relatively lower % ID/g, was seen up to 4 hours, p.i.. The ratio of 
A375P β6 tumour uptake and retention to that of A375P puro consistently was 
around 3:1; thus reduced in comparison to linear DTPA-A20FMDV2. At 1 hour 
post-injection, the mean % injected dose per gram was around 1.36% ± 0.5 for the 
A375P β6 tumour, compared with 0.47% ± 0.1 for the A375P puro tumour.  
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Figure 79 
111
In-DTPA-DBD2 (1 MBq / 2µg) injected into groups of tumour-
bearing mice.  At 0.5, 1, 2 and 4 hours post-injection three mice were killed and 
tumours removed and the % ID/g tissue determined.   
 
The 30 minute mean %I.D./g within the A375P β6 tumour was 1.79% ± 0.27, for 
111
In-DTPA-DBD2; contrasting with 5.83% ± 1.63 for 
111
In-DTPA-A20FMDV2. 
Furthermore, the 30 minute mean %I.D./g within the A375P puro tumour was 0.9% 
± 0.08 for 
111
In-DTPA-DBD2, and 2.39% ± 1.16 for 
111
In-DTPA-A20FMDV2. 
Nonetheless, the later timepoints for the cyclic DBD2 peptide reveal a higher and 
more persistent mean %I.D./g, in the A375P puro tumour, compared to the linear 
111
In-DTPA-A20FMDV2 (0.32 vs. 0.15 at 4h p.i., respectively). Since DBD2 and 
A20FMDV2 have conserved RGD-integrin-binding motifs (see Section 4.9.2.5), it 
appears that the process of cyclisation indirectly has affected the affinity and 
specificity for vβ6, in vivo. 
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In addition, Figure 80 indicates that several organs retained significant amounts of 
radioactivity at 1 hour.  The lower gastrointestinal (GI) tract, lungs, stomach, skin 
and gall bladder (as well as the A375P 6 tumour) all have retained significantly 
more radioactivity than either A375P puro tumour or spleen.  Therefore, this pattern 
of biodistribution is consistent with that of 
111
In-DTPA-A20FMDV2 (see Section 
4.9.2.4). That is, 
111
In-DTPA-DBD2 is also able to recognise and bind to endogenous 
vβ6-expressing tissues.   
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Figure 80 
111
In-DTPA-DBD2 tissue biodistribution. 
111
In-DTPA-DBD2 was 
injected into tumour bearing mice. After 1 hour animals were killed and tumours and 
major organs were harvested and the % ID/g tissue determined.  Data show that 
several organs retained significant amounts of radiopeptide.   
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5.3.2 The DOTA Chelator Variant of A20FMDV2 
The DOTA chelator has some advantages over its DTPA counterpart (see 
Section 2.2.3). DOTA is able to chelate a range of radioisotopes, which include 
those necessary for PET imaging or peptide radiotherapy. Furthermore, DOTA 
complexes tend to be more thermodynamically and kinetically stable than the DTPA 
complexes [219]. These properties could explain the significantly higher specific 
uptake of the DOTA-bound somatostatin analogue, compared to the DTPA variant, 
in octreotide receptor-expressing tissues [191]. Therefore, DOTA-A20FMDV2 was 
designed, purified and studied. 
 
5.3.2.1 DOTA-A20FMDV2 Radiolabelling and Quality Control 
DOTA-A20FMDV2 was radiolabelled with indium to generate 
111
In-DOTA-
A20FMDV2. Reverse-phase HPLC was used to analyse the labelling efficiency and 
to evaluate the structural integrity of the radiolabelled targeting ligand. 
111
In- DOTA-
A20FMDV2 was eluted in a single peak, with a retention time of around 21 minutes 
(see Figure 81). The radiochemical purity of the radiolabelled 
111
In-DOTA-
A20FMDV2 was over 99%, according to this analysis. Furthermore, there was no 
evidence of fragmentation or aggregation during the labelling process, as indicated 
by the sharp single peak. 
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Figure 81 Reverse phase HPLC trace measuring 
111
In-DOTA-A20FMDV2 
radiolabelling efficiency. 
 
5.3.2.2 Biodistribution of 
111
In- DOTA-A20FMDV2  
The previous experience with DTPA-A20FMDV2 suggested that the addition of a 
chlelating agent and 
111
In radiolabelling would not adversely affect A20FMDV2’s 
affinity to αvβ6 (see Sections 4.3 & 4.8). Therefore, 111In-DOTA-A20FMDV2 was 
injected intravenously into each ‘bi-xenografted’ mouse and biodistibution 
experiments performed, at selected timepoints (described in Methods). The 
associated radioactivity of each organ was quantified and expressed as a percentage 
of injection dose per unit mass of tissue.  
Initially, 1 MBq of 
111
Indium was radiolabelled onto 4μg of DOTA-A20FMDV2 and 
peptide uptakes in the xenografts were compared, at pre-selected time points (see 
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Figure 82). It should be noted that the 4μg mass for injection was derived from the 
previous peptide mass experiments with DTPA-A20FMDV2 (see Section 4.9.2.2).  
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Figure 82 
111
In-DOTA-A20FMDV2 (1 MBq / 4µg) injected into groups of 
tumour-bearing mice.  At 0.5, 1, 2 and 4 hours post-injection three mice were killed 
and tumours removed and the % ID/g tissue determined.   
 
Maximal differential uptake between the A375P β6 and the A375P puro tumours 
occurred at 2 and 4 hours (post-injection). Unfortunately, the 4h p.i. timepoint was 
the latest timepoint planned in this experiment, and so it is not known whether a later 
timepoint would have resulted in a greater differential. However, the combination of 
properties (maximal differential uptake between the A375P β6 and the A375P puro 
tumours and high %I.D./g in the A375P β6 tumour) seemed to occur between 1 to 2 
hours p.i. (post-injection) timepoints. The ratio of A375P β6 tumour uptake and 
retention to that of A375P puro was around 4:1 at the 1 h p.i. timepoint; but around 
12:1 at the 2 h p.i. timepoint. At 1 hour post-injection, the mean % injected dose per 
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gram was around 2.89% ± 0.35 for the A375P β6 tumour, compared with 0.65% ± 
0.18 for the A375P puro tumour. Therefore, these values were at least on a par with 
those of 
111
In-DTPA-A20FMDV2. Although, the 30 minute mean %I.D./g within the 
A375P β6 tumour was 2.73% ± 0.41 for 111In-DOTA-A20FMDV2 (cf. 5.83% ± 1.63 
for 
111
In-DTPA-A20FMDV2), the pattern of uptake and retention within both 
xenografts was otherwise not significantly different.  
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Figure 83 
111
In-DOTA-A20FMDV2 tissue biodistribution. 
111
In-DOTA-
A20FMDV2 was injected into tumour bearing mice. After 1 hour animals were 
killed and tumours and major organs were harvested and the % ID/g tissue 
determined.  Data show that several organs retained significant amounts of 
radiopeptide.   
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The biodistribution of 
111
In-DOTA-A20FMDV2 (see Figure 83) reveals that several 
organs retained significant amounts of radioactivity at 1 hour.  The lower GI tract, 
lungs, stomach, skin and gall bladder, in addition to the A375P 6 tumour, all have 
retained significantly more radioactivity than either A375P puro tumour or spleen.  
Therefore, this pattern of biodistribution again is consistent with that of 
111
In-DTPA-
A20FMDV2 (see Section 4.9.2.4). That is, 
111
In-DOTA-A20FMDV2 is also able to 
recognise and bind to endogenous vβ6-expressing tissues.  
 
 
5.3.2.3 DOTA-A20FMDV2ran Radiolabelling and Quality Control 
In addition, the scrambled A20FMDV2 DOTA variant, DOTA-A20FMDVran, was 
radiolabelled with 
111
In to generate 
111
In-DOTA-A20FMDVran. Reverse-phase 
HPLC analysed the labelling efficiency and evaluated the structural integrity of the 
radiolabelled targeting ligand. 
111
In- DOTA-A20FMDV2ran was eluted in a single 
peak, with a retention time of around 20 minutes (see Figure 84). The radiochemical 
purity of the radiolabelled 
111
In-DOTA-A20FMDV2 was over 99%, according to this 
analysis. Furthermore, there was no evidence of fragmentation or aggregation during 
the labelling process, as indicaed by the sharp single peak. 
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Figure 84 Reverse phase HPLC trace measuring 
111
In-DOTA-A20FMDV2 
radiolabelling efficiency. 
 
 
5.3.2.4 Biodistribution of 
111
In- DOTA-A20FMDV2ran  
111
In-DOTA-A20FMDV2ran (1MBq / 4μg / mouse) was injected into a cohort of bi-
xenografted mice. After 1 hour the animals were killed, tumours and major organs 
were harvested, and the %I.D./g tissue determined. Figure 85 reveals that there was 
no significant difference in uptake by the A375P β6 versus the A375P puro (0.10 +/-
0.02% versus 0.2 +/-0.08% ID/g, respectively) tumours. Furthermore, no significant 
uptake occurred in most of the other tissues (excluding kidney, the site of excretion). 
Inset displays data for xenografts only, with scale adjusted, confirming the minimal 
% I.D./g of 
111
In-DOTA-A20FMDV2ran in these tumours. These data corroborate 
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that for 
111
In-DTPA-A20FMDV2ran and reinforces the necessity of the RGD motif 
for αvβ6 recognition and binding, in vivo. 
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Figure 85 Biodistribution of 
111
In-DOTA-A20FMDV2ran (scrambled peptide). 
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5.3.2.5 NanoSPECT/CT Small Animal Imaging 
In summary, 
111
In-DOTA-A20FMDV2 also now has been confirmed to exhibit high 
affinity and specificity for αvβ6, in vivo. However, to determine whether 111In-
DOTA-A20FMDV2 (4µg/10-35 MBq per mouse) could be used as a molecular-
specific imaging agent, it again was injected intravenously into the ‘bi-xenografted’ 
athymic mice. The mice were anaesthetised and imaged at pre-selected time-points, 
using a high-resolution single photon emission computed tomography small animal 
imager fitted with a separate, computed tomography scanner (NanoSPECT/CT).  
The imaging findings generally were consistent with the biodistribution results and a 
representative coronal image is shown (see Figure 86A). Signals from the A375P β6 
tumours consistently were found to be higher than those from the non-β6 expressing 
control tumours. Images, with a clearly identifiable β6-positive tumour, routinely 
were obtained as early as 30 min, and as late as 4 hours, post-injection. However, the 
best images, delineating ideal differentiation between the A375P β6 and the A375P 
puro tumours and other background tissues, occurred at 1 hour post-injection; 
correlating with the biodistribution results (see Section 5.3.2.2). High signals were 
observed from the kidneys and bladder, reflecting the primary exretion route. Figure 
86B also shows a Maximal Intensity Projection (MIP), which displays uptake in the 
GI tract, corresponding with localisation of endogenous vβ6 expression. Thus 111In-
DOTA-A20FMDV2 now also has been shown to be retained specifically within 
v6-expressing tissues, using a non-invasive NanoSPECT/CT small animal imager. 
These findings suggest that the DOTA chelator has not adversely affected 
A20FMDV2’s ability to recognise and bind to αvβ6, in vivo.   
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Figure 86 NanoSPECT/CT imaging of v6-expressing tumour with 111In-
DOTA-A20FMDV2: 
A. Coronal slice showing that the radiopeptide has accumulated selectively in the 
A375P 6 tumour in discrete areas or ‘nodules’.  In contrast the A375P puro tumour 
was negative. The kidneys also are clearly labelled.  
B.  Maximum Intensity Projection (MIP) of images from same mouse.  The A375P 
6 tumour labelled strongly with radiopeptide again showing clearly that peptide 
does not distribute uniformly. In contrast the A375P puro tumour again was negative.  
The kidneys and bladder were labelled strongly, as is the lower GI tract, in accord 
with the biodistribution of 
111
In-DOTA-A20FMDV2 and the results of 
111
In-DTPA-
A20FMDV2.  
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Chapter VI: Discussion  
 
Integrins are the principal cell surface receptors that enable both normal and 
transformed cells to attach, and respond, to their extra-cellular environment. 
Integrins have been shown to mediate cell-to-cell or cell-to-ECM adhesion, traction  
during cell movement and the promotion of many signalling pathways that regulate 
diverse processes including proliferation, migration, cell survival, differentiation, 
tumour invasion and metastasis [12]. Increased expression of αvβ6 has been shown 
to be important in cell migration, cell proliferation, activation of TGF-β, suppression 
of anoikis, modulation of protease activity and invasion of carcinoma cells [33, 104, 
140-142, 152]. Additionally αvβ6 has been proposed as a marker of malignant 
transformation in oral epithelial tumours [104] and more recently it has been 
identified as a prognostic marker for the behaviour of a range of carcinomas. 
Epidemiological studies of colon, cervical and non-small cell lung cancer all have 
noted that high expression of v6 correlates with poor prognosis; increasing the 
hazard of dying by greater than 60% in colon cancer for example [101, 248, 249]. 
Therefore, identification of this marker in vivo could be a valuable aid in the 
management of cancer patients. Additionally, the integrin αvβ6 appears to fulfil all 
the criteria necessary to be an ideal targeted imaging agent, in cancer patients. It is 
expressed on the cell surface, is weak or absent on normal tissues and is associated 
with cancer progression. The aforementioned associations and attributes led to 
development of v6-specific targeting agents that function effectively in vivo. The 
primary objective of this project was to develop and characterise radiolabelled agents 
for targeting αvβ6 and to show that such reagents could localise specifically to 
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cancer. This would permit selective visualisation of αvβ6 regions within tumours, 
using gamma cameras combined with conventional imaging techniques. My data 
describe the development of αvβ6-directed peptide probes in vitro; and demonstrates 
the selective localisation of such probes to αvβ6-positive tumours in vivo, for SPECT 
and PET imaging. Furthermore, I show that αvβ6 receptor localisation by peptide 
targeting correlates closely with αvβ6 receptor detection by immunohistochemistry.  
 
6.1 The v6 Receptor and Peptide Pharmacology 
DiCara et al originally described the characterisation of A20FMDV2, a peptide 
derived from the VP1 coat-protein of foot-and-mouth-disease virus [229].  DiCara 
and colleagues reported that αvβ6 is capable of forming high affinity, long-lived 
complexes with short RGD peptides [229]. The paper described the importance of 
the RGDLXX(L/I) motif and post-RGD helix in promoting anti-αvβ6 activity. This 
stable integrin-peptide binding may be a multi-step process and certainly it features 
cation-dependence. Furthermore, since αvβ3 and αvβ6 share a high degree of 
homology [250], it has been proposed that, as for αvβ3, the aspartate from the RGD 
sequence (Asp
9
 in A20FMDV2) will bind to the beta subunit of the integrin, via its 
MIDAS while arginine binds to the alpha subunit’s β propeller domain [251].  
In order to take advantage of the high resolution and sensitivity of the 
NanoSPECT/CT small animal imager, it was decided to develop A20FMDV2 into a 
SPECT targeting agent for v6. Therefore, synthesised biotinylated-A20FMDV2 
was conjugated to the chelating agents, DTPA and DOTA, via the N-terminal 
residue.  Flow cytometry, described in Sections 4.3 & 4.4, with and without v6-
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blocking antibodies, revealed that the addition of DTPA (and chelate formation) had 
no effect on the specificity or affinity of the peptide compared with A20FMDV2; 
both exhibiting >1000-fold selectivity for v6 over the other RGD-directed 
integrins present (51, v3, v5, v8).  
 
Radiolabelling with Indium was not expected to further change the spatial structure 
of the peptide. However, HPLC analysis allowed formal evaluation of this 
expectation and the assessment of labelling efficiency. Optimal radiolabelling 
conditions are required to ensure maximal labelling efficiency. That is, unbound 
radionuclide (Indium) should be kept to a minimum, with maximal radionuclide 
attached to the peptide complex. Free radionuclide, when injected into test subjects, 
has the potential to disseminate throughout the body without necessarily targeting the 
desired tumour; lowering the target-to-backround ratio and increasing the radiation 
dose to non-target tissues [252]. Fortunately, the radiolabelling efficiency was 
greater than 95% for 
111
In-DTPA-DBD2, 
111
In-DTPA-A20FMDV2 and 
111
In-DOTA-
A20FMDV2, using HPLC analysis. Furthermore, the HPLC traces for all the probes 
did not reveal any evidence of fragmentation or aggregation. Therefore, HPLC 
analyses seemed to indicate that indium radiolabelling did not affect the structural 
integrity of the probes adversely. 
 
Nevertheless, cell binding assays were required to confirm that the radiolabelling 
procedure did not affect the targeting-ligand’s functional capacity for recognition of 
v6. Saturation binding assays measure specific radioligand binding, at 
equilibrium, for various concentrations of the radioligand. The subsequent data 
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analysis is able to determine receptor number (maximum specific binding, Bmax) and 
affinity (equilibrium dissociation constant, Kd). It clearly is desirable for the probe to 
have a high affinity for the target receptor, since this forms the basis of tumour 
sensitivity and specificity. The calculated equilibrium dissociation constant (Kd) for 
111
In-DTPA-A20FMDV2 on A375P 6 cells was 1.73×10−9M. Furthermore, since 
the difference between 10% and 90% of the specific binding spans a 100-fold 
concentration range (i.e. two logs), it can be assumed that only one-binding site is 
involved [253]. This assumption is consistent with the previous competition flow 
cytometry experiments, which demonstrated that the binding of DTPA-A20FMDV2 
to A375P 6 cells was totally αvβ6-dependent. Typical Kd values of useful 
radioligands range between 10 pM and 10 nM; and thus 
111
In-DTPA-A20FMDV2 is 
within this range and has a high affinity for the αvβ6 receptor [253]. In summary, it 
appears that conjugation of the DTPA chelator and indium radiolabelling of the 
A20FMDV2 have not significantly influenced its affinity for v6. 
The previous experiments on A20FMDV2 studied IC50, rather than Kd, to confirm 
that the radiolabelling did not affect peptide specificity or efficacy [228]. Hausner 
and colleagues, using competitive binding ELISA experiments, tested the ability of 
either A20FMDV2 or 
19
F-FBA-A20FMDV2, to inhibit binding of biotinylated 
fibronectin to immobilised, recombinant soluble αvβ6. With this model, the authors 
reported that both A20FMDV2 and 
19
F-FBA-A20FMDV2 had IC50 values of 3 ± 1 
nmol/L; confirming that the addition of 
19
F-FBA to A20FMDV2 did not affect its 
potency [228, 229]. Of note, cyclo-(RGDy(Me)K), an αv-binding peptide, was 
shown to have an IC50 value of 35 ± 15 nmol/L, using the same system [228]. 
During the course of this PhD project, other groups also have sought to explore 
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v6-specific targeting agents, in vivo. Hausner and colleagues recently have 
described the ‘PEGylated’ A20FMDV2 variants: 18F-FBA-PEG-A20FMDV2, 18F-
FBA-PEG28-A20FMDV2, 
18
F-FBA-(PEG28)2-A20FMDV2,
 64
Cu-DOTA-PEG-
A20FMDV2 and 
64
Cu-CB-TE2A-PEG-A20FMDV2 [254, 255]. Using the same 
competitive ELISA system described above, the PEGylated variants were shown to 
possess equivalent IC50 values with the parent A20FMDV2 peptide (3 to 6 nmol/L) 
[254, 255]. Furthemore, a group from Germany described the development of 
another linear RGD peptide, HBP-1, and its 
125
I radiolabelling (
125
I-HBP-1) [256]. 
An IC50 value for 
125
I-HBP-1 of 38.9 nM was calculated, using an αvβ6-expressing 
head and neck squamous cell carcinoma line (HNO97) and increasing concentrations 
of unlabelled HBP-1 (competitor) [256]. However, since different systems were used 
for IC50 calculations, of 
125
I-HBP-1 and 
19
F-FBA-A20FMDV2, it is not possible to 
compare these values directly. Ideally, the different peptides (and their variants) 
should all be tested on the same experimental system to compare the affinity of each 
compound to αvβ6 fairly. 
 
In addition to high receptor affinity, probe internalisation is a valuable property; 
allowing the radioligand to accumulate within the tumour cell before it can dissociate 
and increasing the tumour-to-background ratio. The internalisation experiments 
measured the net amount of probe specifically ‘trafficked’ to the interior of the cell, 
at various incubation times and at body temperature (37
o
C). These experiments 
revealed relatively rapid internalisation of 
111
In-DTPA-A20FMDV2 into A375P β6 
cells, reaching a plateau after about one hour. This quantification was consistent with 
the peptide’s spatial distribution, detecting DTPA-A20FMDV2 via its biotin tag and 
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using confocal microscopy. The absence of significant radioligand internalisation, by 
A375P puro cells, suggested that the cellular internalisation of 
111
In-DTPA-
A20FMDV2 was v6-dependent. 
Elayadi et al recently described another 20-mer RGD peptide, TP H2009.1, which 
targets v6 [248]. This peptide subsequently was synthesised on a trilysine core 
and conjugated to a streptavidin-coated, fluorescent quantum dot (SAQdot605). 
Elayadi demonstrated, with the aid of fluorescence microscopy, that SAQdot605 
association with αvβ6-expressing (H2009) cells was mediated via the RGD peptide 
[248]. Furthermore, the authors also suggested that the mechanism of peptide-Qdot 
internalisation was via v6-mediated endocytosis [248]. However, these 
experiments suggesting internalisation were analysed with 2-D microscopy only, 
without quantification and at one peptide incubation timepoint (10 minutes) [248]. 
Nonetheless, this timeframe for TP H2009.1 internalisation into H2009 cells appears 
to be quicker in comparison to that for A20FMDV2 into A375P β6 cells (see Figure 
56). The same group later published on a tetrameric, but truncated, H2009.1 peptide 
[257]. This tetramer was conjugated with fluorochrome (Alexa Fluor 488 or 
SAQdot605), incubated for 10 minutes with H2009 cells and analysed with confocal 
microscopy using a Z-stacking protocol [257]. The Z-stacked series confirmed the 
cellular internalisation of the tetramer, co-localisation of the tetramer with v6, but 
still lacked quantification and later timepoints [257]. 
Nothelfer and colleagues also performed internalisation experiments with 
125
I-HBP-1 
and HNO97 cells [256]. This group’s internalisation assays were more similar to 
those described with A20FMDV2. Quantitative studies were undertaken at several 
timepoints, and internalisation expressed as a percentage of the applied dose per 10
6
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cells. However, glycine buffer acid washes (50 mM glycine, 100 mM NaCl, pH 2.8) 
were chosen to remove the membrane-bound radioligand fraction. No mention of 
acid wash exposure time to the HNO97 cells was reported, nor is any reference made 
to any optimisation procedures performed prior to the cell internalisation assay. The 
absence of these optimisation procedures casts doubt on the effectiveness of glycine 
to remove the membrane-bound radioligand fraction, in their cell model. Table 11 
(page 180) revealed that the glycine acid wash buffer was the least effective reagent, 
at removing membrane-bound 
111
In-DTPA-A20FMDV2, from the A375P β6 cell 
model. Indeed, the A375P β6 could not be exposed to longer than 5 minutes of 
glycine acid wash; longer exposure resulted in significant numbers of cells which 
underwent permeabilisation and death, with consequent release of the internalised 
radioligand. These factors have an enormous bearing on the accuracy of 
internalisation calulations. Taking this into account, Nothelfer reported fast 
internalisation into HNO97 cells, with values of 78.6%, 60.5%, and 46.3% of total 
bound peptide after 10, 60 and 120 min, respectively [256]. This compares to values 
of approximately 38%, 90% and 90% after 5, 60 and 120 min, respectively (
111
In-
DTPA-A20FMDV2 into A375P β6 cells). Although different cell lines were used, it 
seems that the rate and pattern of internalisation are different. Nothelfer and 
colleagues suggested that the decrease in intracellular radioactivity was as a 
consequence of cytosolic peptide degradation [256]. This phenomenon did not seem 
to happen with 
111
In-DTPA-A20FMDV2, which had a slower initial internalisation 
rate, but achieved higher internalisation levels at later timepoints. However, the 
aforementioned lack of optimisation procedures with the 
125
I-HBP-1 system may 
make direct comparisons impossible. 
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Hausner et al also studied internalisation in the PEGylated A20FMDV2 variants, 
within the DX3 puro β6 and BxPC-3 cell lines [255]. This DX3 melanoma cell 
model has similarities to the A375P model, but Hausner chose an acetate acid buffer 
(0.2 mol/L sodium acetate, 0.5 mol/L sodium chloride, pH 2.5) to release surface-
bound activity [255]. Again, no optimisation procedures seemed to be carried out to 
determine the appropriateness of the acetate acid buffer wash; the referenced paper 
justifying this choice of acid buffer wash actually examined a different cell and 
receptor model [258]. Furthermore, only the 1 hour incubation time point was 
studied. Hausner reported that approximately two-thirds of the bound radioactivity 
was internalised, in αvβ6-expressing cell lines, for the two PEGylated A20FMDV2 
variants; whereas less than half of the bound 
18
F-FBA-A20FMDV2 was internalised 
[255]. The value for the 1 hour internalisation of 
18
F-FBA-A20FMDV2 is lower than 
that found for 
111
In-DTPA-A20FMDV2. However, the absence of other timepoints, 
the differing cell systems and the lack of optimisation procedures all inhibit direct 
comparisons. However, Hausner’s findings suggest that internalisation experiments 
with PEGylated 
111
In-DTPA-A20FMDV2 variants are warranted. 
To sum up, the current evidence indicates that the aforementioned RGD peptides are 
being internalised, through association with v6, and by a variety of cancer cells. 
As yet, the precise mechanism of internalisation is not clear. However, since FMDV 
infects cultured cells via its highly conserved
 
RGD motif (located on GH loop of the 
viral surface protein VP1) [259], mechanisms of internalisation may be similar. It is 
known that FMDV, utilising the v integrins as receptors, enters the cell via a 
clathrin-mediated endocytic pathway, trafficking throughout the acidified endocytic 
vesicles, where its capsid rapidly dissociates with resultant release of the RNA 
 242 
genome [124, 260]. In addition, Ramsay et al have shown that v6 endocytosis is 
clathrin-mediated and this process is important for carcinoma cell motility and 
invasion [261]. Therefore, it is highly plausible that the RGD peptides are 
internalised, by cancer cells, through a clathrin-dependent pathway. However, formal 
experiments, which may use specific inhibitors of clathrin-mediated endocytosis, 
would need to be performed to prove this hypothesis.   
  
Plasma stability assays simulate in vivo protease exposure and thus are necessary to 
provide an indication of probable probe degradation in recipient animals. It is clearly 
undesirable for the probe to degrade prior to reaching its target tumour. Furthermore, 
if degradation results in release of free radionuclide or even radionuclide attached to 
peptide fragment, the radionuclide complex may be directed away from its original 
target. These factors may contribute to decreased target-to-background signal and 
increased radiation exposure to non-target organs. A PBS (at physiological pH 7.2) 
control incubation was performed simulataneously with the plasma incubation. 
Although the PBS incubation occurred at 37
o
C, 
111
In-DTPA-A20FMDV2 showed 
high stability with minimal loss of purity after 24 hours; indicating an adequate level 
of radiolytic resistance. In addition, since the storage and transport of 
radiopharmaceuticals at 4
o
C is possible, this lower energy state may further reduce 
the kinetics of degradation. Therefore, it seems that 
111
In-DTPA-A20FMDV2 does 
not demand extreme storage and transport conditions in order to maintain probe 
stability. Nevertheless, as expected for a linear peptide, there was decreased 
111
In-
DTPA-A20FMDV2 stability in plasma.  This clearly has an impact on optimal 
imaging times and non-target radiation exposure. Nonetheless, the in vitro stability 
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of 
111
In-DTPA-A20FMDV2 compares favourably to the 
125
I-HBP-1 peptide. 
Nothelfer and colleagues reported that the half-life of 
125
I-HBP-1 was 55 minutes 
(human plasma) [262], and this contrasts with the calculated half-life of 
111
In-DTPA-
A20FMDV2 at 210 minutes (athymic mouse plasma). Therefore the improved 
plasma stability of 
111
In-DTPA-A20FMDV2 enables a larger timeframe in which to 
acquire images of the putative target confidently. However, it should be noted that 
Nothelfer et al have stated that the TP H2009.1 and A20FMDV2 peptides have 
human plasma half-lives of 14.5 and 42 minutes, respectively [256]. It seems that 
Nothelfer and colleagues synthesised TP H2009.1 and A20FMDV2, as well as their 
125
I-HBP-1 peptide. Although Nothelfer used human plasma and the experiments 
performed in this thesis used athymic mouse plasma, the exact details of Nothelfer’s 
comparative plasma stability studies were not documented [256], casting doubt on 
the reported half-lives and perhaps explaining the discrepancy (210 vs. 42 minutes) 
in the stability results. 
Cyclisation also has been mentioned previously as a technique to improve peptide 
stability (see Table 6, page 105). However, cyclisation unexpectedly resulted in a 
reduction of specificity to v6. Flow cytometric experiments revealed binding of 
both DBD1 and DBD2, at higher peptide concentrations, to the A375P puro line. 
Currently, it is not known whether the higher concentrations imparted greater non-
specific binding, or whether cyclisation even led to increased binding of the other 
RGD integrins (51, v3, v5, and v8). However, once the appropriate 
materials are available, my successor intends to test the binding affinity to the 
aforementioned individual integrins. Nonetheless, the reduced specificity 
phenomenon mainly was a characteristic of the DBD1 peptide. DBD2 still had 
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relatively good affinity and specificity for v6, and so in vivo experiments 
proceeded with this compound. The DTPA chelating agent was conjugated to DBD2 
and this facilitated indium radiolabelling (
111
In-DTPA-DBD2). The plasma half-life 
of 
111
In-DTPA-DBD2 was calculated to be 495 minutes (in vitro, athymic mouse 
plasma); thus it was superior to that of 
111
In-DTPA-A20FMDV2. However, the 
%I.D./g of 
111
In-DTPA-DBD2 in the A375P 6 tumour did not seem as high as for 
the linear peptide. There are many potential reasons for this reduced tumour uptake 
and retention. However, it should be noted that the net charge is the same (positive 
and so basic) for A20FMDV2 and DBD2. Therefore, since the plasma stability is 
superior for DBD2, it might be peptide delivery, internalisation or retention which 
could be affected adversely by its cyclic structure. It is possible that cyclic 
conformation might hinder penetration of tumour vasculature, limiting delivery of 
the radioligand to the tumour. Alternatively, the cyclic structure may inhibit 
111
In-
DTPA-DBD2’s internalisation by tumour cells; thereby affecting the retention of the 
radioligand within the cancer mass. Furthermore, 
111
In-DTPA-DBD2 seemed to have 
greater and more persistent retention in background tissues (including non-v6 
expressing tumours), when compared with the linear peptides. This finding, 
ultimately, led to lower target-to-background ratios and thus this was considered to 
limit its efficiency as an imaging agent. It already has been mentioned that linear 
peptides tend to be degraded / metabolised in vivo, allowing their rapid clearance 
from blood and other non-target tissues. Peptide cyclisation potentially would delay 
degradation and thus the chances of non-specific localisation could increase. This 
clearly is not desirable in terms of non-target (normal) tissue radiation exposure, as 
well as for imaging efficiency. Therefore, a fine balance seems to exist between too 
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little stability (decreased target delivery) and too much stability (increased 
background exposure). Similar problems with high background tissue exposure have 
been described with the larger multimers of H2009.1 [257]:  
Probe multimerisation has the potential to improve target-to-background ratios. 
Multivalent Foot-and-Mouth-Disease-Virus capsids have been shown to stimulate 
endocytosis of the integrin and that the integrin serves to deliver the virus into the 
early and recycling endosomes [124]. This virus-induced uptake of αvβ6 seems to 
have resulted from cross-linking of the integrin by the multivalent ligand and not 
merely from integrin ligation alone [124]. Therefore, multimerisation may trigger 
neoplastic cell internalisation as well as permitting a greater chance of receptor-
ligand interaction. That is, the possibility of multiple αvβ6 receptors binding to a 
probe (avidity) may alter integrin-peptide interactions to prolong ‘receptor-on’ 
kinetics favourably or even trigger cell internalisation. Consequently, Li and 
colleagues analysed the plasma stability (in vitro and rat plasma) of 
111
In-DOTA 
labelled, tetrameric H2009.1 peptide variants, but only at two timepoints [257]. The 
tetrameric H2009.1 peptide variants were approximately 75% and 65% intact, after 
1h and 4h plasma incubation, respectively [257]. The same group also examined the 
stability of a monomeric, PEGylated H2009.1 peptide, finding 60% and 46% 
intactness at 1h and 4h timepoints, respectively [257]. The corresponding 1h and 4h 
values for: 
111
In-DTPA-A20FMDV2 were 78% and 45%, respectively; 
111
In-DTPA-
DBD2 were 89% and 64%, respectively. Firstly, it is noted that the plasma stability 
of 
111
In-DTPA-A20FMDV2 seems initially superior to its 
111
In-DOTA labelled, 
PEGylated H2009.1 counterpart. Furthermore, cyclic DBD2 also seems, initially, to 
have superior plasma stability in comparison to the tetrameric H2009.1 peptide 
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variants. However, the different species used to donate plasma does hinder direct 
comparison. The tetrameric H2009.1 peptide variants subsequently were tested using 
biodistribution experiments, in v6-expressing, tumour-bearing, severe-combined-
immunodeficiency mice [257]. At 1 hour p.i., the %I.D./g in the tumour was 3.15 ± 
0.47, but tumour-to-blood ratio was only 1.37 ± 0.14; at 4 hours p.i., the tumour 
demonstrated 2.25 ± 0.47 %I.D./g, with a tumor-to-blood ratio which was 2.43 ± 
0.14 [257]. Although the %I.D./g within the tumour was good, it was at the expense 
of very high uptake and retention within background tissues; limiting the value of 
this agent to discern cancers from other tissues in imaging experiments. Therefore, 
for in vivo target delivery and imaging, there does seem to be a fine balance between 
affinity, stability, non-specific uptake and clearance [257]. However, Li and 
colleagues only published the biodistribution results of the tetrameric H2009.1 
peptide variants [257]. A comparision with the monomeric, PEGylated H2009.1 
peptide was not documented; thus, without this study, the increased uptake and 
retention within background tissues cannot totally be ascribed to tetramerisation. 
Therefore, the reduced specificity phenomenon of DBD2 (found in the flow 
cytometry experiments) and the potential binding to other RGD integrins 
predominantly may explain the retention in non-v6 expressing tissues.  
 
6.1.1 Limitations of Peptide Pharmacology Experiments 
In contrast to the other flow cytometry studies, the competition assays in mouse 
keratinocytes utilised a buffer system in which Mn
2+
 was the only bivalent metal 
present. Mouse keratinocytes terminally differentiate in the presence of high calcium 
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concentrations [239]. Therefore, for practical reasons, calcium-containing buffers 
had to be substituted with Mn
2+
-TBS buffer, in flow cytometry experiments. This 
buffer system is less physiological than the Mg
2+
/Ca
2+
-containing buffers, but still 
promotes an ‘activated’ integrin conformation with high ligand affinity [17].  
The HPLC setup is important for the recognition of radiolabelled products. An 
acetonitrile and 0.1% aqueous TFA system was used as the standard approach for 
radiopeptide analysis. This system eluted radiolabelled products at approximately 20 
minutes. Previously, an ethanol and 0.1% aqueous TFA system was tested for 
111
In-
DTPA-A20FMDV2 analysis (data not shown). Unfortunately, this alternative 
resulted in the elution of the probe at 40 minutes; thus the extra 20 minute analysis 
time would delay the commencement of in vivo experiments, performed later in the 
day. In certain situtations, Ion Pair Chromatography can be employed for greater 
separation of ionic or polar compounds. This technique uses an ‘ion pair reagent’ 
(e.g. alkylsulphonate), which modulates the retention of ionic species [263]. 
However, since 
111
In-DTPA-DBD2, 
111
In-DTPA-A20FMDV2 and 
111
In-DOTA-
A20FMDV2 were eluted as single peaks on the RP-HPLC, no further development 
of the RP-HPLC system was necessary.   
Although, the RP-HPLC demonstrated structural integrity of 
111
In-DTPA-
A20FMDV2 and the cell binding assays demonstrated good affinity of 
111
In-DTPA-
A20FMDV2 for A375P 6 cells, indium radiolabelling still may have had an effect 
on the targeting ligand’s selectivity for v6. Ideally, competition and internalisation 
experiments, using v6-blocking antibodies (similar to flow cytomery), would be 
performed with 
111
In-DTPA-A20FMDV2. However, the availability of the v6-
blocking antibodies was limited and thus prohibited this experimental design. 
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Nevertheless, the internalisation experiments were performed on A375P puro cells, 
which demonstrated negliglible internalisation of the 
111
In-DTPA-A20FMDV2 in 
cells without v6 expression; suggesting maintenance of specificity for v6. 
Pre-collected plasma and a 37
o
C incubation attempted to simulate the blood 
environment, with regards to protease exposure, likely to be encountered in vivo. 
However, an alternative method may be to inject the radiolabelled peptide into a 
murine subject and collect plasma samples, at various timepoints. This alternative 
method would be more representative of the probe’s exposure to in vivo conditions, 
and would additionally factor in the clearance rate of the peptide within an animal. 
However, repeated blood sampling from a mouse is not always practical, and this 
difficulty may cause problems in subsequent calculations, while the situation with 
regard to ethics and Home Office regulations tend to militate against such a study. In 
addition, the resultant peptide fragments after exposure to plasma were not fully 
characterised. For example, mass spectrometry could help elucidate the sequence of 
the resultant peptide fragments and thereby determine the sites of enzymatic 
vulnerability. This information would not only confirm the intactness of the RGD 
binding site (validating the proposed mechanism of peptide attachement), but would 
also help with subsequent peptide re-designs to strengthen against plasma 
degradation. However, practical considerations, such as timing and the introduction 
of radioactive and biological material into a controlled equipment resource, 
prevented this experiment. 
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6.2 Tumour Xenograft Model in Mice 
Biodistribution experiments quantify the amount of radioactivity within tissues, after 
the administration of a radioligand to an animal; it is the standard technique for the 
study of a probe’s organ dissemination and its pharmacokinetics. The initial 
biodistribution results demonstrated that 
111
In-DTPA-A20FMDV2 selectively 
localises to αvβ6-expressing tumours, in vivo. In order to maximise the tumour to 
background ratios, the optimal time for imaging, the optimal peptide mass for 
injection and the optimal strain of mouse all were investigated. These experiments 
suggested that imaging / biodistribution optimally should occur 1 hour after injection 
of 2-4 µg of 
111
In-DTPA-A20FMDV2.  Using these parameters, it was established 
that A375P 6 tumours retained up to 9-fold more 111In-DTPA-A20FMDV2 than the 
v6-negative control tumour on the opposite shoulder.  Over multiple experiments, 
these optimal conditions resulted in the retention of 
111
In-DTPA-A20FMDV2 by 
A375P 6 xenografts consistently at around 2 – 4 %I.D./g; significantly higher (p < 
0.0001, n=15, using Wilcoxon matched-pairs signed rank test) than the uptake and 
retention seen in the A375P puro xenografts. Tumour-to-background ratios were also 
favourable, with αvβ6-expressing tumours showing a tumour-to-muscle ratio of 
around 7:1, for the same parameters. Low levels of 
111
In-DTPA-A20FMDV2 
retention were found in the blood, such that these were negligible at 4 hours p.i.; 
suggesting minimal plasma protein association with either free radionuclide, probe or 
probe fragment. These promising results do not seem to be mouse strain-specific, 
since similar ratios were obtained using Balb-C and CD1 nude mice. In addition, 
111
In-DTPA-A20FMDV2 was retained in tissues at 4 hours p.i., and so it is likely 
that some of this retention was due to αvβ6’s ability to internalise 111In-DTPA-
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A20FMDV2; protecting the probe from plasma degradation and dissociation from 
the membrane. Hausner et al showed that radiolabelling A20FMDV2 with fluorine-
18 permitted non-invasive imaging of v6-positive versus –negative paired 
tumours [228].  Although these initial studies promisingly showed that injected 
18
F-
A20FMDV2 could discriminate between the two tumours, tumour retention of 
radioactivity was relatively low (0.66% ID/g at 1 hour post-injection). Furthermore, 
the v6-positive tumour-to blood and tumour-to-muscle ratios, at 1 hour p.i., were 
just 2.4:1 and 1.2:1, respectively [228]. Translation of imaging into humans ideally 
requires improved tumour to background ratios. In this thesis, the systematic 
enhancement of the specific uptake and retention of 
111
In-DTPA-A20FMDV2 has 
been described; routinely showing a threefold increase in the original target to 
background ratio, reported with 
18
F-A20FMDV2 [228].  
Hausner and colleagues later performed biodistribution experiments, using v6-
positive versus –negative paired DX3 tumours and PEGylated A20FMDV2 variants 
[255]. Unfortunately, the uptake of the PEGylated radiotracers in the target tissue (at 
1 hour p.i.) was slightly below the level previously seen for the non-PEGylated 
18
F-
FBA-A20FMDV [255]. However, the introduction of the PEG unit(s) seemed to 
permit higher tumour retention of radioactivity, at the 2 and 4 hour time points, 
enabling greater target-to-background ratios at these later post-injection times [255]. 
These findings have proposed the synthesis of PEGylated 
111
In-DTPA-A20FMDV2 
variants and biodistribution experiments currently are being explored. Nevertheless, 
the higher renal retention seen with PEGylated 
18
F-FBA-A20FMDV variants [255] is 
of concern and may limit the utility of the PEGylated 
111
In-DTPA-A20FMDV2 
model. 
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The optimal peptide mass established for 
111
In-DTPA-A20FMDV2 was extrapolated 
to 
111
In-DOTA-A20FMDV2 and 
111
In-DTPA-DBD2 biodistribution experiments, 
resulting in similar retention within the v6-expressing tumour.  
However, it should be noted that there are other possible explanations for the 
selective uptake in αvβ6-expressing tissues and these include:-  
1.  αvβ6-specific and dependent binding  
2.  Specific binding to a different (unknown) receptor to αvβ6 
3.  Differences in vascularity, or vascular permeability, of the two tumours implanted 
in recipient animals. 
 
Clearly the first option is the desired scenario, fulfilling the objective of this project 
and thus providing evidence for the development of a selective, targeted, imaging 
probe.  
However, the second explanation also remains a possible alternative, though it is less 
likely given the correlation of the murine αvβ6 expression pattern found using 
immunohistochemistry with results of the biodistribution analysis (see below). 
Furthermore, the A375P cell lines seem to differ only in αvβ6 expression, and not in 
any other RGD binding integrin. Nevertheless, at this time, the presence of a 
different co-existent receptor cannot be ruled out formally – see limitations, below.  
The immunohistochemistry pattern, and its consistency, also makes the third 
explanation for enhanced delivery less likely. Nevertheless, to demonstrate whether 
the two xenografts have no significant differences in vascular supply, endothelial 
staining in representative tumour sections could be performed and the results 
compared. Comparable numbers of blood vessels in tumours originating from both 
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lines would provide formal evidence that there was no difference in evoked 
angiogenesis, between αvβ6 non-expressing and αvβ6-expressing growths (as 
inferred by the comparable growth rates of the two lines). Additionally, real-time 
tracking of the radiolabelled peptide by the SPECT/CT could demonstrate that there 
is an equal chance of the peptide reaching both tumour destinations. However, the 
co-injection method was chosen to elucidate the mechanism of tissue peptide 
retention. The intravenous injection of ‘excessive’ unlabelled (cold) DTPA-
A20FMDV2 a few minutes prior to radiolabelled peptide was fundamental to 
answering this question. In a targeted event, the cold peptide would be expected to 
bind to the integrin receptor and to inhibit the radiolabelled peptide competitively, 
thereby reducing tumour uptake and, therefore, subsequent levels of gamma ray 
signals. However, if there were no decrease in tumour uptake, peptide retention 
would be less likely to be due to a saturable receptor-ligand phenomenon; implying 
that simple pooling or non-specific peptide excretion may be alternative explanations 
for peptide residency within tissue. The results of the co-injection of a 100-fold 
excess of ‘cold’ DTPA-A20FMDV2 revealed suppression of uptake in A375P 6 
tumours, and other v6-positive tissues (see Figure 62); thus confirming that the 
uptake of 
111
In-DTPA-A20FMDV2 was receptor-mediated, rather than via a peptide-
dependent increase in vasodilatation and vessel permeability. This type of in vivo 
mechanistic result has not been shown previously for any v6-specific agent, or 
indeed for many other integrin-targeting peptides. 
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6.2.1 Limitations of the Tumour Xenograft Model in Mice 
It should be noted that Hausner’s study used 18F-A20FMDV2 and the human 
melanoma cell line, DX3, expressing puromycin-resistance alone (DX3puro) or, 
v6 as well as puromycin resistance (DX36) [228, 264]; whereas in this project a 
similar model, based on the A375P human melanoma cell line, for optimisation of 
111
In-DTPA-A20FMDV2 was used: the two, related lines being A375P 6 and 
A375P puro.  Characterised recently for their patterns of integrin expression [235], 
the A375P cell lines have identical levels of four RGD-directed integrins, 51, 
v3, v5 and v8, and differ only in that v6 is expressed exclusively by 
A375P 6. Nevertheless, there may be other subtle differences between DX3 and 
A375P melanoma cell lines (e.g. differing levels of pathological angiogenesis; 
unequal expression levels of the target receptor; or incongruent levels of necrosis 
within each tumour model), which may hinder direct comparisons. Furthermore, it is 
for these reasons that the biodistribution results of 
111
In-DTPA-A20FMDV2 cannot 
be directly compared to those for 
125
I-HBP-1 and indium-labelled H2009.1 peptide 
variants. The differing tumour and mouse models, used for each RGD peptide, 
introduce too many variables. Ideally, the different peptides (and their variants) 
should all be tested on the same experimental model to compare fairly the uptake and 
retention of each compound in an αvβ6-expressing tumour, in vivo. 
 
  
The presence of a different (unknown) receptor being responsible for targeted tissue 
retention of 
111
In-DTPA-A20FMDV2 also cannot be ruled out at this time (see 
Section 6.2). Ideally, to prove the tissue retention mechanism is an v6-dependent 
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system, co-injection with 
111
In-DTPA-A20FMDV2 should occur with a different 
known v6-specific agent. Previously, 68G6 [231] antibody was used for in vitro 
blocking experiments in order to test for potential v6-dependent mechanisms (see 
Sections 4.4 & 4.5). However, it is not known whether this antibody effectively 
blocks v6 in vivo. Indeed, at present, there is no universally accepted reagent 
which is known to block v6 in vivo; thus creating a barrier to the proposed 
experiment. 
Ideally, separate optimisation experiments should have been performed with 
111
In-
DOTA-A20FMDV2 and 
111
In-DTPA-DBD2, rather than a simple extrapolation from 
the results of 
111
In-DTPA-A20FMDV2. However, owing to the constraints of 
resources and the similar single RGD binding site of each peptide variant, it was 
decided only to study tissue dissemination and their variation over time (i.e. not to 
vary peptide mass or strain for the DOTA or cyclic variants). 
The targeting of v6, by 111In-DTPA-A20FMDV2, was validated in the 
endogenously v6-expressing breast cancer lines, CA1a and DCIS.com (cf. A375P 
- genetically-engineered) and described in Section 5.1. However, the subcutaneous 
xenograft model may not always be representative of the genetics and histology of 
the corresponding cancer found within humans [265-267]. Firstly, xenografts have to 
grow in an immunodeficient mouse and metastasis is not always evident [267]. 
Furthermore, although human cancer cells lines tend to be used for xenografting, 
these cells have been passaged and maintained on a plastic plate for many years. 
Selection pressures, under these artifical culture conditions, mean that the passaged 
lines often are not representative of the original tumour and its native state. For 
example, cells in culture lack the complex cellular networks found in vivo. Growth 
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and communication with inflammatory cells, vasculature, and other stromal 
components all are absent within culture conditions [266]. On the other hand, 
transgenic mouse models usually arise in immunocompetent animals, and the 
tumours develop spontaneously in situ, within the appropriate tissue compartment. 
Furthermore, the stages of tumour progression can be studied over time with the 
opportunity to investigate a cancer, at early timepoints. Nonetheless, there are several 
disadvantages with the transgenic model [267]. These include the relatively long 
length of time required to develop neoplasia and the unpredictable nature of tumour 
development, with regards to frequency and latency of tumour formation [266]. This 
heterogeneity can lead to the requirement of greater mouse numbers and study costs. 
Therefore, both human tumour xenograft and transgenic mouse models have 
advantages and disadvantages in the study of cancer development and treatment 
[265]. Ideally, transgenic mouse models, such as those described for colon cancer 
(see Section 5.2), also would be used to validate the targeting of v6, by 111In-
DTPA-A20FMDV2. Unfortunately, the projected schedule for proposed 
collaborative experiments was beyond the time limits of my training degree and such 
studies will be undertaken by my successors 
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6.3 Immunohistochemical Correlation with Flow Cytometry and 
Biodistribution 
A systematic analysis of murine tissues was performed, which has not been reported 
previously in the literature. Xenografts of the two A375P cell lines were examined 
for expression of v6 and it was confirmed that A375P puro tumours lacked any 
v6, whilst A375P6 expressed v6 at high levels (+7 score) uniformly 
throughout tumours (Figures 49 & 50). Furthermore, Table 10 (page 174) 
documents that while most tissues examined do not express v6, several murine 
tissues express significant amounts of v6, particularly the stomach and the lower 
gastrointestinal tract. Such data suggest that the reagent-attracting capacity of these 
v6-positive organs should be taken into consideration whilst using mouse models 
for developing v6-specific targeting. This possibility was supported further by the 
previous flow cytometry experiments, which showed that A20FMDV2 specifically 
binds to mouse keratinocytes through murine v6 (Figure 40). Confirmation of this 
hypothesis was achieved when it was shown that 
111
In-DTPA-A20FMDV2 was 
retained significantly in the lower gastrointestinal (GI) tract, lung, stomach, skin and 
gall bladder, as well as the A375P6 tumours; which all have more radioactivity than 
either A375P puro tumour or skeletal muscle. Subsequent co-injection studies using 
a 100-fold excess of ‘cold’ DTPA-A20FMDV2 (Figure 62), indicated that the 
uptake of 
111
In-DTPA-A20FMDV2 was receptor-mediated in the peptide-retaining 
tissues, rather than via a peptide-dependent increase in vasodilatation and vessel 
permeability. As a result, with the exception of the kidneys and lungs, since these 
tissues all endogenously express v6, it suggests that 111In-DTPA-A20FMDV2 
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recognises and binds to endogenous vβ6 receptors on these tissues. Furthermore, 
the inability of a random peptide, 
111
In-DTPA-A20FMDV2ran, to be retained 
differentially further supported the premise that 
111
In-DTPA-A20FMDV2 localises 
specifically to v6-integrin-positive tissues via its RGDLXXL/I motif (Figure 63). 
Finally, the biodistributions patterns of 
111
In-DOTA-A20FMDV2, 
111
In-DTPA-
DBD2 and their relevant scrambled variants, were all consistent with the results 
obtained for 
111
In-DTPA-A20FMDV2 and 
111
In-DTPA-A20FMDV2ran, 
respectively; suggesting a ‘RGD class effect’.  
Nothelfer et al studied squamous cell carcinoma of the head and neck (HNSCC) and 
selected cell lines [256], and initially reported that their HNSCC cell lines were all 
positive, via fluorescence-activated cell sorter analysis, for the v6 integrin [256]. 
These v6-expressing cell lines were later injected subcutaneously into nude mice, 
which subsequently formed into tumours. Frozen sections from these xenografts 
were obtained and immunhistochemistry performed using fluorescence-labelled 
HBP-1 and Bright field microscopy. The authors illustrated moderate to strong 
staining in most tumour cells, and the absence of staining in the surrounding stromal 
cells [256]. Although, Nothelfer did not directly show the maintenance of v6 
expression within the HNSCC tumours, the HBP-1 immunhistochemistry is in 
keeping with the results discussed earlier in this section. 
The expression of αvβ6, in adult tissues, has been studied in other species [106, 123, 
134, 240, 260, 268]. Brown et al screened normal ovine and bovine tissues for the 6 
integrin, by RT-PCR and immunocytochemistry [268]. Of note, Brown and 
colleagues performed immunohistochemistry using the mouse monoclonal antibody, 
10D5 (described in Section 3.2), and frozen sections. αvβ6 expression was detected 
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in epithelia of the airways, oral cavity, gastrointestinal tract, kidney, sweat glands, 
hair follicle sheaths, and the epidermis of pedal coronary band, but not of normal 
skin [268]. There was no evidence of 6 transcription in ovine liver, spleen, or 
mesenteric and bronchial lymph nodes. These histochemical and RT-PCR results 
generally are consistent with the murine αvβ6 expression pattern (detected with 
immunohistochemistry) in this thesis. However, Brown reported that the integrin 
αvβ6 appeared to be constitutively expressed in the normal airways of both cattle and 
sheep; proposing an inhalatory route of infection by FMDV [268]. Although the 
murine respiratory epithelium was not positive for αvβ6 expression in the 
immunohistochemistry experiments (Table 10, page 174), biodistribution 
experiments, consistently within this thesis and by other groups, suggest significant 
uptake and retention of radiolabelled RGD radioligands in the lungs (see Sections 
4.9.2, 5.1.5, 5.3.1.4, 5.3.2.2 and [262]). Macroscopically, there was no evidence of 
overt pulmonary haemorrhage during the biodistribution experiments and so these 
results simply are not explained by blood pooling. Notably, Brown and co-workers 
and colleagues stated that there was minimal evidence for specific staining when 
labelling was performed in standard PBS containing 0.5% Tween 80. However, well-
defined labelling of the membranes of airway epithelial cells was observed when the 
staining buffer was supplemented with 4 mM MgCl2 [268]. In addition, even though 
Brown did not show the data, it was suggested that the epitope targeted by 10D5 was 
readily denatured by methanol [268]. The immunohistochemistry technique 
(employed in this thesis) used the 62G2 monoclonal antibody [231], paraffin-
embedded sections, and specifically used methanol / hydrogen peroxide (destruction 
of endogenous peroxidase), but did not supplement cations. However, the 62G2 
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antibody has been classified as ‘nonligand-mimetic’ and not cation-dependent; thus 
binding to a different epitope when compared to 10D5 [231]. Nevertherless, these 
variances may explain the absence of αvβ6 staining seen in murine pulmonary 
tissues within this report. Future experiments could adjust for these factors and if 
subsequent testing does detect αvβ6 within airway epithelium, it could explain the 
relatively high uptake and retention of 
111
In-DTPA-A20FMDV2, of 
111
In-DOTA-
A20FMDV2 
111
In-DTPA-DBD2 and 
131
I-HBP-1 seen in murine lungs (see Sections 
4.9.2, 5.1.5, 5.3.1.4, 5.3.2.2 and [262]). Furthermore, differences in experimental 
technique and model may also explain why Munger and colleagues could only detect 
diffuse and low-level expression of αvβ6, in airway and alveolar epithelial cells of 
wild-type β6+/+ (129/terSVEMS strain) mice; contrasting with focal areas of 
markedly increased expression of αvβ6 within lungs of bleomycin-treated animals 
[106]. The immunohistochemistry performed by Munger’s group was on frozen 
section and using the rabbit anti-β6 monoclonal, B1 [106]. It is possible, that 
bleomycin exposure up-regulated and / or focally concentrated αvβ6 expression into 
a ‘threshold’ level, previously not adequately detected by the B1 antibody system. 
Alternatively, bleomycin may further expose the epitope for B1, which initially was 
hidden / cryptic in normal lungs. Repeat immunohistochemistry using a range of 
monoclonal antobodies, which recognise a variety of epitopes, could help address 
this issue and determine whether there indeed is a difference in pulmonary αvβ6 
expression within species. 
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6.3.1 Limitations of Immunohistochemistry 
Variations in immunohistochemical conditions, as suggested in Section 6.3, could be 
trialled in order to detect αvβ6 expression within the lungs. However, prior to these 
tests, RT-PCR could be attempted on appropriately prepared murine tissues. 
Evidence of 6 transcription would help justify subsequent immunohistochemical 
optimisation procedures. Indeed, appropriate primers have been designed and RNA 
from various murine organs is stored. Unfortunately, these experiments could not be 
completed during the time set for this training degree and are now being attempted 
by my successor.    
The murine antibody, 62G2, was used to immunostain mouse tissues for αvβ6, with 
the aid of a mouse-on-mouse kit (Vector BMK-2202). Although this created certain 
technical issues, a number of controls within the procedure ensured a valid system of 
αvβ6 detection. Furthermore, a novel human Fc / mouse chimeric monoclonal 
antibody, 2A1, is now available to detect αvβ6 within murine tissues [269]. Although 
the data on murine tissues have yet to be formally published, the manufacturers of 
2A1 have confirmed that the immunohistochemical results are qualitatively similar to 
those obtained using 62G2 (see Section 4.6). 
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6.4 Peptide Excretory Experiments 
The highest levels of radioactivity per unit mass were found in the bladder and 
kidney. Owing to the absence of αvβ6-immunostaining in the murine kidney (see 
above) and high levels of radioligand in the urine (data not shown), these data 
probably are representative of the high and rapid peptide excretion through the 
urinary tract. The next highest levels of radioactivity per unit mass were found in the 
A375Pβ6 (β6 expressing) tumour and the stomach; which does correlate closely with 
histochemical results (see above).  
 
Furthermore, since there is a relatively low %I.D./g within the liver, renal excretion 
is most likely the major route of clearance for the peptide; and the associated 
radiation exposure could be dose-limiting. However, it should be noted that co-
injection of cold DTPA-A20FMDV2 caused the renal retention of 
111
In-DTPA-
A20FMDV2 to decrease by >50% and, since expression of v6 was not detected by 
immunohistochemistry in the kidney, renal radiopeptide retention may not be related 
to receptor (v6)-specific binding. That is, a different saturable mechanism may be 
responsible. This non-v6-specific renal retention hypothesis is supported by the 
fact that co-injection of a 100-fold excess of a scrambled peptide (DTPA-
A20FMDV2ran) together with 
111
In-DTPA-A20FMDV2 had no effect on v6-
specific uptake, but suppressed the kidney uptake by nearly 50% (Figure 64).  
DTPA-A20FMDV2ran does not recognise β6 in vitro and in vivo and, since the 
kidney retention of 
111
In-DTPA-A20FMDV2 can be suppressed by saturating the 
retention mechanism with this scrambled peptide, it confirms that the mechanism of 
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retention is not RGD-specific; possibly via a generalised peptide uptake mechanism, 
rather than an v6-dependent system.  
Previous studies have reported that peptides can be reabsorbed by the renal system 
[270, 271]. The transmembrane scavenger-receptor, megalin, is one important 
mechanism of peptide re-absorption [272]; although many other mechanisms have 
been proposed and they are not fully understood [270]. Once reabsorbed, the renal 
tubular cells have the potential to further metabolise (e.g. lysosomal degradation) the 
radiopeptide and could, in theory, uncouple the 
111
In from the DTPA-A20FMDV2 
[271]. It is known that metals (e.g. 
111
In) are retained in certain tissues to a greater 
degree than other ions (e.g. 
18
F) [254, 271] and this may be a possible explanation for 
the different renal handling after 1 hour, of 
111
In-DTPA-A20FMDV2 (97.56 ± 14.67 
%I.D./g) compared to [
18
F]FBA-A20FMDV2 (3.56 ± 1.38 %I.D./g) [228]. Saturation 
of the renal uptake mechanisms by DTPA-A20FMDV2ran may minimise the amount 
of 
111
In-DTPA-A20FMDV2 exposed to uncoupling agents and thus reduce retention. 
Furthermore, different labelling moieties may alter peptide properties, such as 
hydrophobicity and lipophilicity. The DTPA chelating agent may also affect the 
peptide’s properties. Attachment of a hydrophilic 111In-DTPA chelating moiety to a 
peptide has been reported to enhance renal excretion and minimise hepatobiliary 
clearance, thus reducing abdominal radioactivity levels [273]. Hydrophobicity 
transformation may alter peptide quaternary structure and so alter its binding affinity. 
Moreover the lipophilic profile of the peptide may affect organ uptake and excretion 
and thus other blocking strategies could be explored, such as infusion with 
gelofusine [270] 
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Other mechanisms for renal uptake and retention were explored in the 
comparison of the biodistibution of non-biotinylated 
111
In-DTPA-A20FMDV2 and 
the wild-type peptide. There was a significant difference in renal handling of the 
non-biotinylated and biotinylated forms of the peptide. The biotinylated form had 
50% less renal retention and it was thought that this may be due to its larger size. The 
larger molecule may have reduced filterable, or reabsorbable, capacity in comparison 
with the non–biotinylated peptide. Alternatively, the biotinylation may have had 
substantial effects on steric hinderance or lipid solubility [254, 271]. Whatever the 
precise mechanism, these results suggest that re-designing the peptide has the 
potential to reduce renal uptake and retention. That is, if the peptide could be 
redesigned so that uncoupling of the 
111
In from DTPA-A20FMDV2 could be 
resisted, then this strategy might also reduce renal radioactivity exposure. However, 
the detailed exploration of potential renal blocking mechanisms and peptide 
manipulation was beyond the scope of this project. Furthermore, the single doses of 
radiopeptide required for human imaging studies minimise any potential renal 
hazards. Nevertheless, it is possible that a similar peptide renal retention mechanism 
may occur in humans and this potential radiation accrual could have an impact on 
future therapeutic studies (see Chapter VII). Therefore, the important discovery that 
renal retention can be suppressed by pre-saturating appropriate receptors suggests 
that a similar strategy could be employed in humans, to limit dose-limiting toxicity 
during peptide receptor radiotherapy trials. If the targeted agent could be labelled 
with a β-emitting isotope, it could home in on the tumour, cause local cell death and, 
potentially, provide a useful therapeutic tool. However, β-emitter metals, such as 
Yttrium, when coupled to DTPA-A20FMDV2 would possibly require multiple doses 
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to be an effective therapeutic agent and thus would require strategies to minimise 
renal radioactivity exposure. However, peptide receptor radiotherapy is one possible 
therapeutic approach; coupling of the peptide to a non-metallic chemotherapeutic 
agent is another potential manoeuvre [274]. The uncoupling mechanism in the renal 
tubular cells may not be as effective for a non-metallic substance and thus the 
potential renal toxicity could be minimised through rapid excretion. 
 
6.4.1 Limitations of Peptide Excretory Experiments 
Brown et al reported that the integrin αvβ6 appeared to be expressed in the normal 
distal convoluted tubular epithelium, in the kidneys from sheep [268]. Although the 
murine kidneys were not positive for αvβ6 expression in the immunohistochemistry 
experiments (see Table 10, page 174), the biodistribution experiments reported in 
this thesis consistently have suggested significant retention of radiolabelled RGD 
radioligands within the kidneys (see Sections 4.9.2, 5.1.5, 5.3.1.4 and 5.3.2.2). 
Although peptide excretory mechanisms are assumed to be the primary reasons for 
this retention, the questions regarding probable immunohistochemical variables 
(described in Section 6.3) suggest that constitutive αvβ6 expression within murine 
kidneys cannot totally be ruled out. RT-PCR and evidence of 6 transcription would 
help clarify this dilemma. However, post-translational modifications, the presence of 
co-activators and receptor turnover will not be necessarily addressed by RT-PCR 
techniques, and so proof of the presence of a functional αvβ6 cell-surface receptor in 
the kidney may still require further investigation.  
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Ideally, to prove that the peptide renal retention mechanism is not an v6-
dependent system, co-injection with 
111
In-DTPA-A20FMDV2 should occur with a 
different known v6-specific agent. In vitro blocking experiments utilised the 68G6 
monoclonal antibody [231] and tested for potential v6-dependent mechanisms. 
However, it is not known whether this antibody effectively blocks v6 in vivo. 
Indeed, at present, there is no universally accepted reagent known to block v6 in 
vivo; thus creating a barrier to the proposed experiment. 
The theory of metal radiolabel being uncoupled from 
111
In-DTPA-A20FMDV2 (or 
the DOTA variant) being responsible for the differences in renal retention (as 
compared to [
18
F]FBA-A20FMDV2) is difficult to prove. Future experiments could 
use different labelling methods and non-metals, as well as re-designing the peptide. 
However, this investigation is beyond the scope of this project. 
It also is possible that this peptide renal retention mechanism is only pertinent to the 
mouse model. Therefore, other animal models could be tested prior to human trials. 
However, this is time-consuming, expensive and there is no guarantee that data from 
other species are more representative of humans, compared to murine models. 
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6.5 In vivo Imaging 
In order to take advantage of the high resolution and sensitivity of the multi-pinhole 
NanoSPECT/CT small animal imager, A20FMDV2 was modulated into a SPECT 
targeting agent for v6. The biodistribution results were reflected in the imaging 
experiments; revealing selective localisation of labelled peptide in αvβ6-expressing 
tissues. Figure 66 shows a coronal slice, taken by a NanoSPECT/CT, 1 hour after 
injecting 10MBq 
111
In-DTPA-A20FMDV2 into a mouse bearing paired A375P 
6/A375P puro tumours.  It clearly is apparent that there is little or no activity in the 
A375P puro tumour whereas the A375P 6 tumour has distinct ‘hot-spots’ within the 
growing tumour mass.  The kidneys also show significant radioactivity but no other 
organs are revealed in this analysis. Maximum Intensity Projections (MIPs) were 
also generated in separate studies from several mice. Although represented in 2-
dimensions, Figure 66 shows that, again, the A375P 6 tumour retained significant 
amounts of radioactivity whereas the A375P puro tumour effectively is negative. The 
MIP (especially when rotated through 360 degrees) confirms that the distribution of 
the radioactivity in the A375P 6 tumour was not uniform, but rather appears as a 
series of higher activity nodules, approximately 1mm diameter, interconnected by 
lower activity areas.  The reasons for this localised distribution are not known, but 
may relate to local blood supply or regions of hypoxia.  The MIP image also reveals 
the significant retention of 
111
In-DTPA-A20FMDV2 by the lower GI tract as well as 
by the kidneys and bladder. Therefore 
111
In-DTPA-A20FMDV2 is retained 
selectively by v6-expressing tissue and is the first specific radioligand for the non-
invasive imaging of v6-positive cancers by SPECT.   
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Hausner et al’s [228] imaging of DX3-paired tumours using PET did not reveal 
discrete areas within the growing mass of the v6-positive tumour. Instead, the 
[
18
F]FBA-A20FMDV2 tumour uptake images were less well-defined and more 
dispersed; possibly as a result of the inferior resolution of their microPET system 
(see Section 2.1.4.2). This resolution difference may also explain the absence of 
images revealing uptake of [
18
F]FBA-A20FMDV2 in the stomach and gallbladder, 
despite the high %I.D./g shown in their biodistribution experiments [228]. Hence the 
superior resolution of a multi-pinhole NanoSPECT/CT has provided interesting data 
as well as opening up future research questions. 
 
6.5.1 Limitations of NanoSPECT/CT Experiments 
Hausner et al imaged DX3-paired tumours on a microPET system using [
18
F]FBA-
A20FMDV2 [228], PEGylated and 
64
Cu variants [254]; whereas the imaging 
experiments performed in this thesis studied A375P-paired tumours on a 
NanoSPECT/CT system using 
111
In-DTPA-A20FMDV2 and the DOTA variant, thus 
making direct comparisons between the two studies somewhat difficult. It may be 
that the differential distribution seen within the A375P 6 tumour is not really 
present in the DX3puro 6 tumour; and so not related to resolution differences 
within the imaging systems. The Department (at Queen Mary’s, University of 
London) recently has purchased a PET scanner, which currently is being optimised. 
Sequential imaging using the different imaging systems on the same mice may help 
provide an answer to this question.  
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It has been hypothesised that potential reasons for the localised distribution of 
radioligand within the A375P 6 tumour might relate to local blood supply or 
regions of hypoxia. However to prove these theories, markers of hypoxia or of 
tumour vasculature would need to be imaged simultaneously with 
111
In-DTPA-
A20FMDV2. It should then be possible to compare corresponding areas within the 
tumours. However, although there have been numerous agents which have been 
published and claimed to image tissue hypoxia [275] and tumour angiogenesis [276], 
in vivo, none have yet been accepted as a universal standard for use in murine 
models. Furthermore, some of these published agents have been optimised on 
different imaging modalities (e.g. MRI, rather than PET or SPECT). Therefore, 
issues of standardisation and image registration (from multiple imaging modalities) 
will create further problems when testing the proposed hypotheses. 
Ideally, one would like to correlate tissue %I.D./g found in biodistribution 
experiments with NanoSPECT/CT estimates. SPECT quantification of radioligand 
dissemination has been shown to be very accurate in rat kidney models [277]. 
However, at present, the sensitivity of our machine is not sufficient to do this type of 
quantification in all organs, especially with relatively moderate amounts of 
radioactivity (data not shown). Once the sensitivity can be optimised, the reduction 
of time-consuming and laborious biodistribution experiments could be a useful 
objective. Consequently, imaging would have the additional advantage in that small 
tissues (which usually may not be sampled in biodistribution experiments) could be 
examined for radioactivity in situ and at a time distant from the original experiment. 
However, some organs may be hard to fully delineate using imaging techniques e.g. 
intestines; thus quantification of these organs may not be as accurate. Recently a 
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number of investigators have used Standardised Uptake Values (SUVs), to measure 
and compare tumour uptake, within microPET systems and mice; instead of the 
standard %I.D./g measures [255, 278]. However, SUVs can be influenced by a 
number of different factors and so it is not known how accurate these values are (as 
compared to data from the gold standard biodistribution experiments), so that one 
should be cautious about over-emphasising the value of such approaches [278]. 
 
6.6 Summary  
The integrin v6 is not expressed by most normal tissues but is upregulated 
strongly on many carcinomas [134].  
It has been shown that v6 promotes carcinoma cell migration as well as invasion 
[140], matrix-metalloproteinase production [141], and tumour cell survival [152], 
both in vitro and in vivo. 
85-95% of oral squamous carcinomas and 40% of breast cancers express v6, 
whereas corresponding normal tissues are negative. Recently a study of nearly 500 
colon cancers showed that the hazard of dying was 60% higher in patients with 
strong expression of v6 [101]. Together these data suggest that v6 actively 
promotes cancer progression; possibly explaining the poor prognosis associated with 
its expression by tumour cells. 
 
High affinity v6-binding peptides have been generated, whose activity is 
dependent on an RGD motif.  
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The work presented in this thesis has shown that these peptides are selective and 
specific for v6–positive tumour cell lines, in in vitro assays. 
Furthermore, it has been demonstrated that these peptides selectively locate to v6-
expressing tumours in vivo. 
111
In-DTPA-A20FMDV2 is internalised by v6-
expressing cells and this may be important for in vivo tumour retention, given that 
peptides are degraded by plasma proteases.  
A systematic improvement in the uptake and retention of 
111
In-DTPA-A20FMDV2 
has been described and this forms the basis of the first documented, v6-specific 
SPECT imaging agent (see Appenidix for publication).  
In addition, a method to reduce renal toxicity during peptide receptor radiotherapy 
has been developed, which may have widespread applicability. 
 
Finally it has been discovered that, unlike the situation reported for human tissues, 
several murine tissues express v6 and this characteristic must be accounted for 
when screening for v6-specific targeting agents.    
 
In conclusion, this project provides valuable information on the best type of v6-
targeting agents to translate from bench to the clinic and can serve as a paradigm for 
pre-clinical evaluation of targeting agents in general. Future experiments could 
exploit these findings to target human cancer. 
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Chapter VII: Potential Human Trials 
 
7.1 Proposed Phase I trial schema: 
68
Ga-DOTA-A20FMDV2 
The pre-clinical experiments were performed in order to form the basis of a rationale, 
for the translation of the v6-targeting agents into a useful imaging tool for the 
clinical investigation of human cancers. Currently, imaging in oncology helps with 
diagnosis, staging, prognostication, the monitoring of treatment response and 
screening (see Chapter II). However, prior to widespread use of a proposed imaging 
agent, its potential toxicity / safety profile must be established. A Phase I trial is the 
generally accepted method to evaluate tolerability and identify a safe dosage range. 
. 
 
Background 
 
DOTA-A20FMDV2 has been shown to detect v6-expressing tumours in pre-
clinical models; and serve as a diagnostic imaging agent. v6 is over-expressed in 
many human epithelial cancers, such as pancreas, oral and breast. Therefore, this 
new agent permits the opportunity to examine these cancers through their biomarker. 
Future studies could correlate the plasticity of v6 expression with 68Ga-DOTA-
A20FMDV2 imaging and survival, following targeted therapy.  
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Objective  To determine 
68
Ga-DOTA-A20FMDV2 safety 
  To determine its plasma stability 
  To study the distribution and kinetics of the tracer 
  To accrue preliminary data on potential diagnostic value 
 
Requirements: 
MHRA approval  – Investigational Medicinal Product 
ARSAC (Administration of Radioactive Substance Advisory Committee) approval 
GCP Radiopharmacy and Gallium generator 
PET and CT scanners 
Ethics approval 
Nuclear Medicine Physician 
Informed consent 
 
Methods 
 
Inclusion Criteria:  
 Biopsy proven stage IV breast cancer  
 Aged over 18 years old 
 ECOG performance status 0-2 
 Post-menopausal, surgically sterile, post-hysterectomy, or having a negative 
pregnancy test on day of scan. 
 At least one lesion of greater than 1cm diameter, that has not been irradiated 
previously. 
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Exclusion Criteria: 
 Receiving chemotherapy within four weeks of scan 
 Received a trial drug within four weeks of scan. 
 If in lactating period 
 Impaired renal function (serum creatinine > 106 µmol/L) 
 
Records:  Patient demographics 
  Number of previous treatments 
  Hormonal and c-erbB2 status 
  Whether primary has been removed 
Other disease sites found on recent CT, MRI, 
18
F-FDG-PET or 
Clinical Examination.  
 
Procedure:     
Physical Examination pre PET scan 
Slow bolus (over 1 minute) intravenous injection of radioligand 
Dynamic scan of selected lesions from t=0 and acquire ten second frames for 5 
minutes. After this period 1 minute frames for next ten minutes; followed by 5 
minute frames for next fifteen minutes. The final sequence involves 10 minute 
frames for thirty minutes. 
Static scan at 60 minutes post-injection for whole body and thus all lesions. 
Define region of interest / lesions from scout and low-dose CT scans and previous 
18
F-FDG-PET emissions. 
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Pharmacokinetic Measures: 
Blood sampling at 5, 10, 30 and 60 minutes post-injection to determine plasma : 
blood activity; and HPLC analysis examining stability  and metabolite formation. 
PET measures of tissue activity over time (decay corrected and normalised for 
injection dose; SUV m
2
/ml)  
Patlak graphical method: Rate constant (Ki) measure of net irreversible retention of 
radioligand, within imaging time (assuming that the metabolites do not bind to the 
receptor). 
Assessment of the fractional retention of the radioligand and the mean residence time 
(MRT) 
 
Toxicity Measures: 
Before, during and up to 24 hours post injection:- 
Vital signs 
Physical Examination 
ECG and continuous lead II during and up to 15 minutes post administration of 
radioligand 
Blood tests (FBC, clotting and full biochemistry profile) at 30  minutes, 150 minutes 
and 24 hours post-injection.  
Urinalysis 
 
Two weeks post scan:- 
Telephone interview with subject; with clinic review, if symptoms warrant further 
investigation. 
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Biomarker Correlation: 
Immunohistochemistry of biopsy sample for v6 expression. 
 
Data analysis and Statistics: 
Two-tailed Wilcoxon matched-pairs test to compare the uptake and kinetic 
parameters in tumour lesions with corresponding normal tissues. 
 
7.1.1 Limitations of Proposed Phase I trial schema 
Traditional phase I studies can be a slow and costly process [279], especially if the 
other peptide variants are to be examined within human subjects. Furthermore, the 
dose of investigational agent producing a ‘dose-limiting toxicity’ (a limit of 
tolerability) may not be relevant to the dose required to detect its related biomarker 
[279, 280]. Therefore, a relatively recent development is the phase 0 study. In this 
type of study, ‘microdoses’ (sub-therapeutic) of the investigational agents are 
administered to gather initial pharmacokinetic and pharmacodynamic data [281]. A 
microdose is defined as less than 1/100th of the dose calculated to yield a 
pharmacological effect of the test substance based on primary pharmacodynamic 
data obtained in vitro and in vivo (typically doses in, or below, the low microgram 
range) and at a maximum dose of ≤ 100 microgram [282]. In addition, owing to 
differences in molecular weights, as compared to synthetic drugs, the maximum dose 
for protein products is ≤30 nanomoles [279]. That is, the exact microdose (selected 
for study) is based on pre-clinical safety studies. These studies should demonstrate 
that a large multiple (e.g. 100x) of the proposed human dose does not induce adverse 
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effects in the experimental animals; establishing a margin of safety and limiting the 
risk to future human subjects [279]. However, controlled allometric scaling from 
animals to humans (based on body surface area or pharmacokinetic / 
pharmacodynamic modelling) may be possible to select the dose for use in the 
subsequent clinical trial [279]. It should be noted that Phase 0 studies do not give 
detailed data on safety and efficacy and so later phase studies still will need to be 
performed [283]. Furthermore, phase 0 trials are limited to investigational agents 
with a wide therapeutic index, a known target, and a validated biomarker [281]. 
Notwithstanding these conditions, phase 0 studies potentially are able rank similar 
candidate investigational compounds with respect to pharmacokinetic / 
pharmacodynamic parameters; narrowing down the the number of agents to take 
forward into further development.  
Clinical trials of radioactive substances must follow the Ionising Radiations 
Regulations [284] and should be approved by the Administration of Radioactive 
Substances Advisory Committee (ARSAC). ARSAC guidelines state that the 
radiation dose to a trial subject should be as low as reasonably practical and must not 
exceed 10 milliSievert per annum [285]. ARSAC expects trial investigators to 
estimate the radiation to a trial subject by referencing the best information available 
at the time of their applications. Where such estimates are not possible (from similar 
existing human studies) data from animal dosimetry studies, or where practicable 
from human studies involving extremely low radiation doses, should be utilised 
[285]. Therefore, this data will be taken together with other experiments (e.g. 
labelling efficiency) to determine the initial activity to be used within early phase 
trials.  
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7.2 Proposed Phase II / III trial schema: A20FMDV2 
Once initial safety data have been accrued, a further evaluation of toxicity is made, in 
a larger group of subjects (phase II).  However, an initial evaluation of the diagnostic 
performance (efficiency) of the imaging agent can also be performed (phase II/III). 
This involves the assessment of whether the imaging agent can detect the presence of 
absence of disease (sensitivity, specificity and accuracy). It may be that the threshold 
criteria, for deciding whether a test is positve or not, is a fine balance between 
acceptable sensitivity and specificity rates. Ideally, these rates would be compared 
against a standard imaging agent, currently in clinical use (phase III). 
 
Objective  Extension of toxicity data 
Compare A20FMDV2 to FDG in primary lesions, as well as 
metastatic lesions.  
  To determine sensitivity of A20FMDV for lesion identification. 
 
Requirements: 
MHRA approval  – Investigational Medicinal Product 
ARSAC (Administration of Radioactive Substance Advisory Committee) approval 
GCP Radiopharmacy 
PET and CT scanners 
Ethics approval 
Experienced Radiologist to interpret scans 
Informed consent 
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Methods 
Inclusion Criteria:  
 Biopsy proven stage IV breast cancer 
 Aged over 18 years old 
 ECOG performance status 0-2 
 Post-menopausal, surgically sterile, post-hysterectomy, or having a negative 
pregnancy test on day of scan. 
 At least one lesion of greater than 1cm diameter, that has not been previously 
irradiated 
 
Exclusion Criteria: 
 Receiving chemotherapy within three weeks of scan 
 Received a trial drug within thirty days of scan, or due to receive a 
investigational medicine up to 24 hours after scan. 
 If undergoing occupational monitoring for radiation exposure 
 If in lactating period 
 Impaired renal function (>106 µmol/L) 
 Diabetic patients or fasting glucose >7. 
 
Record:  Patient demographics 
  Number of previous treatments 
  Hormonal and c-erbB2 status 
  Whether primary has been removed 
  Other disease sites found on recent CT or Clinical Examination.  
 279 
Procedure:   
Patient to be fasted 6 hours before FDG PET scan    
Physical Examination pre PET scan 
CT scan is required to be within four weeks of PET scan for formal comparison. 
Calibrate PET with suitable source 
Bolus intravenous injection of radiolabelled A20FMDV2 
Scan at 60 minutes post-injection 
Define up to 5 target lesions for each patient (choose lesion with highest tracer 
uptake if afflicted organ has multiple lesion). Outline a volume of interest for 
calculations of SUV. 
 
Pharmacokinetic Measures: 
Blood sampling at 5, 10, 30 and 60 minutes post-injection to determine plasma : 
blood activity; and HPLC analysis examining stability  and metabolite formation. 
PET measures of tissue / lesion activity over time (decay corrected and normalised 
for injection dose and body surface area; SUV m
2
/ml)  
Rate constant (Ki) measure of net irreversible retention of radioligand, within 
imaging time (assuming that the metabolites do not bind to the receptor). 
 
Toxicity Measures: 
Before, during and up to 24 hours post injection:- 
Vital signs 
Physical Examination 
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ECG and continuous lead II during and up to 15 minutes post administration of 
radioligand 
Blood tests (FBC, clotting and full biochemistry profile) at 30 minutes, 150 minutes 
and 24 hours post-injection.  
Urinalysis 
 
Biomarker Correlation: 
Immunohistochemistry of biopsy sample for v6 expression. 
 
Statistics: 
Sensitivity comparisons between FDG and A20FMDV2 are based on lesion 
identification, number of lesions in each scan and comparison to Clinical and CT 
staging. 
Correlations of parameters using linear regression and Pearson’s coefficient 
Comparisons of qualitative parameter using ANOVA 
Wilcoxon test. 
 
 
Outcomes: 
To compare and correlate SUV for primary lesions against metastatic lesions (organ 
by organ) for both A20FMDV2 and FDG. 
Any missed lesions for either radiotracer. 
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7.3 Diagnostic, Therapeutic and Health Impact 
 
One of the measures of the effectiveness of an imaging agent is its diagnostic impact. 
Ultimately, if the results of an imaging agent do not influence a clinican’s diagnostic 
confidence, then it has no diagnostic impact. Alternatively, if the diagnostic impact 
of the investigational imaging agent is superior to the standard technique, it may 
diplace older technologies. The calculation of diagnostic impact will be aided by the 
biomarker correlation studies included in the proposed trial schemes for A20FMDV2 
(see Section 7.1 & 7.2).  
Future studies may also look at the therapeutic impact of  an A20FMDV2-based 
imaging agent. Since v6 expression is associated with poor prognosis in several 
cancers, the use of 
111
In-DTPA-A20FMDV2 could enable non-invasive identification 
of higher risk cancers and, thus, might  be a prognostic marker. Consequently, these 
higher risk cancers could be stratified into different treatment arms. If a certain 
treatment is benefical to ‘poor-prognosis’ cancers, identified by the A20FMDV2-
based imaging agent, then this imaging agent has therapeutic, and thus health, 
impact. 
 
 
 
 
 282 
7.4 Possible Barriers to the Translation of A20FMDV2 into a 
Successful Clinical Imaging Agent 
 
Although clinical trials ultimately will decide the future of A20FMDV2, a few 
problems may be predicted from human trials of other RGD peptides and pre-clinical 
experience: 
 
7.4.1 Adverse Effects  
A technetium-99m labelled RGD-containing synthetic peptide already has 
been used in human imaging studies to localise αvβ3 tumour expression [286]. 
Fourteen patients, previously diagnosed with metastatic melanoma, underwent 
gamma camera imaging 20–180 min after intravenous administration of the 
radiolabelled, synthetic, linear, decapeptide αP2 [286]. However it needs 
documenting that neither in vitro nor pre-clinical in vivo studies have been published 
to demonstrate the sensitivity and specificity of the binding of this peptide to αvβ3. 
Nevertheless, encouraging results were obtained regarding sensitivity in humans and 
the peptide even detected a metastatic site within the brain [286]. Furthermore, no 
toxicity or adverse events were recorded during administration and in the 12-month 
follow-up period. Platelet function, as well as prothrombin time, remained within 
baseline values. It should be noted that the linear peptide showed high persistent 
background activity in certain organs and therefore was limited in its imaging 
efficacy; as a consequence, none of the mediastinal metastases were detected [286]. 
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7.4.2 Potential Immunogenicity of A20FMDV2 
Peptides have been proposed to have low immunogenicity in vivo owing to their 
rapid degradation [190]. RGD peptides, and their potential to induce neutralising 
antibodies, have been studied in their role as a potential vaccine for FMDV [287]. 
FMDV C-SC1 has a conserved RGDL sequence at its antigenic site. As a 
consequence, one study generated FMDV C-S8C1-based peptide immunogens 
(coupled to keyhole limpet haemocyanin in complete Freund’s adjuvant) and 
explored their ability to evoke neutralising antibodies in rabbits and guinea pigs 
[287]. Although, anti-peptide antibody titres generally were high, the sera bound 
with heterologous RGDL-containing antigens to a much lesser extent than with the 
homologous peptide; this finding suggesting that there was a low proportion of 
antibodies directed to RGDL, as the sole target [287]. Of note, although the first 
booster improved anti-peptide antibody levels, later inoculations had no effect. 
Furthermore, the neutralising activity by the anti-peptide sera on C-S8cl FMDV itself 
was investigated. Neutralising activity of the sera generally was low, confined to the 
IgM isotype, and significant decreases in neutralising titres were observed with 
boosting (two to three times every three weeks). The confinement of neutralising 
activity to the IgM subtype strongly suggests that auto-antibodies are produced at an 
early stage of the immune response and later suppressed, thus preventing the switch 
to IgGs from lymphocyte clones recognising both self antigens, FMDV virions and 
peptides [288]. This is not surprising, since the RGD sequence is found in a variety 
of widely distributed proteins involved in cell adhesion / signalling (mentioned in the 
Introduction), and the immune system could limit the anti-RGD antibody 
production for self tolerance. Therefore, the rapid degradation, and relatively low 
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potential for neutralisation, permits the repeat administration of peptides for imaging, 
without the concern for reduced targeting and detection. The low potential for 
neutralisation is also important when using peptides as therapeutic agents (see 
Section 7.4.4). A therapeutic agent which triggers the  immune system of the host 
may cause neutralisation of the agent before it can even achieve its intended 
therapeutic benefit. Furthermore, the relatively low immunogenicity of RGD 
peptides also suggests that the potential for troublesome allergic or anaphylactic 
reactions is low.  
 
 
7.4.3 The Gastrointestinal Tract and the v6 Integrin 
Hsiung et al recently have demonstrated successsful delivery of topically 
administered peptide into the colonic lumen, via an endoscope [289]. Detection of 
the fluorescently labelled peptide occurred using the aforementioned fluorescence 
confocal microendoscope. The authors stated over 80% sensitivity and specificity for 
dysplastic colonocytes over normal cells [289]. This different route of peptide 
administration and novel method of dysplasia detection could be examined with the 
A20FMDV2 peptide; particularly in view of the encouraging results obtained with 
the murine colon  cancer models (see Section 5.2). 
The radioimaging and fluorescent peptide applications of A20FMDV2 (and other 
RGD peptides) have been proposed, owing to the perceived minimal v6 
expression within normal human tissue [134, 240]. However the expression data 
which have given rise to this premise are based on, immunohistochemistry and in 
situ hybridisation, results performed on Rhesus monkey tissues [134, 240]. Breuss 
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and colleagues did report luminal v6 expression on the surface epithelium of 
colon, but described it as ‘low-level’ [134]. However, this relatively ‘low-level’ 
expression may still be clinically significant. Furthermore, Brown and colleagues 
have demonstrated v6 expression in the gastrointestinal tract, of normal ovine and 
bovine subjects [268]. This species variation questions any extrapolation, albeit 
within the primate family, from monkeys to humans. For these reasons, samples of 
normal human colon were obtained and examined for v6 expression, using 
immunohistochemistry. 
 
 
Figure 87 Colonic Tissue samples from two ‘normal’ human donors (A & B). 
Left image (i) is Haematoxylin stain and right (ii) is corresponding 62G2 staining. 
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Human colon tissues were obtained from a total of six different, ‘normal’, human 
donors. Firstly, figure 87 reveals colonic specimens, from two different donors (A & 
B), with normal morphological appearances, using a Haematoxylin stain. However, 
case B (right side) displays strong αvβ6 staining at the surface of enterocytes, 
forming the mucosa of the colon, similar to that previously described in the 
immunodeficient mice (see Section 4.6). Again, the intensity decreases as the 
epithelial layer is followed down to the crypts. Notably, case A (right side) does not 
show any evidence of αvβ6 staining; thus there is absence of αvβ6 expression. This 
lack of αvβ6 staining was seen in the majority of normal human donors (four of the 
six). Nevertheless, from this small sample, it seems that a third of normal donors 
stain positively with respect to 62G2; thereby constitutively expressing αvβ6 on their 
colonic mucosa. This analysis would have to be replicated on a larger sample, to 
validate the exact proportion of ‘constitutive expressers’. Furthermore, although 
these donors were labelled ‘normal’, their full clinical details are not known, owing 
to anonymised data requirements. Nonetheless, if these αvβ6-expressers are assumed 
to be normal, it follows that there is a proportion of normal humans who will 
constitutively express αvβ6. This constitutive expression will have implications, 
regarding the sensitivity and specificity of detection for αvβ6-expressing cancers, 
within the lower gastrointestinal tract. Furthermore, gastrointestinal toxicity also 
must be factored in for a radionuclide imaging study or in potential therapeutic roles 
(see Section 7.4.4). 
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7.4.4 Peptide Therapeutics  
My PhD project was concerned primarily with targeting αvβ6 for imaging. 
However, if the primary tumour and metastases can be tracked specifically using 
such selective agents then the potential for targeted therapy exists. This therapy 
simply could comprise the peptide itself or the peptide attached to a 
chemotherapeutic agent [290] or a β-emitting agent [291]. In theory, the latter two 
options would permit local tumour cell death and overcome the non-specific toxicity 
of chemotherapy and external beam radiotherapy towards normal tissues. The former 
option (peptide alone) may result in a variety of consequences depending on which 
cell pathways are stimulated. Therefore, future projects could investigate the cell 
signalling mechanisms activated upon peptide binding. Furthermore, dose-finding 
and toxicity studies would need to be carried out. Imaging experiments in humans 
are not expected to cause significant toxicity, since plasma peptide concentrations are 
expected to be in the nanomolar range. However, therapeutic studies may require 
higher doses, as well as repeated administrations. Peptides containing the RGD motif 
can inhibit platelet aggregation [292], and therefore careful haematological studies 
should be included in any such toxicological assessments. 
Furthermore, the high renal excretion seen with 
111
In-DTPA-A20FMDV2 could be a 
major issue in therapeutic development. During imaging the ‘once-off’ dose, rapid 
peptide destruction and excretion are parameters which are protective to renal 
toxicity. However, if a β-emitter is coupled to the peptide and repeated courses of 
peptide administration are planned, kidney damage and loss of function potentially 
are of major concern [270]. Therefore the mechanisms already described to limit 
renal retention may need to be further explored. 
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7.4.5 Cancer Cell Plasticity  
Cell plasticity refers to the ability of one lineage of cells to take on the characteristics 
of a different cell lineage [293]. This plasticity may arise from the exposure of a 
cancer cell to a different micro-environment and is entwined in the cancer stem cell 
hypothesis [294]. A discussion on the cancer stem hypothesis is beyond the scope of 
this PhD thesis. Nonetheless, it is accepted that the molecular progression of αvβ6-
expressing cancers, within humans, still is unknown. That is, it is currently not 
known whether αvβ6-expressing cancers lose their αvβ6 expression, in response to 
various treatments (e.g. chemotherapy or radiotherapy). Furthermore, if an αvβ6-
expressing cancer is exposed to an RGD-radiopeptide, during imaging, it is not 
certain whether the αvβ6 expression is maintained for subsequent imaging / 
therapeutic studies. In other words, if the integrin expression profile of a tumour 
changes in response to 
111
In-DTPA-A20FMDV2 imaging, an initial ‘positive’ result 
indicating αvβ6 expression may not be truly informative for subsequent αvβ6-
directed therapy. 
  
However, all of the aforementioned potential barriers to A20FMDV2, becoming a 
successful clinical agent, can only be ascertained once it has been tested in properly 
designed and controlled human trials. 
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Appendix A 
 
GROUP NAME SEQUENCE COMMENTS 
    
Biotinylated 
linear peptides 
A20FMDV2 
Bio-eahx-
NAVPNLRGDLQVLAQKVART 
N- terminal 
biotinylation with 
EAHX spacer 
 
A20FMDV2ran 
Bio-eahx-
RQLNVDALNVAGVRALKPTQ 
Biotinylated 
cyclic peptides 
DBD1 
Bio-eahx-
EY*KCPNLRGDLQVLAQKVCRTK    
DBD2 
Bio-eahx-
CKVPNLRGDLQVLAQKVAKC   
    
Non-
biotinylated 
linear peptides 
DTPA-
A20FMDV2
§
  
DTPA- 
NKVPNLRGDLQVLAQKVART 
N-terminal 
addition of 
DTPA. 
§
indicates non-
biotinylated form 
    
DTPA / linear 
biotinylated 
peptides 
 
DTPA- 
A20FMDV2 
DTPA- 
N*KVPNLRGDLQVLAQKVART 
N-terminal 
addition of 
DTPA. 
Asterisk 
indicates 
biotinylated 
lysine 
DTPA-
A20FMDV2ran 
DTPA- 
N*KLRDQTGLKNPVQLARVAV 
DTPA / cyclic 
biotinylated 
peptides 
 
DTPA-DBD2 
DTPA-
C*KVPNLRGDLQVLAQKVAKC   
DTPA-DBD2ran 
DTPA- 
C*KLRDQVGPKNLAQKVLAVC 
    
DOTA / 
biotinylated 
peptides 
 
DOTA-
A20FMDV2 
DOTA–
N*KVPNLRGDLQVLAQKVART 
N-terminal 
addition of 
DOTA 
Asterisk 
indicates 
biotinylated 
lysine 
DOTA-
A20FMDV2ran 
DOTA–
N*KLRDQTGLKNPVQLARVAV 
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 321 
 322 
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